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Abstract 
 
The ageing of the population, while a societal success, presents many challenges to 
healthcare systems. One such challenge relates to prescribing practices for older people. 
While many older people remain robust and independent, others become frail, suffer 
chronic diseases, receive multiple medications, and are susceptible to adverse drug 
events (ADEs). Prescribing is further influenced by age-related changes in drug 
pharmacokinetics and pharmacodynamics. Identifying ways for optimising prescribing and 
minimizing harm in this vulnerable population is increasingly a priority for health care 
providers and policy makers.  
 
The overall aim of this thesis was to determine how to optimise medication prescribing in 
frail older people. Four connected study phases were conducted to address the overall 
aim and to inform the development of a best practice guideline for prescribing in frail older 
people. 
 
The first part of this thesis explored the relationship between polypharmacy and adverse 
outcomes among older hospital inpatients stratified according to their frailty status. This 
was a secondary analysis of a prospective study of 1418 patients, aged 70 and older, 
admitted to 11 hospitals across Australia. Patients had a mean (SD) age of 81 (6.8) years 
and 55% were female. Polypharmacy (5-9 drugs per day) was observed in 684 (48.2%) 
and hyper-polypharmacy (≥10 drugs) in 497 (35.0%) patients. In total, 591 (42.5%) 
patients experienced at least one adverse outcome. The only adverse outcome associated 
with polypharmacy was delirium. Within each polypharmacy category, frailty was 
associated with adverse outcomes and the lowest overall incidence was among robust 
patients prescribed 10 or more drugs.  While polypharmacy may be a useful signal for 
medication review, in this study it was not an independent predictor of adverse outcomes 
for older inpatients. Assessing the frailty status of patients better appraised risk. Extensive 
de-prescribing programs in all older inpatients may not be an intervention that directly 
improves outcomes. 
 
The second part of this thesis assessed the frequency and nature of risk factors for 
potentially inappropriate prescribing (PIP) in patients discharged to residential aged care 
facilities (RACF) (from the larger cohort of 1418 patients in the previous study). The study 
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revealed that 54.4% of patients were on at least one potentially inappropriate medication 
(PIM) at admission to hospital with a non-significant trend to fewer PIMs on discharge 
(49.5%). The frailty status of patients and in-hospital cognitive decline were the only 
significant predictors of the number of PIMs received at both admission and discharge. 
The findings of this study provided a basis for designing interventions to rationalize 
prescribing in frail older patients in RACFs. 
 
In third part of this thesis, the recommendations on medication by specialist geriatricians 
were evaluated in a prospective observational study conducted on residents in four RACFs 
in Queensland, Australia via video-conferencing (VC). Four geriatricians assessed a total 
of 153 patients. They were prescribed a mean (SD) of 9.6 (4.2) regular medications. Of 
total 1469medications prescribed, geriatricians recommended withdrawal of 145 (9.8%) 
and dose alteration of 51 (3.5%).  New medications were initiated in 73 (47.7%) patients. 
Of the 151 (10.3%) medications considered as potentially inappropriate, 26 (17.2%) were 
stopped and the dose altered in 4 (2.6%). Geriatricians made relatively few changes, 
suggesting either that, on balance, prescription of these medications was appropriate or, 
because of other factors, there was a reluctance to adjust medications. A structured 
medication review using an algorithm for withdrawing medications of high disutility might 
help optimise medications in frail patients.  A follow up study on 50 patients was also 
conducted to review the impact of these recommendations 3 months after the initial 
consultation to determine the extent to which the medication changes had been 
implemented and maintained. A total of 126 recommendations were made by a geriatrician 
of which only 17 (13.5%) were not followed.  
 
In the final part of this thesis, we developed a pragmatic, easily applied algorithm for 
medication review to help clinicians identify and discontinue potentially inappropriate 
medications that predispose older patients, particularly those who are frail, to develop 
various geriatrics syndromes. The algorithm captures a range of different clinical situations 
in relation to PIMs and offers an evidence-based approach to identifying and, if 
appropriate, discontinuing such medications. Decision support resources were developed 
to complement the algorithm in ensuring a systematic and patient-centred approach to 
medication discontinuation. Further studies are required to evaluate the effects of the 
algorithm on prescribing decisions and ultimately, patient outcomes. 
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In conclusion, optimising prescribing in frail older people is achievable by accurate 
identification of frail patients in clinical settings and individualisation of medication 
prescribing based on each patient’s own goals of care and frailty status. Future work 
should focus on the incorporation of frailty measures into clinical studies to improve 
medication use in frail older people. A routine use of a medication review algorithm may 
improve the quality of prescribing. 
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Chapter 1 – Introduction and Literature Review 
 
1.0 Introduction 
Old age is associated with chronic diseases and disabilities. Balancing the costs and 
benefits of healthcare will be the key aim for ageing societies. A strategic shift to 
prevention and early intervention for those at high risk for dependency and disability is 
necessary. There is limited evidence on the safety and efficacy of medications in older 
people, particularly in the frail, who often have multiple comorbidities and functional 
impairments.(1) The implementation of disease-specific guidelines for the management of 
the elderly with their multiple chronic diseases results in a large number of prescribed 
medications. An increasing number of medications is associated with a significantly 
greater risk of adverse health outcomes.(2) This has been a global problem and limited 
attention has been given to addressing the medication related factors in the frail older 
population. Understanding the concept of frailty may help to optimise medication 
prescribing in older people. Optimisation of prescribing in this vulnerable population using 
a multidisciplinary approach with frequent monitoring and review might have a major 
clinical impact.  
 
This chapter describes the demographic changes seen in the elderly and considers 
prescribing practices in older people. The concept of frailty and its measurement are 
critically appraised. An overview of the assessment and prevalence of potentially 
inappropriate medications (PIMs) provides the context for a systematic review that 
evaluates appropriateness of medications in frail older people using different prescribing 
criteria.  
 
 
1.1 The ageing population 
The global perspective: In 2013, the population of older individuals aged 60 years or 
over was 841 million. This is projected to increase to more than 2 billion by 2050.(3)At that 
point, the older population will exceed the population of children (0-14 years). More than 
half of the world’s older population is in Asia (55%) followed by Europe (21%). The oldest 
old (aged 80 years and over), account for 14% of those aged 60 years or over. This age 
group is the most rapidly increasing segment of the older population. It is projected that by 
2050, 20% of the older population will be aged 80 years or over. The trend is even more 
rapidly growing in centenarians (aged 100 years or over) with a projected tenfold increase 
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from approximately 343,000 in 2012 to 3.2 million by 2050.(4)The demographic trends in 
both developed and developing countries are moving towards a society with an increasing 
percentage of people above 60 years of age as shown in Table 1.  
 
Australians setting: The population of older people in Australia is growing absolutely 
because of an increasing life expectancy and relatively because of the sustained low 
fertility levels. Australia enjoys one of the highest life expectancies in the world. Among 
similarly developed countries, Australia was ranked sixth with a mean life expectancy at 
birth of 84.3 years for females and 79.9 years for males.(5)The population of Australian 
aged 65 years and over was 2.7 million in 2006, representing 13% of the total population. 
Of those aged 65 years and over,52% were aged 65-74 years, 36% aged 75-84 years and 
12% were over 85 years. In 30 years, the projected growth in those aged 65 years and 
over is expected to be more than double, from 2.7 million to 6.3 million, representing 24% 
of the total population at that time.(6) 
 
This demographic shift in the age distribution to an increasingly older population has 
significant social, health and economic impacts. It drives the current focus of governments 
worldwide in implementing healthy aging services, policies, guidelines and investigations 
so that the functional decline associated with aging that leads to poorer health outcomes 
and increased disability, dependence and chronic disease are addressed.(6) 
 
Table 1: Demographic trend in developed and developing countries 
Source: United Nations. Department of Economic and Social Affairs Pd. Population Ageing and Development. 2012. 
* Persons aged 80 years or over (the “oldest-old”) as a percentage of the population aged 60 years or over. 
Population aged 60 years or over 
 
Country or area 
Number 
(thousands) 
Proportion of 
total 
population 
(percentage) 
Share of 
persons aged 80 
years or over* 
(percentage) 
2012 2050 2012 2050 2012 2050 
WORLD 809,743 2,031,337 11 22 14 20 
Developed countries 279,287    418,326 22 32 20 29 
Less developed countries 530,455 1,613,011   9 20 11 17 
Least developed countries 46,389    181,568  5 11  8 10 
4 
 
1.2 Pharmacotherapy in older people 
Although pharmacotherapy represents one of the successes of modern medical 
interventions, it is a complex process that is not limited to drug prescribing. 
Pharmacotherapy is not synonymous with drug prescribing: it should encompass age-
appropriate drug development and manufacturing, appropriate drug testing in clinical trials, 
improving quality of life, safety, ease of use, levels of patient adherence, reducing the 
overall caring costs and age-appropriate outcome monitoring.(7)Prescribing is a critical 
feature of geriatric medical care. The main aims of prescribing are to cure disease, 
eliminate or reduce symptoms relating to an underlying disease states and improve 
functional capacity of the patients.(8) 
 
The appropriate use of available pharmacotherapy requires a balance between the risks 
and benefits of medications. In older people, prescribing is complex because of the limited 
evidence on effectiveness of medication in this age group.(9) While most research has 
focused on the middle-aged, there is a significant knowledge gap in the study of 
pharmacotherapy in older people. In this group, prescribing is guided mostly by evidence 
from randomized controlled trials, from which older people, particularly those who are frail, 
have been excluded.(10) Despite the fact that these populations are rapidly increasing 
along with the subsequent significant increase in consumption of health care services and 
their costs, elderly patients have seldom been involved in clinical trials. Regulatory 
authorities and healthcare industries have for a long time ignored the age-specific aspects 
of medications in older individuals.  As such, the need for a detailed ‘geriatric’ approach in 
drug development and registration has been recognized and acknowledged by medicine 
agencies.(11) 
 
1.2.1 Appropriate prescribing 
“Safe”, “rational” and “optimal”, are words often used to define standards that should be 
achieved in prescribing. In the early 1970s, the term ‘appropriate prescribing’ was 
introduced,(12) as a general concept that comprises a range of different prescribing values 
and practices. According to the World Health Organization (WHO), appropriate prescribing 
or the rational use of medicines requires that "patients receive medications appropriate to 
their clinical needs, in doses that meet their own individual requirements, for an adequate 
period of time, and at the lowest cost to them and their community" (WHO 
1985).(13)Appropriate prescribing is essentially a measure the quality of prescribing.(14) 
More general descriptions of what constitutes good prescribing have included: maximising 
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effectiveness, minimising risks, minimising costs and respecting patient choices.(15) While 
defining the appropriate prescribing practices for an individual patient, a number of factors 
need to be considered, such as: 
 
- What the patient wants, 
- What the patient needs and  
- Scientific rationalism (that encompasses clinical pharmacology of certain drugs).  
 
Buetow et al. defined appropriateness as “the outcome of a process of decision making 
that maximises net individual health gains within society’s available resources”.(16) 
Appropriateness is then the outcome if the patient receives the “right” drug; regardless of 
on what grounds the prescribing decision is based. Prescribing can be rational, regarding 
the process of decision making, but still inappropriate, if the decision is for example based 
on too little or incorrect information. A ‘risk-benefit’ approach to appropriate care is defined 
by the Research and Development (RAND) Corporation as that where ‘the expected 
health benefit (e.g. increased life expectancy, relief of pain, reduction in anxiety, improved 
functional capacity) exceeds the expected negative consequences (e.g. mortality, 
morbidity, anxiety of anticipating the procedure, pain produced by the procedure, 
misleading or false diagnoses) by a sufficiently wide margin that it is worth providing’.(17) 
However, Hopkins made the point that many clinicians will view examinations of 
appropriateness as ‘cost-cutting’ exercises(18) and subsequently added two further 
dimensions to the definition of appropriateness: the individuality of the patient under 
consideration, and the availability of healthcare resources.(19) 
 
Appropriate prescribing in older people is further complicated by a number of other factors 
that increase the complexity of prescribing. Hence, the operational definition of appropriate 
prescribing has been modified in relation to prescribing for older people as greater 
heterogeneity is observed in these populations as compared to others.(20, 21) In general, 
these definitions suggest that the expected benefits to health should outweigh any 
negative effects.(22) It has also been recommended that the term ‘appropriate prescribing’ 
be expanded to include misuse, overuse and underuse of treatments.(23) Since the 
clinical evidence for the effects of drugs in older people is limited, goals of treatment might 
change, and social and economic factors might be different or more important for these 
patients than for a younger population.(24)The following factors must be considered when 
prescribing for older people (25): 
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- Life expectancy of the patient 
- The right therapeutic approach in patients with a poor prognosis 
- Selection of the pharmacotherapy with the most favourable benefit/risk ratio 
 
In theory, appropriate prescribing, can be identified by taking into account the factors that 
should be addressed in an ideal context. However in practice, many factors are difficult to 
quantify and they may influence the individual prescriber’s decision.  
 
1.2.2 Inappropriate prescribing 
Inappropriate prescribing (IP) has been defined as the use of a particular medicine that 
poses greater risk of harm than benefit, especially when safer and more effective options 
are available for the same condition.(14, 26) The concept of IP recognises that there are 
no medications without any risk, whereby appropriate use of medications requires that the 
risks associated with its use outweigh the anticipated benefits.(27) IP also includes not 
prescribing sub-optimal doses of medication.(28) Based on the concept of risk-benefit 
definition of appropriateness, inappropriate medications has been defined as: (29) 
 
1) overuse of a medication where there is no clear indication, 
2) misuse of a medication in relation to wrong drug, dose, and duration, or 
3) underuse of a medication where there is a clear indication.  
 
Inappropriate prescribing can result from many components of the prescribing context(14, 
28, 30-32) such as:  
 
1) Polypharmacy: Polypharmacy indicates the prescribing practice of multiple medications 
that are considered clinically necessary.(28) The minimum number of medications used to 
define “polypharmacy” is variable, but generally ranges from 5 to 10.(33, 34)  It also 
includes the practice of prescribing medications at a higher dose, greater frequency or for 
a period longer than is clinically indicated. Polypharmacy is associated with suboptimal 
and inappropriate prescribing. Many medications that have an increased tendency to 
cause problems for older patients have been labelled as inappropriate drugs.(14) 
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2) Unfavourable risk benefit ratio: IP occurs when the risks of an adverse event associated 
with a medication use outweigh the clinical benefits, where safe and more effective 
alternative therapy is available.(35) 
 
3) Prescribing medications with high risk of drug-drug or drug-disease interactions.(35) 
 
4) Prescribing certain medications where there are no specific indication and clinical 
significance for a specific patient.(14) 
 
5) Under prescribing or underutilization of medications: IP occurs when there is the failure 
to prescribe a clinically significant medication for a patient for whom there is no valid 
reason not to prescribe the said medication and for which there is no contraindication to 
this beneficial pharmacotherapy e.g. if a patient is suffering from a particular disease and 
no drug is prescribed to treat that particular condition, or the dose of the medication is 
insufficient to treat that condition effectively.(14) 
 
 
1.3 Frailty in older people 
1.3.1 What is frailty? 
While one person may appear fit and well, another, who had seemed just as robust (fit) in 
recent times, starts to weaken and slow down, sometimes as early as middle age. This is a 
central issue that is now being systematically addressed by many researchers – that being 
why some people age well and others do not, often heading along a path that ends up with 
a medical condition known as frailty.(36)Frailty is a fast emerging research area in geriatric 
medicine.(37) 
 
In the past, the term “frailty” had many different definitions, often linked with disability and 
chronic diseases, with most definitions addressing the adverse health outcomes of 
frailty.(38, 39)Prior to the 1990s, the term frailty was not often used. Winograd et al .in 
1991, suggested one of the first definitions of frailty based on specific criteria.(40)In the 
same year, Speechley and Tinetti defined frailty as the occurrence of at least four of the 
following characteristics: more than 80 years of age, depression, balance and gait 
difficulties, no exercise, consuming sedatives, diminished shoulder strength, any lower 
extremity disability, diminished knee strength, and loss of proximate vision.(41) Later 
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studies defined frailty based on certain types of impaired physiological functioning while 
the adverse outcomes were not considered.  
 
For example, Buchner and Wagner in 1992 defined frailty as “the state of reduced 
physiologic reserve associated with increased susceptibility to disability.”(42) Similarly in 
1997, Campbell and Buchner defined frailty as “a loss of the person’s capability to 
withstand minor environmental stresses”(43)In 1998, Woodhouse and colleagues tried to 
differentiate between fit and frail older people. According to their definition, fit older people 
were those individuals more than 65 years of age, freely ambulant and living 
independently at their home or in sheltered accommodation whereas, frail elderly were 
individuals aged 65 years and over, often living in institutional care with several diseases 
and highly dependent on others for activities of daily living.(44) A very frequently used 
definition by Fried et al. is criteria based, as a “phenotype characterizing an older people 
with a high risk of falls, disability, hospitalization and mortality.(45) 
 
The term “frail” is intended to identify those older people at greatest risk of adverse 
outcomes. Although there is frequent use of this term in medical practice and published 
papers, there are not any widely accepted definitions or criteria for frailty. While there are 
different approaches to the definition and measurement of frailty, it is progressively used to 
identify a vulnerable group of older people at high risk of adverse outcomes including falls, 
worsening disability, prolonged hospital stays, institutionalization and death.(46)Studies in 
community-dwelling older populations reported that those who are frail are more likely to 
die, be admitted to an institution or become more disabled.(45, 47)Predominantly, frailty is 
linked with increasing age (48)and with co-morbidities.(49)However, frailty is not identical 
with either advanced age or the presence of disease. Chronological age alone cannot 
predict inpatient mortality, for example.(50) 
 
 
1.3.2 Measurement of frailty 
Frailty can be measured using three established methods as shown in Table 2. The first 
method; a rules-based approach identifies frailty as a ‘clinical syndrome or phenotype’ (a 
set of symptoms and signs that tend to occur together, thus characterizing a specific 
medical condition). The most well-known and widely used phenotype was developed by 
Fried et al. in 2001;it identifies frailty as the presence of ≥ 3 of 5 criteria: weight loss, 
exhaustion, weak grip strength, slow walking speed, and low physical activity.(45)People 
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having three or more of these deficits are considered to be frail and those with none are 
considered robust while when one or two of these deficits is present the term ‘pre-frail’ is 
used. This phenotype has been validated as a predictor of adverse outcomes in large 
epidemiological studies (51)and was used to define frailty as the most common condition 
leading to death in community-dwelling older people.(52) While this model is clinically 
coherent and reproducible, the omission of disorders of cognition and mood made it 
controversial since some argue that frailty consists of more than weakness, slowness and 
wasting.(53, 54) 
 
The second method, is based on clinicians ‘subjective opinion’ (55, 56)though this has 
strong face validity, generalizability is limited.  
 
The third method conceptualizes frailty as a ‘multidimensional risk state’ that measures 
frailty based on the quantity rather than by the nature of health problems.(48)This concept 
is termed Frailty Index (FI), deficits are counted as an aggregation of features such as 
symptoms, signs, diseases and disabilities with the principle that ‘the more deficits a 
person has, the more likely that person is to be frail.’(46)The FI is expressed as a ratio of 
deficits present to the total number of deficits considered. For example, if a patient has 14 
of 40 assessed deficits, the FI of that person would be 14/40 = 0.35.  Several studies have 
shown consistent results using the FI which suggests, the higher the deficit count, the 
frailer the person is and more vulnerable to adverse outcomes.(57-61) 
 
These approaches differ not only in their processes for measuring frailty but also in their 
conceptualisation of the aetiology and implications of frailty itself. The frailty phenotype 
views frailty as a clinical syndrome with the core pathophysiological feature of sarcopenia 
(the loss of skeletal muscle mass and strength as a result of ageing) caused mainly by 
age-related changes in hormones.(62) In this model, co-morbidity is distinct from frailty, 
though the presence of multiple chronic diseases is recognised, somewhat separately, as 
necessitating a different approach to prescribing.(63) The Frailty Index approach, on the 
other hand, conceptualises frailty as a state of increased risk of adverse health outcomes 
due to a variety of accumulated health deficits.(64) These deficits may or may not relate to 
sarcopenia, and are sometimes, but not always, secondary to comorbid disease.  
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Table 2: Methods of frailty measurement
Authors Frailty 
(Definition) 
Components Grades of frailty Measurement Pros/Cons 
Fried et 
al.(45) 
Phenotype/Rules-
Based Approach 
Performance on 
five variables 
Robust: no problems 
Pre-frail: one or two 
problems 
Frail: three or more 
problems 
Clinical 
Performance-based 
measures 
Pros: Performance based, 
easy to apply 
Cons: challenging in 
immobile patients 
Rockwood 
et al.(65) 
Frailty Scale (e.g., 
Canadian Study of 
Health and Aging- 
Clinical Frailty 
Scale) 
Single descriptor 
of a person’s state 
of frailty (fitness) 
CSHA-CFS: A 7 point 
scale ranging from ‘very 
fit’ to ‘severely frail’ 
Clinical Judgment Pros: Subjective, easy to 
use/implement 
Cons: Validated for use by 
specialists, insensitive in 
some populations 
Mitnitski et 
al. (57) 
Frailty Index (e.g., 
Rockwood-
Mitnitski Frailty 
Index) 
Deficit count or 
proportion of 
potential deficits 
that a person has 
accumulated 
Range: 0-1.0 
Empirical cut-off: <0.25 
(robust/pre-frail) 
≥ 0.25 (frail) 
0.67 (99% upper limit of 
FI) 
Comprehensive 
Geriatric 
Assessment 
Population-based 
data (survey) 
Pros: Simple approach, 
robust indicator of frailty, 
reproducible mathematical 
properties, precise grading 
Cons: Burdensome in 
clinical setting 
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1.3.3 Frailty assessment as a part of a comprehensive geriatric assessment 
Comprehensive geriatric assessment (CGA) is a multidimensional process that has long 
been recognised as the best approach to the management of the clinical complexity in 
older populations.(66) A CGA explores clinical, functional, cognitive, nutritional and social 
parameters, leading to an all-inclusive assessment which helps to optimize long-term 
management, resource planning and the use of services.(67) The proven benefit of CGA 
has been supported by several studies. One study that randomly assigned 63 frail elderly 
inpatients with a high probability of nursing-home placement to an innovative geriatric 
evaluation unit showed that a multidimensional assessment led to an improvement in 
functional status, discontinuation in the number of prescribed drugs, lower mortality and 
less time spent in hospital.(68) Another study showed an increased survival in frail older 
patients with a CGA admitted to a geriatric ward as opposed to a general medical 
ward.(69) CGA has the potential to optimize drug therapy by the detection of both over- 
and under-treated disease conditions.(70, 71)Importantly, a FI can be derived from the 
information collected as part of CGA.(72) 
 
 
1.3.4 Pharmacokinetics/Pharmacodynamics changes in frail older people 
Age and frailty are both likely to affect the pharmacokinetics and pharmacodynamics of 
medications, and hence should influence prescribing(73) as shown in Figure 1.(74) Age-
related physiological changes affect drug absorption, distribution, metabolism and 
excretion; effects well documented in the literature.(75-78) However, the evidence on the 
drug responses and evaluation of differences in pharmacokinetics and pharmacodynamics 
in fit versus frail older people is limited to few studies.(79) 
 
Pharmacokinetics 
Absorption: Previous studies reported that age-related changes are associated with drug 
absorption (80)however recent findings suggest that there is no change in drug absorption 
with frailty.(81) 
 
Distribution: In frailty, there are an increase in body fat, and decrease in lean body mass; 
these affect the volume of distribution of drugs. The increased body fat especially alters 
the distribution of lipophilic drugs such as lidocaine, verapamil and benzodiazepines.(82) 
This particularly impacts the drug’s half-life and estimation of loading dose; shortening at 
the beginning and prolonged release later which may result in higher plasma levels.(73) 
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Hence, a smaller volume of distribution is observed in frail adults than in non-frail 
adults.(74)As well, the serum albumin level is significantly reduced in frail older people. 
Acidic drugs such as warfarin, valporic acid, lorazepam, digoxin, and ceftriaxone are 
bound strongly to albumin which makes frail older people receiving acidic drugs prone to 
toxicity even with normal drug levels.(73) 
 
Metabolism: Drug biotransformation reactions are described as either phase I (oxidation, 
reduction, hydrolysis) or phase II (methylation, sulphation, glucuronidation). While no 
change was observed in phase I metabolism,(83) phase II metabolism is likely to be 
reduced in frail older people.(84) Some enzymes involved in drug metabolism are 
impacted by frailty but not by chronological age. Studies on paracetamol and 
metoclopramide revealed that paracetamol clearance was reduced in both fit and frail 
older people compared to younger controls but when corrected for liver size, the 
glucuronidation of paracetamol was markedly lower in frail older people compared to their 
fitter peers.(85) Similarly, clearance of metoclopramide by sulphation was similar in young 
controls and fit older people but significantly reduced in those with frailty.(86)A study by 
Hubbard et al. that compared the plasma esterase activity in fit and frail older patients 
found normal plasma esterase activity in the healthy volunteers, which fell significantly with 
increasing frailty.(87) 
 
Elimination: Drug clearance is likely to be impaired with frailty due to the reduced hepatic 
and renal size and function in old age (88)which is aggravated by the development of a 
chronic inflammatory state.(89)There is limited evidence of reduced renal clearance in frail 
older people. However, older people with chronic renal insufficiency, as demonstrated by 
higher serum creatinine levels, are more likely to be frail.(90) 
 
Pharmacodynamics: Pharmacodynamic changes in frail older people have not been well 
documented. Older people have an increased sensitivity to warfarin (91)and to 
benzodiazepines.(92) A study by Wynne et al. reported that frail older people are more 
sensitive to metoclopramide-related sedation.(86) Moreover, the pharmacodynamics of 
anticoagulant and immune-modulating medications are influenced by the presence of the 
procoagulant state seen in chronic inflammation in frail older people.(74) 
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Figure 1: The effect of frailty-associated physiological changes on the pharmacological 
response in frail older people compared with non-frail older people. 
 
Frailty syndrome 
 Unintentional weight loss 
 Exhaustion 
  Muscle weakness 
 Slow walking speed 
 Limited physical  activity 
 
Effects on pharmacokinetics 
• No change in absorption 
 • Change in volume of 
distribution due to the increased 
sarcopenia and adiposity 
No change in Phase I hepatic 
metabolism 
 • Reduced Phase II metabolism  
 • Limited evidence on further 
reduction in renal clearance  
 
Effects on pharmacodynamics 
• Reduced physiological reserve 
and impaired adaptive responses 
may affect the 
pharmacodynamics of drugs 
 
 • Pro-coagulant state and 
chronic inflammation may affect 
the pharmacodynamics of 
anticoagulant and immune-
modulating drugs  
 
Physiological changes 
 
 Coagulation 
 Inflammation 
 Increased adiposity 
 Increased sarcopenia 
 Heart rate variability  
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1.3.5 Prescribing in frail older people 
Frail older persons often have multiple comorbidities with signs of impairment in activities 
of daily living.(93) Prescribing drugs for these vulnerable individuals is a difficult and 
potentially unsafe activity as there is a lack of evidence on drug efficacy in these 
groups.(94) The anticipated outcome of medication in frail older people is usually 
generalized from non-frail or robust populations.(95) Rational prescribing in frail older 
people needs specific expertise knowledge of the factors that contribute to the differences 
in response to medicines in this group. Factors such as age-related changes in 
pharmacokinetics and pharmacodynamics, multiple comorbidities, polypharmacy and 
adherence issues modify drug responses that contribute to an augmented likelihood of 
adverse drug reactions (ADRs) in frail older people. (88, 96, 97) Also, the wide inter-
individual variability with increasing age contributes to different drug responses between fit 
and frail older people. Avoiding inappropriate medications in the frail older people 
minimises the risk of adverse drug events (ADEs) since medication-related ADRs are 
common in frail older people.(98) 
 
Prescribing in frail older people should differ from that in non-frail older people. The 
primary focus in frail patients with life-limiting conditions is to improve quality of life by 
reducing the severity of symptoms or by controlling a disease in the short term.(99) Many 
medications that are commonly prescribed in older people such as psychotropic drugs, 
cardiovascular agents, and analgesics, are commonly associated with high risk of 
ADRs.(100) It is essential that frailty status be considered when treatment plans shift away 
from a curative towards an individualized symptom controlling approach. Understanding 
frailty could assist the treating medical practitioner to better manage patients who do not fit 
well into clinical practice guidelines (CPG) and management algorithms.(101) Prescribers 
need to appreciate that following evidence-based clinical guidelines is appropriate for 
patients with no or minimal comorbidities but, in those who are frail and disabled, the goals 
of care and treatment targets need to be readjusted.(67) 
 
Potentially vulnerable older patients should benefit from an approach that evaluates their 
frailty, considers their remaining life expectancy and identifies diseases with highest 
priority for treatment instead of treating all diseases. A common example in a frail patient 
with a life expectancy of few months is the use of statins to lower serum cholesterol levels 
and hence improve long term cardiovascular disease risk or antiresorptive therapy for 
osteoporosis, which will have no benefit as the onset of measurable effects, will occur too 
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late to be of any benefit.(67) If a disease with high priority for treatment is identified, the 
most appropriate therapy based on the recommendations of the CPGs could be followed, 
taking into consideration the frailty status of the patient. This involves the use of various 
tools, guidelines and algorithms to optimize appropriate use of medication. Unfortunately, 
the available guidelines are not practically applicable to frail older people. 
 
1.4 Optimising pharmacotherapy in older people 
The continuing challenge for prescribing physicians and patients is to thoroughly 
reconsider medications that are really needed (prioritization) and medications that could be 
stopped (discontinuation).(102) These aspects of pharmacotherapy are central, especially 
in the care of older people since the goals of care for older patients with reduced life 
expectancy becomes palliative rather than curative.(103)Discontinuation of unnecessary 
medications in this vulnerable population demands several considerations such as 
assessment of geriatric syndromes (those clinical conditions in older persons that do not fit 
into disease categories such as delirium, falls, incontinence), regular follow up and 
monitoring of effects, dose adjustments over time as well as discontinuation of medication 
when indicated.(104) 
 
While many studies focus on the safe and effective initiation of medications in older 
people, only a handful of studies are conducted with particular attention on the cessation 
of medications that are no longer required.(79)The cessation of medications has been 
defined by terms such as deprescribing, discontinuation and withdrawal which should be 
considered in cases of polypharmacy, ineffective treatment, the presence of ADRs as well 
as with changes of treatment goals. However, deprescribing should be based on a 
principle of stopping one medication at a time and gradual weaning of doses over weeks 
or months.(105)Developing a pragmatic and easily applied algorithm for medication review 
that offers an evidence-based approach to identifying and, if appropriate, discontinuing 
such medications might help optimise medications in frail older people.  
 
1.4.1 Screening tools to assess inappropriate medications 
Given that pharmacotherapy in older people is challenging and complex, several criteria 
and tools have been developed to identify IP.(106)Inappropriate prescribing in older 
people can be detected using explicit (criterion-based) or implicit (judgment-based) 
methods. These criteria have been developed based on literature reviews, scientific and 
clinical expertise and on previous established criteria, most of which were validated using 
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consensus methods while others by using patient medical records.(106)The factors 
addressed by these tools and criteria in assessing quality of medication prescribing in 
older people are shown in Table 3. Some criteria assess medications alone; some assess 
medication and disease states and others factors related to the individual patient. Some 
approaches use a combination of all of these. None address frailty although several 
consider some surrogates of frailty. 
 
1.4.1.1 Explicit Criteria:Explicit criteria are generally derived from expert reports or 
published reviews, consensus methods and pre-determined standards.(14) These criteria 
include the lists of drugs, dosages or drug classes that should be avoided in older people. 
They have high reliability and reproducibility but focus mainly on specific drugs and 
disease states.(74)They do not address patient related factors such as life expectancy, 
cognition, functional status, co-morbidities and patient preference.(107) Hence, one cannot 
rely only on explicit criteria for assessing the appropriateness of pharmacotherapy in an 
individual patient.(108) Yet, explicit criteria are considered applicable in detecting 
inappropriateness of prescribing in drug charts or databases of larger population. Some 
commonly used explicit criteria include:  
 
Beers Criteria: The Beers criteria have been the most widely used tool to evaluate PIM 
use among older people since their development in the US in 1991.(109) Developed by a 
consensus panel of 13 experts in geriatric care, they were originally designed for older 
nursing home residents. They identified a total of 30 medications where 19 medications 
were to be avoided irrespective of diagnoses, doses, durations, and frequencies; while for 
11 medications, certain doses, durations, and frequencies of medication therapy were not 
be exceeded. These criteria were updated in 1997 so that they were applicable to all 
adults of 65 years and older, regardless of their place of residence.(27) Later in 2003, the 
list was updated again to include 48 medications to be avoided regardless of diagnosis 
and 20 medical conditions in which certain drugs should be avoided.(110)Recently in 
2012, the criteria have been revised again to address three main domains: i) PIMs to avoid 
in older people irrespective of diagnoses or conditions; ii) PIMs to avoid with certain drug 
disease/syndrome interactions; and iii) list of medications to be used with caution.(111) 
The quality of criteria has been improved using an evidence based approach that now 
includes a clear indication of the strength of the evidence and of the recommendation. 
Although the Beers criteria have widespread utilization, they possess several limitations. 
Many medications in the Beers list are not available in countries other than the USA and 
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some medications from the list, for example methyldopa, are rarely used in everyday 
clinical practice in older patients. Moreover, the Beers criteria do not address other 
important domains of IP such as under-prescribing, drug duplication and drug-drug 
interaction.(26) 
 
Screening Tool of Older Person’s potentially Inappropriate Prescriptions (STOPP) 
and Screening Tool to Alert to Right Treatment (START): In 2008, a group of 18 
specialists in geriatric pharmacotherapy from Ireland and the UK validated the Screening 
Tool of Older Person’s potentially Inappropriate Prescriptions (STOPP) and Screening 
Tool to Alert doctors to Right Treatment (START) using the Delphi consensus 
methodology (a widely used and accepted method for gathering data from respondents 
within their domain of expertise).(112)The STOPP criteria address 65 indicators of 
inappropriate prescribing with special attention to drugs that adversely affect older patients 
at risk of falls, drug-drug interaction, drug-disease interaction and drug duplication. Each 
criterion is supported by a concise description that explains why the specific medication is 
potentially inappropriate.(107) 
 
The START criteria include 22 evidence-based prescribing indicators highlighting 
potentially serious errors of prescribing omission in older people.(112) In cases where the 
life expectancy and functional status of patients justifies the prescribed medicines and 
where there is no contraindication to prescribed medications, these criteria identify under-
prescribing.(107) Both STOPP and START criteria have good inter-rater reliability between 
pharmacists and physicians.(113, 114) Studies using the STOPP criteria identified 21% of 
prescriptions as IP in primary care (115), 35% in hospitals (116) and 60% in long term 
residential care.(117) On the other hand, studies using the START criteria in primary care 
identified prescribing omission in 23% of patients and in 57% in hospitals.(117) However, 
the application of the STOPP and START criteria make them time consuming and further 
studies across different settings and countries are needed. 
18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Studies that included some surrogates of frailty. 
STOPP: Screening Tool of Older Person’s Prescriptions; START: Screening Tool to Alert Doctors to Right Treatment; IMU & PIT: Inappropriate Medication  
Use and Prescribing Indicators Tool; MAI: Medication Appropriateness Index.
Components that 
measure prescribing 
appropriateness 
 Assessment criteria 
Addressed by Beers criteria32 McLeod  
Criteria33 
STOPP  
and 
START35 
IMU  
& PIT36 
MAI38 A 10-step 
Conceptual 
Framework3
9 
Good Palliative-
Geriatric 
Practice 
Algorithm40 
1991 1997 2003 2012 
 Medication and disease related factors 
Drugs           
Dose           
Duration           
Under prescribing           
Drug-drug interactions           
Drug-disease interactions           
Effectiveness           
Drug indication           
Drug duplication           
Medication cost           
 Patient related factors 
Frailty (Cognition, mood 
and behaviour, functional 
status (ADL), continence, 
etc.) 
      *  * * 
Falls, fatigue           
Life expectancy           
 
 
Table 3: Prescribing indicators that are addressed by the Tools/Criteria involved in assessing quality of medication prescribing in 
older people 
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McLeod Criteria: These criteria for identifying inappropriate prescribing in older patient 
were developed by a 32 member national board of experts in 1997 in Canada.(118) They 
developed a list of 71 indicators in prescribing for older patients and ranked the clinical 
implication of each on a scale of 1 (not significant) to 4 (highly significant). IP was initially 
classified into three types: i) medications that are contraindicated for older people because 
of an unacceptable risk-benefit ratio. ii) medications that are prone to cause drug-drug 
interactions and iii) medications that are prone to cause drug-disease interaction.(118) 
Unfortunately, these criteria have a limited applicability to geriatric clinical practice.(119) 
The major limitation for application of this criteria was the need for patient-specific 
information such as indication for the medication, its intended duration of use and 
detecting co-morbidities.(120) 
 
Improved Prescribing in the Elderly Tool (IPET): Naugler et al. published the IPET 
criteria in 2000, updating McLeod’s criteria of assessing IP.(121)IPET contains a list of 14 
situations where IP could be avoided.  Although the IPET criteria are brief and concise, 
they have a number of limitations. They had a strong focus on cardiovascular and 
psychotropic drugs as well as NSAIDs and other drug categories are under-
represented.(107)Moreover, the recommendation to avoid beta-blockers in heart failure 
and avoidance of benzodiazepines with long half-lives under any circumstances makes 
IPET even more difficult to use in contemporary clinical practice.(122) 
 
Zhan’s Criteria: The Zhan criteria were developed in 2001 in North America by a group of 
seven experts in geriatric medicine, pharmacy and pharmaco-epidemiology.(123)They 
used a modified Delphi technique to identify a total of 33 inappropriate medications that 
are based on the 1997 version of the Beers criteria. Zhan divided inappropriate 
medications into three groups: i) those medications to be avoided always ii) those 
medications that are rarely appropriate; and iii) those medications that have some 
indications but are frequently misused. Like Beers, Zhan’s criteria contain medications that 
are not available or prescribed outside of the US.(123) 
 
A 10-step Conceptual Framework: To minimize inappropriate medications in older 
population, a quality use of medicine framework was developed by a panel of researchers 
in Australia.(124) This framework comprises 10 steps that aim to decrease IP in older 
patients to the minimum number of essential drugs. The systematic and individualized 
approach of this framework identifies the medications that are of little or no benefit in 
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individual older patients with assistance on discontinuing them. Unlike other tools and 
criteria, it focuses on both medication related and medication management related aspects 
of appropriate prescribing which ultimately addresses the gap observed in other tools. 
However, further studies are needed to validate this framework as a practical approach for 
clinical decision making for appropriate prescribing in vulnerable older patients.(124) 
 
1.4.1.2 Implicit Criteria: Implicit tools and criteria of identifying IP usually focus on the 
individual patient and rely on professional judgment of clinicians to assess every 
medication the patient receives. This makes implicit criteria more time consuming and 
impractical in busy clinical settings and the result depends upon the clinical knowledge and 
skills of the person using them.(14)Unlike explicit approaches that focus predominantly on 
medication or disease, implicit criteria address patient preferences and certain aspects of 
patient’s vulnerability.(74) Moreover, implicit criteria are independent of national drug 
formularies that make them easily transferable across countries.(106) 
 
Some commonly used implicit criteria are: 
 
Medication Appropriateness Index (MAI): The Medication Appropriateness Index (MAI) 
was developed in the US in 1991;it evaluates each drug with 10 elements of prescribing: 
indication, effectiveness, dose, correct directions, practical directions, drug–drug and 
drug–disease interactions, duplication, duration and cost.(125) The evaluator rates the 
medication as ‘appropriate’, ‘marginally appropriate’, or ‘inappropriate’ for each criterion. 
Whilst the method can be applied to older populations, it has several limitations. The MAI 
does not identify under-prescribing and whilst it has a good reliability in ambulatory 
settings, but there is no clear evidence of its effectiveness in the community setting and 
the generalizability of the instrument as used by other clinicians is unknown.(126, 127) 
 
Lipton Criteria: In 1990, Lipton et al. developed and validated these criteria in the US 
using a panel of experts assessing patient cases.(128, 129)To assess the appropriateness 
of each prescription, these criteria were grouped into six categories: dosage, frequency, 
drug allergy, appropriate choice of drug therapy, duplication and drug-drug interactions 
(DDIs). An advantage of the Lipton’s criteria is its use of explicit categories and definitions, 
together with the ability of the prescriber to apply implicit judgment. However these criteria 
were tested in a small patient population and therefore warrant further reliability and 
validity testing among larger geriatric populations.(130) 
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Assessment of Underutilization of Medication (AOU) Tool:  This tool was developed to 
address under-prescribing, an important aspect of inappropriate prescribing, which was 
lacking in the MAI.(131) It identifies the omission of indicated medications by comparing 
the list of chronic conditions with prescribed medicines. 
 
1.4.1.3 Combined explicit and implicit criteria: A few researchers have combined 
explicit and implicit criteria to assess inappropriate prescribing. Examples are: 
 
Australian Prescribing Indicators Tool: A list of prescribing indicators for older people 
(aged >65 years) based on the most frequent medications prescribed to Australians, and 
the most frequent medical conditions for which elderly Australians consult medical 
practitioners was developed in Australia in 2008. These criteria involve 48 prescribing 
indicators: 45 are explicit and 3 implicit with explanatory footnotes and associated tables to 
address the common problem of adverse medication-related events in the older Australian 
population. Unlike other IP criteria, the Australian Prescribing Indicators Tool was derived 
from Australian clinical guidelines and prescribing databases rather than from a consensus 
panel. In addition to addressing the medication related indicators, they also address 
medication management factors.(132) Unlike other tools to assess IP, the presence of 
important health interventions such as ‘smoking cessation’ and ‘seasonal vaccination’ 
make this tool unique. In addition, this tool has been validated using consensus 
methods.(133) However, since the reference is specific to Australian sources, their 
usability in other countries might be limited.(107) 
 
Swedish Criteria for Prescribing Indicators: The Swedish National Board of Health and 
Welfare developed a set of indicators to assess the quality of pharmacotherapy in older 
people.(134) These indicators were based on the international literature and included 9 
drug-specific and 11 disease-specific indicators (134, 135) representing the mix of explicit 
and implicit criteria.  
 
1.4.1.4 Other approaches: A number of additional methods and approaches of detection 
as well as prevention of IP have been reported. One method includes comprehensive 
geriatric assessment (CGA) that comprises a multidisciplinary team of physician, 
pharmacist, nurse and other health care workers who evaluate the older patient’s overall 
health status as well as functional, physical, cognitive and nutritional abilities. This type of 
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assessment helps support the informed decision making for prescribers with a more 
appropriate use of services and resources.(67)The proven benefit of CGA has been 
supported by several studies.(136-138) Despite the widespread advantage of CGA for 
managing older people, a further multidimensional approach is needed to optimize 
medication in older people. A standardized comprehensive assessment linked to a 
coordinated and integrated plan for treatment and follow-up ideally should improve the 
healthcare of older people.  
 
An expert pharmacist review providing pharmaceutical care that involves the process 
through which a pharmacist collaborates with other health professionals and patients in 
designing, implementing, and monitoring a therapeutic plan to produce specific therapeutic 
outcomes for the patient is another approach that has been reported to minimize the 
inappropriate medication prescribing in older patients.(24) Pharmacists conduct a 
standardized pharmaceutical assessment of prescription medications and provide 
feedback to the patients and their physicians. A recent study by Spinewine reported that 
pharmacotherapy in older people is improved when pharmacists conduct an 
comprehensive medication review and active educational interventions for other 
healthcare team.(139)However in several instances, they found mixed outcomes of the 
pharmacist intervention in terms of cost effectiveness and patients’ quality of life. 
 
Educational interventions targeting specifically those involved in prescribing for older 
patients help to minimize inappropriate medication prescribing. Some studies reported that 
most medical practitioners do not receive sufficient training in geriatric pharmacotherapy 
and this impact negatively on prescribing appropriateness.(140, 141) 
 
Computer-based prescribing approaches are effective in minimizing prescribing errors and 
improving appropriateness. They have a significant role at the time of prescribing 
particularly on drug dose, drug-drug interactions, monitoring and cost.(142, 143)However, 
these approaches are costly and are limited to general adult population while the concern 
of older people with multiple comorbidities remains unaddressed.(117) 
 
1.4.2 Prevalence of inappropriate prescribing in older people 
In older people, IP has become an area of major worldwide concern. It is generally 
acknowledged that certain drugs should be used cautiously or avoided completely in this 
age group, if a safer alternative is available.(144) Because of the pharmacokinetic and 
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pharmacodynamics changes associated with ageing, this older population is more 
susceptible to adverse effects.(145, 146) ADRs are the most frequently occurring medical 
error in the United States(147)  a study found that two-thirds of nursing facility residents 
experience at least one ADR in any 4-year period and one in seven of these ADRs lead to 
hospitalisation.(148) In Australia, older people living in care facilities are prescribed 
significantly more medications than older people living in their own homes with the 
consequent increased risk of ADRs.(149) Bates et al. reported that 28% of ADRs, and 
42% of life-threatening and serious events in hospitals, were preventable.(150) These 
findings are comparable with the prevalence reported by Gurwitz, who found that 28% of 
ADRs in an ambulatory setting and 51% in nursing homes were preventable.(151, 152) 
 
Prevalence of IP in the UK: Older people in the UK can receive long term care in ‘care 
homes’ which include nursing homes (for those requiring assistance with activities of daily 
living), residential homes (for people who are more independent) and those with both 
nursing and residential care. Parsons et al. studied residents in six residential care homes 
in England using the STOPP criteria. Of the study population, 46.2% were prescribed at 
least one or more PIM with 9.2% on two or more and 1.7% on three.(153) A similar study 
was conducted by Ryan and colleagues in an older population in primary care using Beers 
and STOPP criteria to assess IP and START criteria to assess potential prescribing 
omissions (PPOs). Beers criteria identified 286 PIPs in 18.3% (243) of patients whereas 
STOPP criteria identified 21.4% (284) IP with 346 potentially inappropriate prescriptions. 
On the other hand, START criteria identified a total of 333 PPOs in 22.7% (302) of 
patients.(115)  Cahir and colleagues investigated the prevalence as well as the total cost 
associated with PIP in the national Irish population aged ≥ 70 years using STOPP criteria. 
The overall PIP prevalence was 36% with polypharmacy being the main issue. Total PIP 
costs in the year 2007 were 9% of the overall pharmaceutical expenditure in those 
populations.(154) 
 
Prevalence of IP in the rest of Europe: A study by Berger et al. from Germany 
investigated the extent of potentially inappropriate prescribing (PIP) in patients 65 years 
and older with anxiety disorder; 40% of patients were receiving potentially inappropriate 
medications based on Beers criteria of inappropriateness.(155) Gallagher et al. assessed 
the use of PIP in older patients admitted to six university teaching hospitals in Switzerland, 
Spain, Belgium, Italy Czech Republic and Ireland. The overall prevalence of PIP using 
STOPP criteria was 51.3%, varying from 34.7% in Czech Republic to 77.3% in 
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Switzerland. By contrast, the overall prevalence using the Beers criteria was 30.4%, with 
22.7% in Czech Republic to 43.3% in Switzerland. They also investigated the overall 
prescribing omissions using START criteria; they found the overall prevalence was 59.4%, 
ranging from 51.3% in Ireland to 72.7% in Italy.(156)  Another European study found a 
20% prevalence of prescribing at least one PIM for the older patients with substantial 
differences among European countries because of varied clinical practices, regulatory 
measures and differences in socioeconomic status.(157) A systematic review to estimate 
the extent of IP in older population in the primary care setting by Opondo et al. reported 
that approximately one in five prescriptions to the older population is inappropriate in this 
setting.(158) 
 
Prevalence of IP in the USA: Lund et al. conducted a study to determine whether implicit 
criteria such as Medication Appropriateness Index (MAI) can predict the risk of ADE. IP at 
baseline was identified by Beers criteria (2003), an explicit measure and MAI, an implicit 
measure. Of 236 patients, 34(14.4%) had an ADE. Beers criteria identified 48.7% of 
patients with IP while MAI identified 98.7% patients with at least one inappropriate 
prescription.  Only the modified MAI was associated with the risk of a subsequent 
ADE.(159) Pyszka et al. studied the incidence of PIMs in older patients aged over 70 in a 
teaching hospital in Wisconsin using the STOPP/START measure of IP. Based on the list 
of patients’ medication, commissions and omission of medications were documented. 
PIMs were prescribed to 22% of patients. The authors suggested that an assessment by a 
clinical pharmacist might help identify patients at risk and minimize PIMS.(160) Zuckerman 
and colleagues used Beers criteria (2003) to assess inappropriateness in nursing homes 
and investigated the association among inappropriate medication use in a community-
dwelling older population and their subsequent admission in nursing home. The 
prevalence of IP was 41.9% that implied the use of PIMs as the cause of increased 
nursing home admission.(161) 
 
Prevalence of IP in Australia: According to Stafford et al., IP is relatively common in 
Australian nursing homes and the prevalence and factors influencing IP are consistent with 
other countries. They investigated the prevalence of IP in older residents of residential 
aged care facilities (RACFs) in Australia using the Beers and McLeod criteria. They found 
43.8% of patients received at least one PIM; Beers criteria identified more patients with 
PIMs (35.3%) than the McLeod criteria (18.7%).(162)In older hospitalized inpatients, 
Wahab and colleagues, using the STOPP criteria identified 60% of patients on PIMs.(163) 
25 
 
In 2008, Basger et al. developed a prescribing indicator tool that addresses drug related 
problems (DRPs) in older Australians.(132)Later in 2012, using this tool to identify 
potential DRPs in a group of older Australian subjects, they found high incidence of under-
treatment, and utilization of PIMs.(164) A prospective cohort study by Beer et al. from 
Western Australia evaluated the prevalence and adverse outcomes of PIM use in 4260 
community-dwelling older men. Under-utilisation of medicines, polypharmacy and PIMs 
were observed in respectively 56.7%, 35.8% and 48.7% of the study population. A total of 
82.3% of participants reported at least one type of PIM use, which was associated with 
hospitalization.(165) Castelino et al. investigated the effect of home medication review 
(HMR) services by pharmacists, focusing on utilization of medications in 372 community-
dwelling, older people and the associated drug burden index (DBI). Beside other aims, one 
of the objectives of study was to identify the prevalence of PIM use among the study 
population.  They found that 60.5% of medications contributed to the DBI, while PIMs were 
observed in 39.8% of population. The authors observed that pharmacist recommendations 
could reduce patients’ drug burden as well as minimize PIMs.(166) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
1.4.3 Published Paper: A systematic review of prescribing criteria to evaluate 
appropriateness of medications in frail older people 
 
Poudel A, Peel NM, Mitchell C, Nissen LM and Hubbard RE. Reviews in Clinical 
Gerontology 2014; 24(04):304-318. 
This paper is reproduced in full in Appendix A. 
 
1.4.3.1 Abstract 
This study systematically reviews the published literature regarding inappropriate 
prescribing in frail individuals aged at least 65 years. Twenty-five of 466 identified studies 
met the inclusion criteria. All papers measured some surrogate indicators of frailty, such as 
performance based tests, cognitive function and functional dependency. Beers criteria 
were used in 20 (74%) studies to evaluate inappropriate medication use and 36% (9/25) 
studies used more than one criterion. The prevalence of inappropriate medications ranged 
widely from 11% to 92%. Only a few studies reported the relationship between PIMs use 
and surrogate measures of frailty. These diverse findings indicate the need for a 
standardized measure for assessing appropriateness’ of medication in frail older 
individuals. Prescribing tools should address both medication and patient related factors 
such as life expectancy and functional status to minimize inappropriate prescribing in frail 
individuals. 
 
1.4.3.2 Introduction 
The number of drug prescriptions for older people has risen progressively and has drawn 
increasing attention worldwide.(167) While older people are the principal drug consumers, 
benefits from the drug therapy can only be achieved if prescribing is appropriate.(168) 
Inappropriate prescribing (IP), defined as a situation where pharmacotherapy does not 
meet the established medical standards, is associated with negative health outcomes such 
as adverse drug events, hospitalization, redundant healthcare utilization and untimely 
death.(8) IP is more likely to have its adverse influence on frail older people who often 
have multiple co-morbidities with signs of impairment in activities of daily living. In frail 
individuals, their ability to tolerate medications becomes less due to age related changes 
in pharmacokinetics and pharmacodynamics, thereby making prescribing a more difficult 
task.(169) Furthermore, the increasing prevalence of chronic illness in frail individuals 
leads to an increase in the number of total prescriptions.  
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Several criteria have been developed to identify potentially inappropriate medications 
(PIMs) in older patients, particularly certain aspects of prescribing such as indication, drug-
drug interactions, drug-disease interaction, drug duplication and under prescribing. PIMs 
can be detected using explicit (criterion-based) or implicit (judgment-based) prescribing 
criteria.(170) Explicit criteria are derived from expert reports or published reviews. They 
have high reliability and reproducibility but focus mainly on specific drugs and disease 
states. In contrast, implicit criteria are person specific and  explore patient preferences 
rather than disease and medications, they rely on evaluator judgment and may have low 
reliability and low practical utility.(9) Yet, these guides and criteria are applicable only to 
robust, healthy older adults and cannot be generalized to frail patients.(74) Consequently, 
optimising prescribing warrants measuring the frailty level of individual patients using 
clinically validated tools and prescribing criteria that consider a patient’s quality of life, 
functional status, life expectancy and goals of care for optimal choice of drug with the 
paramount risk-benefit ratio. 
 
We conducted a systematic review to identify studies that measured the prevalence of 
potentially inappropriate prescribing in older people assessed as ‘frail’, based on the 
presence of deficits defined as symptoms, signs, disabilities and diseases contributing to 
frailty.  
 
 
1.4.3.3 Methods 
Types of Studies 
Original studies measuring inappropriate prescribing using well validated tools in a 
population assessed as frail using at least two indices of frailty were included in the review. 
 
Types of Participants 
Studies involved individuals aged 65 and older with an indication of frailty or disability. 
Patients were included in the study if they met two or more of the following criteria of frailty 
(46); disability in activities of daily living (ADL) and instrumental activities of daily living 
(IADL), impairments in general cognition and mobility, history of falls, malnutrition, low 
level of physical activity, incontinence and depression. 
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Information Sources 
The search was conducted using PubMed and EMBASE. Articles published in English 
between January 1990 and December 2013 were retrieved for analysis.  
 
Search Strategies 
Keyword searches and MeSH headings were used that included the following terms: frail 
elderly, inappropriate prescribing, suboptimal prescribing, potentially inappropriate 
medication, and inappropriate medication.  
 
Study Selection 
Initial eligibility assessment was performed by a single investigator (A.P.) who reviewed 
abstracts based on the inclusion criteria and was confirmed by a second reviewer (N.P.). 
Full articles were reviewed for final inclusion. This systematic review is reported according 
to the PRISMA guidelines.(171) 
 
Data Abstraction and Risk of Bias assessment 
For each paper, data extracted included study design, study setting, sample size, 
participant age, frailty measures, implicit/explicit criteria used and the prevalence of PIM 
use. An association between PIM use and patient characteristics was also recorded in a 
specially designed data abstraction tool.  
 
 
1.4.3.4 Results 
Study Selection 
The initial search found 466 citations (Figure 2). Of these, 135 were excluded because of 
duplication and 284 excluded after reviewing the abstracts, as they failed to meet the 
inclusion criteria. After abstract review, full text was sought for 47 articles, from which 28 
articles were excluded that did not meet the following criteria: not an original study (n=1), 
prescribing criteria not well defined (n=1), age less than 65 years (n=1), frailty 
measurement not well defined (n=9), studies focusing on particular drug or disease 
condition (n= 13), studies on the same population (n=3). Finally, 25 studies met the 
inclusion criteria including six additional studies from manual search in bibliographies.  
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Study Characteristics 
Table 4 summarizes detailed description of reviewed studies. The majority of studies were 
conducted in the inpatient hospital settings (n = 8), nursing homes or assisted living 
settings (n = 8) and in community-dwellers (n = 8) with one study in home care. The 
studies were conducted in Europe (n=12), USA (n= 9) and Oceania & Asia (n= 4). 
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Figure 2: Flowchart of systematic review
 
 
Records identified through database search 
(n=466) 
(PubMed n= 251; EMBASE n= 215) 
Records excluded: duplications (n=135)  
Potentially relevant publications (n= 331) 
Potentially relevant publications, full text 
assessed for eligibility (n= 47)  
Records excluded (n=28) 
- not an original study (n=1) 
- prescribing criteria not defined (n=1) 
- age less than 65 years (n=1)  
- weak frailty measurement method (n= 9) 
- particular disease/drug condition (n= 13) 
- studies on the same study population (n=3) 
 
 
Studies meeting the inclusion criteria 
(n=19)  
Records excluded: didn’t met inclusion criteria (n= 
284) 
 
Records retrieved by manual search (n= 6) 
 
Total studies meeting the inclusion 
criteria (n=25)  
31 
 
Table 4: Studies evaluating frailty status and describing the criteria for evaluating inappropriate prescribing in frail older individuals 
  
Reference/ 
Year/ Country 
Study 
design/setting 
 Sample (N); 
Age(Years)  
Assessment of 
frailty 
Criteria used  Results 
- prevalence of PIMs 
- population characteristics 
associated with PIM use 
Dosa et al., 
2013, 
USA(172) 
Retrospective, 
cross-sectional 
study in 
Veteran Affairs  
nursing homes 
N= 176,168, 
Age ≥75 (75%) 
Minimum Data Set 
(MDS) includes 
- CPS 
- ADL 
 HEDIS 
potentially 
inappropriate 
medications  
Between 2004 and 2009, 16.4 (± 
9.5%) veterans admitted to VA 
nursing homes received at least one 
HEDIS listed high-risk medications 
while in the facility the rate decreased 
from 23.9 (± 10%) in 2004 to 10.0 (± 
6.6%) in 2009.  
 
High-risk medication use was 
associated with being female, age 75 
and older and better cognitive and 
ADL functional status  
Fromm et al., 
2013, 
Germany(173) 
Retrospective 
cohort study 
at discharge 
from 44 
geriatric units 
N= 45809, 
Median Age = 
82 (IQR 78-86) 
Geriatric assessment 
including:  
- Barthel score 
- Timed Up-and-Go 
(TUG) test 
German 
PRISCUS list 
25.9% received at least one PIM. 
 
Use of at least one PIM was 
independently associated with 
- being female 
32 
 
- MMSE 
- GDS 
- slightly higher Barthel score 
- inability to walk independently 
Koyama et al., 
2013, 
USA(174) 
Longitudinal 
cohort study in 
community-
dwelling 
elderly women 
N= 1484, Mean 
Age 78 (±3) 
- GDS  
- Goldberg Anxiety 
Scale 
- MMSE 
 
2003 Beers At baseline, 24.3% of women were 
PIM users and 23.9% at 10 years 
follow-up was associated with: 
- high GDS 
- poor sleep quality 
- lower scores on MMSE 
- increased anxiety 
- urinary incontinence 
 
Over 10 years PIM use increased in 
those who later developed dementia. 
Dalleur et al., 
2012, 
Belgium(175) 
Cross-
sectional study 
in teaching 
hospital 
N= 302, Median 
Age 84 (IQR 81-
88) 
A positive frailty 
profile was defined as 
having two or more of 
the six Identification 
of Seniors At Risk 
(ISAR) items 
including: 
 
- Need for help in 
STOPP and 
START 
Prevalence of PIMs and PPOs was 
48% and 63% respectively.  
 
Overall inappropriate prescribing 
contributed to hospital admission and 
a history of previous falls, 
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activities of daily 
living. 
- Increase in need 
related to the current 
illness. 
- Memory problems 
- Altered vision 
- Hospitalization in 
last 6 months. 
- Daily use of ≥3 
medications at home. 
- History of recent 
multiple falls 
 
Ubeda et al., 
2012, 
Spain(176) 
Descriptive 
study in a 
nursing home 
N= 81, Mean 
Age 84 (±8) 
- Barthel index 
- MMSE 
- 2003 Beers 
-STOPP/START 
The prevalence of PIMs was 25% 
according to Beers criteria while 
STOPP identified 48% of patients 
using at least 1 inappropriate 
medication. START detected 58 
potential prescribing omissions in 
44% of patients. 
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Negative correlation between number 
of PIMs (STOPP criteria) with Barthel 
index and MMSE scores was noted.  
Chang et al., 
2011, 
Taiwan(177) 
Comparative 
study in 
teaching 
hospital   
N= 193, Mean 
Age 76 (±6) 
- Nagi Index 
- IADLs  
- MMSE 
- GDS-15 items 
- Fall 
- Comorbidities 
(including urinary 
incontinence)  
- 2003 Beers  
- Rancourt 
- Laroche 
- STOPP 
- Winit-Watjana 
-  NORGEP 
The prevalence of PIMs varied from 
24% (the NORGEP criteria) to 73% 
(the Winit-Watjana criteria) 
Depending on criteria prevalence of 
PIMs are associated with 
- higher number of chronic conditions 
- higher number of chronic 
medications 
- history of falls 
- higher IADL score 
- higher physical performance 
- higher GDS score 
 
Pozzi et al., 
2010, 
Italy(178) 
Longitudinal 
study in 
community 
dwellers 
N= 1022, Mean 
Age 73 (±7)  
- BADL 
- IADL  
1991 Beers Of the 776 participants receiving at 
least one medication at baseline, 
prevalence of at least one PIM was 
9%. 
 
Berdot et al., Multicentre N = 6343, Age - CES-D scale - 1997 Beers 31.6% of subjects reported 
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2009, 
France(179) 
prospective 
cohort study in 
community 
dwellers 
 
<75 (64%) - MMSE 
- Impaired mobility 
was assessed by 
three items of the 
Rosow and Breslau 
scale:  
- Doing heavy 
housework, 
walking half a 
mile and 
- Going up and 
down to the 
second floor 
- Fick 
- Laroche 
inappropriate medication use at 
baseline. 
 
Use of PIMs is associated with 
increased risk of falling mainly due to 
long acting benzodiazepines and 
other inappropriate psychotropics. 
Gnjidic et al., 
2009, 
Australia(180) 
A cross-
sectional 
survey on 
community-
dwelling older 
men 
N= 1705, Mean 
Age 77 (±6) 
- MMSE (score ≤ 26) 
- GDS (score ≥ 5) 
- IADL 
- 6 m walking speed 
- 20 cm narrow 6 m 
walking speed 
- Chair stand 
- Balance score 
- Grip strength 
DBI Of 1527 medications 21% were 
exposed to anticholinergic and 13% 
to sedative drugs.  
 
Higher DBI was associated with 
poorer physical performance and 
functional status  
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- History of falls 
Hosia-Randell 
et al., 2008, 
Finland(181) 
Cross-
sectional 
assessment of 
nursing home 
residents 
N= 1987, Mean 
Age 84 (±8) 
- RAI depression 
score 
- Mini Nutritional 
Assessment score 
- Dementia 
- Ability to move 
independently 
2003 Beers 34.9% regularly used at least one 
PIM.  
 
Residents taking PIMs were less 
likely to have a diagnosis of 
dementia. 
 
 
Landi et al., 
2007, 
Italy(182) 
 
 
 
 
 
 
 
 
 
 
Prospective 
cohort study in 
community  
N= 364, Mean 
Age 86 (±5) 
- Physical 
performance was 
assessed by the 4-m 
walking speed and 
the S SPPB score. 
- Muscle strength was 
assessed by hand 
grip strength 
measured by a 
dynamometer. 
- BADL 
- IADL 
- CPS 
2003 Beers At baseline prevalence of 
inappropriate drug use was 26%.  
 
Prevalence was associated with 
- cognitive impairment (higher CPS) 
- lower level of physical activity 
- higher number of medicines 
- lower score on SPPB 
 
Two or more PIMs was associated 
with 
- slower gait speed 
- lower ADL score 
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- Physical activity 
level 
- Fall history  
Spinewine et 
al., 2007, 
Belgium(24) 
Randomized, 
controlled trial 
in GEM  unit 
N= 203, Mean 
Age 82 (±6) 
- Cognitive 
impairment 
- Falls 
- ADL 
- Self rated health 
- 2003 Beers 
- MAI 
- ACOVE 
Almost 60% of prescriptions for all 
patients included in the study had at 
least one inappropriate rating at 
baseline (MAI).  
 
Approximately 30% of all patients 
included in the study were taking at 
least one drug to avoid at admission. 
(Drugs to avoid in older people) 
 
Seventy-eight percent of patients 
were eligible for at least one indicator. 
(ACOVE criteria of underuse) 
Niwata et al., 
2006, 
Japan(183) 
Cross-
sectional study 
in long-term 
care facilities 
N= 1669, Mean 
Age 84.5 
MDS assessment 
- ADL  
- CPS 
- Depression Rating 
Scale 
 
2003 Beers A total of 21.1% of the patients were 
treated with PIMs.  
 
Increase in number of medications 
and older age increased risk of PIMs. 
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Fialova et al., 
2005, 
Europe(157) 
 
 
Retrospective 
cross sectional 
study of  
elderly patients 
receiving 
home care 
N= 2707, Mean 
Age 82 (±7) 
The inter- RAI MDS-
HC instrument 
- IADL 
- ADL 
- Cognition 
- Depression 
 
- 2003 Beers 
- McLeod 
 
19.8% of patients in the total sample 
used at least 1 inappropriate 
medication combining all 3 sets of 
criteria. Substantial differences 
across Europe (5.8% in Denmark to 
41.1% in Czech Republic).  
PIM use is associated with 
polypharmacy, depression and 
younger age (< 85 years). 
Hajjar et al., 
2005, 
USA(184) 
Cross 
sectional study 
in VA Medical 
Centres.  
N= 384, Age 
≥75 (46%) 
Patients were defined 
as frail if they meet at 
least two of the 
following 10 criteria:  
-  Limitations in 
at least one 
activity of daily 
living (ADL), 
- Cerebrovascul
ar accident 
within previous 
30 days  
- History of falls, 
MAI 44% of patients had at least one 
unnecessary drug, with the most 
common reason being lack of 
indication.  
 
PIM use is associated with 
polypharmacy. 
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-  Documented 
difficulty in 
ambulating  
-  Malnutrition  
- Dementia 
-  Depression   
Lau et al., 
2005, 
USA(185) 
Longitudinal 
study in 
nursing home 
N= 3372, Age 
≥85 (50%) 
MDS assessment 
- ADL 
- Mental status 
-1997 Beers 
- 2003 Beers 
50% of all residents with an Nursing 
home stay of three months or longer 
received at least one PIMs 
 
A non-dementia mental disorder was 
associated with greater odds of PIMs 
as was having communication 
problems and less impairment in 
ADL. Having dementia was 
associated with less likelihood of PIM 
use. 
Lechevallier- 
Michel et al., 
2005, 
France(186) 
Retrospective, 
cross-sectional 
study in 
community-
dwelling 
N= 9,294, Mean 
Age 74 (±6) 
- Lawton’s IADL 
- MMSE 
- CES-D 
French criteria 
adapted from 
2003 Beers 
Nearly 40% of the participants used 
at least one PIM. 
 
This use was significantly more 
frequent among women, older 
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elderly subjects and poorly educated 
subjects. 
Onder et al., 
2005, 
Italy(187) 
Retrospective 
cohort study in 
81 hospitals 
 
 
 
N= 5152, Mean 
Age 79 (±9) 
- ADL 
- Hodkinson 
Abbreviated Mental 
Test 
 
- 2003 Beers During hospital stay, 28.6% patients 
received one or more inappropriate 
drugs.  
 
Lower prevalence of PIMs was 
observed in those more impaired in 
ADL and cognition. Higher PIM use 
was associated with polypharmacy. 
Saltvedt et al., 
2005, 
Norway(188) 
Randomized 
study in 
geriatric unit 
N= 127 in each 
unit (GEM and 
MW), Age 82 
(±5) 
Winograd targeting 
criteria : 
- Acute 
impairment of 
a single ADL, 
- Impaired 
mobility, 
- Falls, 
- Confusion, 
- Depression, 
- Dementia, 
- Malnutrition, 
1997 Beers 10% of patients in geriatric evaluation 
and management unit (GEMU) had at 
least one PIMs and 9% of patients in 
general medical wards (MW) had at 
least one PIMs. 
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- Vision or 
hearing 
impairment, 
- Urinary 
incontinence, 
- Polypharmacy 
Mamun et al., 
2004, 
Singapore(189
) 
Cross-
sectional study 
in 3 randomly 
selected 
nursing 
homes. 
N= 454, Mean 
Age 80 
Resident Assessment 
Form that measures 
functional category as 
I-IV 
1997 Beers Inappropriate medication use was 
seen in 70% of residents with a 
significant association between 
polypharmacy and inappropriate 
medication use. 
Gray et al., 
2003, 
USA(190) 
A cohort study 
in community 
residential 
care facilities 
N= 282, Mean 
Age 83 (±8) 
- ADL 
- Global Health 
Status 
- Cognitive Status 
 
- 1997 Beers 22% of residents took potentially 
inappropriate medications.  
 
Potentially inappropriate use was 
related to self-reported fair or poor 
health and number of prescription 
drugs 
Raji et al., 
2003, 
USA(191) 
Cross-
sectional study 
of community-
N= 3050, Age 
<75 (65%) 
- MMSE 
- CES-D 
- 1997 Beers 
- Zhan 
Approximately 12% of the patients 
had at least one PIMs 
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dwelling 
elderly 
Those with ≥1 chronic diseases and 
with high depressive symptoms were 
more likely to have used at least one 
PIMs. 
Hanlon et al., 
2002, 
USA(192) 
Cohort study in 
community-
dwelling 
elderly 
N= 3234, Age 
<75 (49%) 
- SPMSQ 
- ADL 
 
1997 Beers At baseline 21.0% of the population 
were using one or more inappropriate 
medications according to the Drug 
Utilization Review (DUR) criteria. 
 
The drugs-to-avoid criteria identified 
no significant associations between 
use of these drugs and decline in 
functional status. With DUR criteria, 
however, the association was 
observed between use of 
inappropriate drugs and basic self-
care 
Sloane et al., 
2002, 
USA(147) 
Cross-
sectional study 
in long term 
care facilities 
N= 2,078, Age 
≥85 (52%) 
- ADL  
- MMSE 
 
- 1997 Beers About 16.0% of these patients were 
receiving PIMs.  
 
PIM use is associated with absence 
of dementia 
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Chin et al., 
1999, 
USA(193) 
Prospective 
cohort study in 
an emergency 
department 
(ED) 
N= 898, Mean 
Age 76 (±8) 
- ADL 
- MMSE 
 
- 1997 Beers A total of 10.6% of the patients were 
taking a PIM. 
 
PIMS and adverse drug-disease 
interactions in the ED were correlated 
with worse physical function and pain. 
ACOVE: Assessing Care of Vulnerable Elders; ADL: Activity of Daily Living; ADR: Adverse Drug Reactions; BADL: Basic Activities of Daily Living; CES-D: Centre for 
Epidemiologic Studies Depression; CPS: Cognitive Performance Scale; DBI: Drug Burden Index; GDS: Geriatric Depression Scale; GEM: Geriatric Evaluation and Management; 
HEDIS: Healthcare Effectiveness Data and Information Set; IADL: Instrumental Activities of Daily Living; ISAR: Identification of Seniors At Risk; MAI: Medication 
Appropriateness Index; MDS-HC: Minimum Data Set for Home Care; MMSE: Mini-Mental State Examination; MW: Medical Ward; NORGEP: Norwegian General Practice; 
SPMSQ : Short Portable Mental Status Questionnaire; SPPB: Short Physical Performance Battery; STOPP: Screen Tool of Older Person’s Prescription; START: Screening Tool to 
Alert doctors to Right Treatment; VA: Veterans Affairs 
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Synthesis of results 
A total of 15 explicit and implicit criteria were used in the 25 studies. Of these, 14 were 
explicit (Beers, HEDIS, German PRISCUS list, STOPP/START, Rancourt, Laroche, Winit-
Watjana, NORGEP, Fick, DBI, ACOVE, McLeod, French criteria adapted from 2003 Beers, 
Zhan) and only one was implicit (Medication Appropriate Index). The most commonly used 
criteria were one of the three versions of Beers criteria (1991, 1997, and 2003) which were 
used in 20 (74%) studies. Beers criteria are one of the best known and widely used explicit 
list of medications for evaluating inappropriate medication use.(194) Three studies used 
Screening Tool of Older Person’s Prescriptions (STOPP)/Screening Tool to Alert doctors 
to Right Treatment (START) criteria to identify inappropriate medications. These latter 
tools identify respectively overuse of inappropriate medications and underuse of potentially 
appropriate medications. This differentiates them from Beers criteria.(195) Two studies 
used Laroche approach developed by a French consensus panel that proposed 36 criteria 
applicable to older people to assess inappropriate medications.(196) More than one 
criteria was used in 34% (9/27) of the studies to evaluate combined inappropriate 
medication use. Clear variation among the prevalence of inappropriate medications use 
was observed that ranged from 10.6% up to almost 92%.  
 
Frailty in patients was measured using different scales. ADLs were assessed in 15 studies, 
mental status in 14, depression and cognitive status each in 10 studies, falls in eight 
studies, IADL and physical performance in six studies. Less frequently, malnutrition was 
reported in three studies, walking speed in three studies, incontinence and grip strength in 
two studies. None of these studies used established frailty measures.  
 
1.4.3.5 Discussion 
In this overview, we compiled studies that measured the prevalence of inappropriate 
prescribing in older people assessed as frail based on presence of geriatric syndromes. 
Large variation was observed in the prevalence of inappropriate medications. The study 
settings, population characteristics and the inter country differences on availability of some 
of the listed drugs(183) might account for this variations. These study settings does not 
fully explain the differences in the prevalence of PIMs. In NH/institutionalised settings 
where the population would be expected to be frail the prevalence ranged from 9.5% to 
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70%.While the maximum prevalence was lower in community settings where the 
participants would be expected to be less frail, the prevalence still ranged from 9% to 
40%.The age of the population under study might have been a factor in determining 
prevalence of PIMs. Since polypharmacy increases with frailty and frailty increases with 
age (197) it might be expected that younger population has lower prevalence of PIMs. For 
example the prevalence of PIMs was 9% in community based study of Pozzi et al.(178) 
with the mean age of 73 years while in the study of Landiet al.(182) where the mean age 
was 86, the prevalence of PIMs was 26%.  
 
The criteria used for assessing PIMs might also have a significant role in this variation as 
some of the studies compared different criteria for prevalence of PIMs in the one 
population. For example a study in geriatric outpatients using six sets of published explicit 
criteria reported the variation of PIMs from 24% (the NORGEP criteria) to 73% (the Winit-
Watjana criteria).(177) The majority of criteria used for identifying inappropriate 
medications specifically focus on the clinical appropriateness of prescribed drugs. The MAI 
is the only criteria that go beyond the pharmacological appropriateness of a drug and 
explore other aspects of the medication management process.(125) The MAI questions 
whether the dose is correct. The MAI is also the only criterion that includes drug 
costs.(125) Most of these criteria are aimed at a healthy or robust population aged 65 
years and older and are probably not appropriate in the frail older population.  
 
Objective measures of physical, cognitive and mental functioning are significant for older 
people as they predict subsequent adverse health outcomes such as disability, 
hospitalization, nursing home admission, and death.(180) Here, frailty in older individuals 
was measured using different clinical features that included functional status, physical 
performance, mental status and vulnerability or a combination of these. Generating a 
composite measure that would meet all the criteria is difficult. Although few studies 
reported the association between PIMs with the surrogate measures of frailty or the 
geriatric syndromes, they had diverse findings. Dosa et al.(172) reported the prevalence of 
PIM was associated with better cognitive and ADL functional status, however Landi et 
al.(182) reported lower level of physical activities and worsening results on ADL score 
associated with the prevalence of PIMs. Similarly, a study by Fialova et al.(157) suggested 
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that PIM use was associated with younger age (<85 years) while a study by Niwata et 
al.(183) found that older age was associated with increased risk of PIMs. Hence, the 
measures of frailty used in these studies cannot be considered as a gold standard. 
 
Frailty can now be measured objectively, rather than by using surrogate markers. While 
several different measures have been validated,(101) the Frailty index derived from 
Comprehensive Geriatric Assessment has high potential utility for older inpatients since it 
does not rely on performance based tests and, as a continuous variable, has greater 
granularity for those at the “frail” end of the health spectrum.(198) Assessment of frailty 
may inform decision making on medication, based on the health status and risk profile of 
an individual patient.(170) Utilisation of a clinically validated tool is of utmost importance in 
identifying frail patients in clinical practice so that their management can be more 
appropriately determined. Ultimately, such a tool combined with the optimal choice of drug 
and patients’ preferences should result in better and more cost effective care.   
 
1.4.3.6 Limitations 
There were limitations to our study. The literature search was limited to articles published 
in English, so criteria published in other languages might have been missed. We 
acknowledge that the search term may not be sufficient, although the most-relevant criteria 
are likely to be included. Although we had a broad definition of frailty we might have 
missed other criteria of assessing frailty in some studies.  
 
1.4.3.7 Conclusion 
Most of the criteria used for assessing inappropriate medications are explicit, which are 
applicable only to the robust older population. While surrogate measures of frailty were 
included in the studies, frailty was poorly defined. Populations were considered frail based 
on age (such as >75) or setting (such as nursing homes).For appropriate prescribing in 
frail populations, implementing a clinically validated tool (such as frailty index) for 
assessing frailty as well as a specific tool to assess the appropriateness of therapy that 
considers patient factors such as quality of life, functional status, goal of care, and 
remaining life expectancy is warranted. 
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1.5 Summary 
Inappropriate prescribing in older populations has attracted significant attention worldwide 
as a major public health concern due to its direct correlation with morbidity, mortality and 
wastage of health resources. Frail older persons often have multiple comorbidities with 
signs of impairment in activities of daily living. Prescribing drugs for these vulnerable 
individuals is complex and potentially unsafe. Factors such as polypharmacy, multiple 
comorbidities, age-related changes in pharmacokinetics and pharmacodynamics and 
functional impairment in frail older people make pharmacotherapy a complex issue. 
Several criteria have been developed to identify the presence of inappropriate prescribing 
in older patients. They address certain aspects of medication prescribing such as 
indication, drug-drug interactions, drug-disease interaction, drug duplication, under 
prescribing. 
 
Unfortunately, there appear to be no specific criteria for assessing appropriateness of 
therapy in frail older patients. Complying with evidence-based clinical guidelines is usually 
acceptable for patients with few if any comorbidities, but as the patients’ clinical and 
functional states deteriorate leading towards frailty and disability, the goals of care and 
treatment targets need to be readjusted. This discrepancy should be addressed either by 
developing new criteria or by refining the existing tools so they are applicable in frail older 
people. These tools should support prescribing practices and improve the overall well-
being of such patients. The first and foremost step is to identify frail patients in clinical 
practice by developing a clinically validated, practical tool. Once frail patients are identified, 
there is a need for specific measures to assess appropriateness of therapy that considers 
each patient’s quality of life and the goals of care such that drugs are chosen with the most 
appropriate risk-benefit ratio. 
 
With these issues in mind, the overall aim of this thesis was to optimise medication 
prescribing in frail older people. The following chapters of this thesis will describe four 
connected phases of research that address this aim. 
 
The second chapter of this thesis concentrates on polypharmacy and frailty. It describes 
the derivation of the frailty index (FI) from an acute care dataset and relates frailty to 
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prescribing. The aim of this chapter is to evaluate the impact of polypharmacy on adverse 
outcomes in older inpatients, stratified according to their frailty status.  
 
The third chapter focuses on the prevalence of potentially inappropriate prescribing (PIP). 
As patients who are frail are often discharged to residential aged care facilities (RACFs), 
this chapter aims to identify the prevalence and nature of potentially inappropriate 
medications (PIM) using the 2012 version of the American Geriatrics Society (AGS) Beers 
Criteria in patients discharged from acute care to RACFs and explores the association of 
risk factors and PIM.   
 
Chapter 4 explores the impact of a geriatrician intervention on patients in RACFs. As 
chapter 3 reported a high prevalence of PIMs in patients in RACFs, the objective here is to 
examine whether geriatric assessment by a geriatric medicine specialist resulted in 
changes to prescribing patterns, and reduced the prevalence of PIM use in RACFs. We 
also aimed to review prospectively the medication charts in RACF to determine if 
medication changes recommended by geriatricians are implemented and sustained.  
 
Chapter 5 focuses on the development of best practice guidelines for prescribing in frail 
older people. Even after the involvement of specialist geriatrician, a moderate prevalence 
of potentially inappropriate medications was observed as noted in chapter four. Hence, the 
aim in chapter five was to develop a pragmatic, easily applied algorithm for medication 
review to help clinicians identify potentially inappropriate medications that predispose older 
patients to develop various geriatrics syndromes so that they may be discontinued.  
 
Finally, chapter six summarizes the main findings of our studies and discusses various 
methodological and theoretical aspects, followed by limitations, overall conclusions and 
implications for future research and practice.  
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Chapter 2: Adverse outcomes, polypharmacy and frailty in older inpatients 
 
2.1 Chapter Introduction 
The literature outlined in Chapter 1highlighted the prevalence of inappropriate prescribing 
practices in frail older people. Evidence suggests that these vulnerable populations often 
have multiple comorbidities, for each of which clinicians, using evidence-based guidelines 
may prescribe the recommended therapy such that these patients are then at risk of 
polypharmacy. Several studies outlined in Chapter 1reported an association between 
polypharmacy and adverse outcomes in older people in both in-patient and community 
settings. Therefore, understanding the relationship between polypharmacy and frailty and 
their consequences in older people is a key challenge from both a clinical and a public 
health perspective.(199)As such, it could be anticipated that the identification of frail older 
patients who are at risk of adverse outcomes would assist in improving their clinical 
management. 
 
The aim of this chapter was therefore to determine the prevalence of polypharmacy and its 
association with adverse outcomes among older hospitalised patients and to assess the 
additional role of frailty status of patient.  
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2.2 Submitted Paper: Adverse outcomes in relation to polypharmacy in robust and 
frail older inpatients 
 
This paper has been submitted to Journal of the American Geriatrics Society. 
 
2.2.1 Abstract 
Background: The association of polypharmacy with adverse outcomes is motivating 
programmes of medication de-prescribing for older people.  
 
Objective: To explore the relationship between polypharmacy and adverse outcomes 
among older hospital inpatients stratified according to their frailty status.  
 
Design and setting: A prospective study of 1418 patients, aged 70 and older, admitted to 
11 hospitals across Australia. 
 
Methods: The interRAI Acute Care (AC) assessment tool was used for all data collection, 
including the derivation of a frailty index calculated using the deficit accumulation method. 
Polypharmacy was categorised into three groups based on the number of regular drugs 
prescribed. Recorded adverse health outcomes were falls, delirium, functional and 
cognitive decline, discharge to a higher level of care and in-hospital mortality.  
 
Results: Patients had a mean age(SD) of 81 (6.8) years and 55% were female. 
Polypharmacy (5-9 drugs per day) was observed in 48.2% (n= 684) and hyper-
polypharmacy (≥10 drugs) in 35.0% (n= 497). Severe cognitive impairment was 
significantly associated with non-polypharmacy compared with polypharmacy and hyper-
polypharmacy groups combined (p= 0.004). In total, 591 (42.5%) patients experienced at 
least one adverse outcome. The only adverse outcome associated with polypharmacy was 
delirium. Within each polypharmacy category, frailty was associated with adverse 
outcomes and the lowest overall incidence was among robust patients prescribed 10 or 
more drugs.  
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Conclusions: While polypharmacy may be a useful signal for medication review, in this 
study it was not an independent predictor of adverse outcomes for older inpatients. A 
measure of frailty status better predicts risk of adverse outcomes in older patients. 
Extensive de-prescribing in all older inpatients may not be an intervention that directly 
improves outcomes.  
 
Keywords: adverse outcomes, frailty, older inpatients, polypharmacy 
 
2.2.2 Introduction 
Ageing is associated with the development of chronic illness and the implementation of 
guidelines for the management of these conditions has resulted in an increase in the cost 
and number of prescribed medications. Global spending on prescription medications is 
growing and is likely to reach $1 trillion by 2017.(200) In Australia, for example, 
medications account for over 14% of the annual $140.2 billion health care 
expenditure.(201) Older people are the major recipients of medications(96) with those 
aged over 65 contributing to over half of all Pharmaceutical Benefits Scheme expenditure 
(202). 
 
There is increasing concern that the prescription of multiple drugs for older people can 
cause significant harm.(203) Pharmacokinetic and pharmacodynamics changes with 
chronological age increase the risk of adverse drug events.(204) In community-dwellers, 
polypharmacy (defined as the use of 5 or more medications per day) is associated with 
falls, functional decline and mortality.(205) Among older inpatients, polypharmacy is widely 
cited as a risk factor for falls(206) and delirium(207), geriatric syndromes which 
independently predict nursing home admission.(208) 
 
On the other hand, medication can be of considerable value to older people, improving 
quality of life through symptom control, preventing cerebrovascular morbidity and reducing 
cardiovascular mortality. The absolute benefits of primary and secondary prevention are 
greatest in the oldest old (209) and the systematic under-prescription of potentially 
beneficial medicines has been implicated in adverse outcomes.(210) Definitive evidence to 
support de-prescribing is currently lacking. Recent Cochrane reviews conclude that 
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interventions to reduce polypharmacy improve prescribing practice with no clinically 
significant improvement in outcomes(211) and that medication review in hospital may 
reduce emergency department contacts but with no effect on mortality or hospital 
readmissions.(212) 
 
The relationship between polypharmacy and adverse outcomes is likely to be complex 
rather than linear. Comorbidity is a clear mediating factor, i.e. patients taking multiple 
drugs may be at greater risk because of the disease conditions triggering prescribing. The 
frailty status of patients may be another important confounder. A recent study suggested 
that frail older people are more vulnerable to the impact of fall-risk-increasing drugs than 
their more robust (fit) peers.(213) Hence, in this study we aim to determine the prevalence 
of polypharmacy and its association with adverse outcomes in hospitalised older patients 
and to assess the additional role of frailty.  
 
2.2.3 Methods 
Study sample and setting 
This was a secondary analysis of three cohorts of older patients (n=1418), aged 70 and 
older, admitted to 11 acute care hospitals in Queensland and Victoria, Australia between 
2005 and 2010, for whom data were collected prospectively. The majority (N = 1220) were 
admitted to general medical units, with 71 in orthopaedic wards and 127 in surgical wards. 
The study sites were diverse, from small secondary care centres with 120-160 beds to 
major tertiary referral centres with more than 650 beds. Patient recruitment has been 
described in detail elsewhere. (214-216) Patients were excluded if they were admitted to 
coronary or intensive care units, for terminal care only or transferred within 24 hours of 
admission to the ward.  
 
Data collection and measurement tools 
The interRAI Acute Care (AC) assessment tool was used for data collection. This 
instrument has been specifically developed for use in the acute setting to support 
Comprehensive Geriatric Assessment (CGA) of older inpatients.(217, 218) It collates 
information across a large number of domains including sociodemographic data, physical, 
cognitive and psycho-social functioning, medications, medical diagnoses, advance 
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directives, and discharge destination. Nurse assessors who were trained to use the 
interRAI AC instrument gathered data at admission (within 24 hours in the ward) and at 
discharge. To obtain information for each item in the interRAI instrument, patient and 
family interviews, direct observations, staff interview and medical records were used. A 
number of scales embedded in the interRAI instruments combine single items belonging to 
domains such as activities of daily living (ADL), instrumental activities of daily living (IADL) 
and cognition; these are used to describe the presence and extent of deficits in these 
domains.(217)  For each patient, all prescribed medication was recorded on admission 
and at discharge. Data were entered by pharmacists or pharmacy students and verified by 
a second pharmacist or geriatrician. 
 
Polypharmacy: Polypharmacy at admission was categorised into three groups based on 
the number of regular drugs prescribed. Hyper-polypharmacy was defined as concurrent 
prescription of 10 or more drugs per day; polypharmacy was defined as prescription of five 
to nine drugs and non-polypharmacy represented patients prescribed four or fewer drugs 
concomitantly. These cut-off points were based on previous studies.(33, 34) 
 
Adverse outcomes 
Fall in hospital: In-hospital fall was defined as having at least one fall during the period of 
hospitalisation. This data were collected prospectively by the research nurses using all 
available sources of information (interviewing the patient and medical staff, daily ward 
visits to review medical records, and checking the forms or systems for recording adverse 
events). 
 
Delirium in hospital: As part of the interRAI AC, varying mental function and acute changes 
in mental status from baseline were evaluated by the nurse assessors at admission and 
discharge. The two items were combined to screen for delirium. This screener has been 
validated in a prospective observational study with good positive predictive value of 
delirium.(219)  Delirium in hospital was recorded if the interRAI delirium screen was 
positive at the admission or discharge assessments or if delirium and/or any acute change 
in cognitive function was noted in the hospital records on daily ward visits by the nurse 
assessor.  
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In hospital ADL function decline: This was assessed using change in the ADL short form 
scale that consists of four items (personal hygiene, walking, toilet use, and eating). Scores 
on the ADL scale range from 0 to 16, with higher scores indicating greater 
impairment.(215) In hospital functional decline was defined as having a worse (higher) 
ADL score on discharge compared to admission. 
 
In-hospital cognitive function decline: The Cognitive Performance Scale (CPS) was used 
to measure cognitive impairment.(215) Scores range from ‘0’ to ‘6’ with higher scores 
indicating greater impairment. In hospital cognitive decline was defined as having a higher 
CPS score on discharge compared to admission.  
 
Discharged to a higher level of care: The residential status on admission was classified on 
an ordinal scale as community (independent), community (supported), institutional care 
(hospice, low or high level Residential Aged Care). Discharge to a higher level of care was 
defined as change to higher score on the ordinal scale at discharge, for example change in 
permanent living arrangement from a community to an institutional setting, and within the 
institutional environment from a low care to a high care setting. Those who died in hospital 
were excluded.  
 
In-hospital mortality: In-hospital mortality was recorded for those patients who died during 
the hospital episode. 
 
Composite adverse outcome 
To explore the association of polypharmacy with adverse outcomes, a composite adverse 
outcome (CAO) was derived as the presence of at least one adverse outcome. 
 
Frailty measurement  
A Frailty Index (FI) at admission was calculated using a well-defined methodology.(220) 
Data collected using the interRAI assessment tool was coded as deficits. Each individual’s 
deficit points were summed and divided by the total number of deficits considered (here = 
52). For example, an individual with 12 deficits out of 52 counted had an FI of 0.23.  In 
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order to tease out the impacts of frailty and polypharmacy on adverse outcomes, the 
number of medications used was excluded as a deficit in calculating the FI in these 
analyses.  
 
The FI has a potential range of 0 to 1, where 0= absence of all deficits and 1= all deficits 
present.(58) Patients were categorised into three FI groups: low (0 - 0.25), medium (0.26 - 
0.39) and high (≥0.4). Although the FI can be considered as a continuum with higher 
values representing greater frailty, a score of 0.25 has been proposed as the cut-off 
between ‘fit’ and ‘frail’ in community-dwelling older people (221) and scores of 0.4 and 
above describe older people who are dependent on others for activities of daily living and 
have a significantly higher risk of death.(65) These cut-points have also been validated in 
the inpatient setting.(222) 
 
Statistical analysis 
Data were analysed using Statistical Package for the Social Sciences 22.0 (IBM SPSS 
Statistics 22.Inc). Frequency distributions were used to describe the data and proportions 
were calculated as percent of available data. To describe characteristics across 
polypharmacy groups, comparison of means (Analysis of Variance) or medians (Kruskal-
Wallis Test) for continuous variables was used, depending on distribution of the data. For 
categorical variables, the Chi-square test was performed. Multivariate logistic regression 
analysis was used to explore the independent effects of polypharmacy on adverse 
outcomes (odds of fall in hospital, delirium in hospital, functional decline, cognitive function 
decline, discharge destination, in-patient mortality), adjusting for age and gender. A p-
value of less than 0.05 was considered statistically significant. Polypharmacy groups were 
stratified by frailty status to investigate the combined effects of polypharmacy and frailty on 
having at least one adverse outcome. Dummy variables were created to compare the risk 
of composite adverse outcome across polypharmacy/frailty groups in a logistic regression 
model. The most robust group with 10 or more medications was coded as 0 for all 
combinations as being the reference group.(223) 
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Ethics 
Ethical approval was obtained from the human research and ethics committee of each 
participating hospital and University of Queensland Medical Research Ethics Committee. 
All patients or their substitute decision-maker gave informed consent for participation. 
 
2.2.4 Results 
Patients’ mean age was 81 (6.8) years, and 55% were female. Prior to admission 86% 
were living independently in the community and 36% were living alone. Sociodemographic 
and clinical characteristics of the study population by polypharmacy categories are shown 
in Table 5. Polypharmacy was observed in almost half of the study population (n=684, 
48.2%) and hyper-polypharmacy in 497 (35.0%) patients. Patients with severe cognitive 
impairment were significantly more likely to be in the non-polypharmacy group compared 
with polypharmacy and hyper-polypharmacy groups combined (p= 0.004). The mean (SD) 
Frailty index was 0.32 (0.15) and the association between FI and polypharmacy categories 
was significant (p=0.003). 
 
Polypharmacy categories in relation to adverse outcomes are shown in Table 6. In total, 
591 (42.5%) patients experienced at least one adverse outcome. The univariate analysis 
showed no association between polypharmacy categories and adverse outcomes studied 
except that those on 5 or more medications were less likely to have delirium compared 
with the non-polypharmacy group. In multivariate analysis, when adjusted for age and 
gender, a significant relationship was observed between hyper-polypharmacy group and 
composite adverse outcomes as shown in Table 7. However, the relationship between 
polypharmacy categories and delirium was not significant when cognitive status was 
added to the model. 
 
The relationship between polypharmacy, frailty and (at least one) adverse outcome is 
illustrated in Figure 3.There was a significant association of polypharmacy and frailty with 
having at least one adverse outcome (see Appendix F). Within polypharmacy categories, 
frailer patients were more likely to have an adverse outcome. The most robust patients 
taking 10 or more drugs had the lowest incidence of adverse events. 
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Table 5: Characteristics of study population (N=1418) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: Unless otherwise stated columns represent n (%), SD Standard Deviation, a Based on the Cognitive Performance Scale (CPS), which ranges from 0 to 6  
categorised as Intact (0-1); Mild to moderate (2-4); Severe (5-6) 
 
 
 
 All 
N = 1418 
Non Polypharmacy 
<5 drugs 
n = 237 (16.7%) 
Polypharmacy 
5 – 9 drugs 
n = 684 (48.2%) 
Hyper-polypharmacy 
≥10 drugs 
n = 497 (35.0%) 
p value 
Age  mean ± SD 81.0 ± 6.8 81.0 ± 7.0 81.5 ± 7.0 80.4 ± 6.3 0.017 
 
Female 780 (55.0) 117 (49.4) 390 (57.0) 273 (54.9) 0.125 
 
Median Length of Stay (IQR) 6 (4-11) 6 (4-13) 7 (4-11) 6 (4-10) 0.640 
Cognitive status a   
 
   
Intact 
Mild to moderate 
Severe 
1016 (71.9) 
289 (20.5) 
108 (7.6) 
153 (64.6) 
55 (23.2) 
29 (12.2) 
467 (68.7) 
157 (23.1) 
56 (8.2) 
396 (79.8) 
77 (15.5) 
23 (4.6) 
 
 
<0.001 
FI 
Low FI (0-0.25)= 503 
     Intermediate FI (0.26-0.39)= 530 
High FI (0.40-1)= 922 
0.32 ± 0.15 0.30 ± 0.17 0.32 ± 0.15 0.34 ± 0.13 
 
0.003 
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Table 6: Medication prescribing in relation to adverse outcomes 
Adverse outcomes Total 
 
 
n=1418 
Non-
Polypharmacy 
(<5 drugs) 
n=237 (16.7%)  
Polypharmacy 
(5-9 drugs) 
 
n=684 (48.2%)  
Hyper 
Polypharmacy 
(≥10 drugs) 
n=497 (35.0%)  
p value 
Fall in hospital 
-no 
-yes 
 
1334 (94.1%) 
83 (5.9%) 
 
224 (94.9%) 
12 (5.1%) 
 
641 (93.7%) 
43 (6.3%)  
 
469 (94.4%) 
28 (5.6%) 
 
0.768 
Delirium in hospital 
-no 
-yes 
 
1071 (76.9%) 
322 (23.1%)  
 
158 (69.0%) 
71 (31.0%) 
 
522 (77.6%) 
151 (22.4%) 
 
391 (79.6%) 
100 (20.4%) 
 
0.006 
In hospital ADL function decline a 
-no 
-yes 
 
1249 (92.3%) 
104 (7.7%) 
 
209 (92.5%) 
17 (7.5%) 
 
601 (91.1%) 
59 (8.9%) 
 
439 (94.0%) 
28 (6.0%) 
 
0.187 
In-hospital cognitive function decline 
a 
-no 
-yes 
 
1287 (95.4%) 
62 (4.6%) 
 
214 (94.7%) 
12 (5.3%) 
 
623 (95.1%) 
32 (4.9%) 
 
450 (96.2%) 
18 (3.8%) 
 
0.610 
Discharged to a higher level of care 
a 
-no 
-yes 
 
1069 (78.6%) 
291 (21.4%) 
 
172 (76.1%) 
54 (23.9%) 
 
510 (76.9%) 
153 (23.1%) 
 
387 (82.2%) 
84 (17.8%) 
 
0.064 
In-hospital mortality 
-no 
-yes 
 
1360 (96.0%) 
57 (4.0%) 
 
226 (95.4%) 
11 (4.6%) 
 
663 (97.1%) 
20 (2.9%) 
 
471 (94.8) 
26 (5.2%) 
 
0.120 
At least one adverse outcome 
-no 
-yes 
 
801 (57.5%) 
591 (42.5%) 
 
122 (52.6%) 
110 (47.4%) 
 
379 (56.4%) 
293 (43.6%) 
 
300 (61.5%) 
188 (38.5%) 
 
0.056 
Notes: Unless otherwise stated columns represent n (%),a Excluding deaths in hospital 
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Table 7: Odds ratios relating individual adverse outcomes to polypharmacy categories 
(adjusted for age and gender) 
Adverse outcomes Polypharmacy 
4 or fewer meds* 5-9 meds 10 or more meds 
Fall in hospital 1.00 1.30 (0.67, 2.51) 
(p= 0.433) 
1.15( 0.57, 2.31) 
(p= 0.687) 
Delirium in hospital 1.00 0.63 (0.45, 0.89) 
(p= 0.007) 
0.60 (0.41, 0.85) 
(p= 0.005) 
In hospital ADL function 
decline 
 
1.00 1.22 (0.70, 2.14) 
(p= 0.495) 
0.80 (0.43,1.50) 
(p= 0.477) 
In-hospital cognitive 
function decline 
1.00 0.89 (0.45, 1.78) 
(p= 0.749) 
0.77 (0.36, 1.65) 
(p= 0.507) 
Discharged to a higher 
level of care 
1.00 0.93 (0.65, 1.33) 
(p= 0.688) 
0.73 (0.50, 1.08) 
(p= 0.115) 
In-hospital mortality 1.00 0.65 (0.31, 1.38) 
(p= 0.263) 
1.22 (0.59, 2.53) 
(p= 0.591) 
Composite adverse 
outcome 
1.00 0.83 (0.61, 1.14) 
(p= 0.250) 
0.72 (0.52, 0.99) 
(p= 0.046) 
*Reference group 
 
Figure 3: Relationship between polypharmacy, frailty and (at least one) adverse outcome 
 
 
 
Note: percentage of adverse outcomes refers to % within each polypharmacy category. 
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2.2.5 Discussion 
In this large and well-characterised cohort of older inpatients, we found no significant 
association between polypharmacy and a range of clinically relevant adverse outcomes. 
The association of polypharmacy and frailty with having at least one adverse outcome was 
significant. Within each polypharmacy category, the incidence of adverse outcomes 
increased with increasing frailty, and the most robust patients taking 10 or more drugs had 
the lowest incidence compared with other polypharmacy/frailty categories. 
 
Here, the only significant association between polypharmacy and an adverse outcome was 
an unexpected one: patients prescribed 5 or more medications were less likely to 
experience delirium compared with the non-polypharmacy group. This contrasts with 
previous studies linking incident delirium with higher numbers of prescribed drugs.(207, 
224) A possible explanation for this finding is that delirium is more frequent in those with 
dementia (225) and in this cohort, patients with dementia were prescribed fewer drugs. 
Prescribers may already be taking account of frailty status and prescribing fewer 
medications to the most vulnerable patients especially those with severe cognitive 
impairment.  The association between polypharmacy and delirium was no longer 
significant when cognitive status was added to the model. 
 
Our results are consistent with previous studies reporting no association between 
polypharmacy and falls. In an Italian nursing home, polypharmacy was not found to be a 
risk factor for fall-related injuries. The association was observed only when an injurious fall 
risk-increasing drug such as anti-arrhythmic or anti-parkinsonian drugs were part of 
patient’s therapeutic regimen.(226) A similar study in an Australian residential aged care 
facility (RACF) also reported that polypharmacy was not significantly associated with 
falls.(227) Other studies of community-dwellers have found no association between 
polypharmacy and ADL impairment in older adults.(228, 229) A randomized trial of 
interdisciplinary medication review reported no change in cognition and physical function 
even though polypharmacy was reduced.(229) Polypharmacy was not associated with 
discharge destination in our study. A similar finding was reported by a study from a tertiary 
care hospital in Australia where polypharmacy (defined as patients with 9 or more 
medications) had no association with discharge destination.(230) The lack of association 
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between polypharmacy and in-hospital mortality observed in our study was also reported 
by a study conducted in 38 hospitals in Italy.(231) 
 
This study has certain strengths. The study population is a large cohort of patients 
recruited from secondary and tertiary care settings with detailed assessment of patients’ 
functional and cognitive status and of medications prescribed. Data collection was 
comprehensive and complete with less than two percent missing data in the final analysis 
models. We also acknowledge methodological weaknesses. We investigated older 
hospitalised patients and results may not be generalizable to populations in different 
settings. Furthermore, our methodology for collection of medication data (documentation 
from patients’ prescription charts) is not the current gold standard. As an observational 
study, we can make inferences about the associations found but interventional studies 
would be needed to determine the optimal number of medications for patients according to 
their frailty status.  
 
Despite these limitations, this study provides a new insight into the relationship between 
polypharmacy and adverse outcomes. While polypharmacy stands as a valuable indicator 
for medication review, it might not be an independent marker of the quality use of 
medicines. More robust patients might tolerate a greater (but appropriate) number of 
medications regardless of their chronological age.(232) However, our results do support a 
link between polypharmacy and adverse events in older inpatients who are frail. 
Individualisation of medication prescribing, based on patients’ own goals of care as well as 
their frailty status, has considerable potential to improve outcomes and this is the focus of 
further enquiries by our group.  
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2.3 Next Steps 
The above article described the relationship between polypharmacy and a range of 
clinically relevant adverse outcomes and outlined the clinical usefulness of the 
measurement of frailty in older inpatients. Most studies use polypharmacy as a marker of 
risk, which may in fact mean the most vulnerable group of patients i.e. those with cognitive 
impairment is missed because they may be taking less medications. Frailty status of a 
patient has the potential to be used in a clinically useful paradigm in predicting adverse 
outcomes in older patients. 
 
The findings from this article could serve as a reference point to commence a rational 
discussion around medication optimisation in this patient population. However, withdrawal 
of medications particularly needs to be carefully considered in the broader context of all of 
the relevant patient factors. Wholesale medication withdrawal in all older inpatients may 
not be an intervention that directly improves outcomes. Therefore, taking into account a 
frailty status of the patient may underpin a more robust approach to these types of 
interventions.  
 
A key observation from this study was that the most frail, older subjects were discharged 
into residential aged care facilities from hospitals. Hence, in Chapter 3, we aimed to 
determine the prevalence of potentially inappropriate prescribing at discharge from acute 
care hospitals to residential aged care facility and the independent risk factors for such 
prescribing.  
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Chapter 3: Potentially Inappropriate Prescribing in Frail Older Patients Discharged 
to Residential Aged Care Facilities 
 
3.1 Chapter Introduction 
Many people who live beyond the age of 75 become frail at some point, and over 40% will 
spend time in a residential aged care facility (RACF).(233) In Australia, approximately 6% 
of people aged 65 and over live in RACF, and this proportion rises to 26% for those aged 
85 and over.(234)  Those discharged from hospital to RACFs had a higher frailty status 
(n= 206; FI = 0.42±0.15) than those discharged to the community (n= 919; FI = 0.28±0.12) 
in our dataset. 
 
For older people requiring nursing home care, admission to hospital is an opportunity to 
review and rationalise medication after weighing up the benefits and significant risks of 
polypharmacy and inappropriate prescribing. The main aim of this chapter was to 
determine the prevalence of potentially inappropriate prescribing in older hospitalised 
people returning to, or newly discharged to, RACF from the acute sector. The published 
paper also aims to identify the independent risk factors for inappropriate medication use.  
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3.2 Published Paper: Potentially Inappropriate Prescribing in Older Patients 
Discharged from Acute Care Hospitals to Residential Aged Care Facilities 
 
Poudel A, Peel NM, Nissen L, Mitchell C, Gray LC, Hubbard RE. Potentially Inappropriate 
Prescribing in Older Patients Discharged From Acute Care Hospitals to Residential Aged 
Care Facilities. Annals of Pharmacotherapy. 2014; 48(11):1425-1433. 
 
This paper is reproduced in full in Appendix B. 
 
3.2.1 Abstract 
Background: The frequency of prescribing potentially inappropriate medications (PIMs) in 
older patients remains high despite evidence of adverse outcomes from their use. Little is 
known about whether admission to hospital has any effect on appropriateness of 
prescribing. 
 
Objectives: This study aimed to identify the prevalence and nature of PIMs and explore 
the association of risk factors for receiving a PIM. 
 
Methods: This was a prospective study of 206 patients discharged to residential aged 
care facilities (RACFs) from acute care. All patients were aged at least 70 years and were 
admitted between July 2005 and May 2010; their admission and discharge medications 
were evaluated.  
 
Results: Mean patient age was 84.8 ± 6.7 years; the majority (57%) were older than 85 
years and mean (SD) Frailty Index was 0.42 (0.15).  At least one PIM was identified in 112 
(54.4%) patients on admission and 102 (49.5%) patients on discharge. Of all medications 
prescribed at admission (1728), 10.8% were PIMs and at discharge of 1759 medications, 
9.6% were PIMs.  Of total 187 PIMs on admission, 56 (30%) were stopped and 131 were 
continued; 32 new PIMs were introduced. Of the potential risk factors considered, in-
hospital cognitive decline and frailty status were the only significant predictors of PIMs. 
 
Conclusion: Although, admission to hospital is an opportunity to review the indications for 
specific medications, a high prevalence of inappropriate drug use was observed. The only 
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associations with PIM use were the frailty status and in-hospital cognitive decline. 
Additional studies are needed to further evaluate this association.  
 
Keywords: Beers criteria, frailty, inappropriate prescribing, older patients, residential aged 
care facilities 
 
3.2.2 Introduction 
Our aging population, while a consequence of societal success, does present a challenge 
to the health care system. Older people are prescribed multiple medications and are more 
prone to adverse drug events (ADEs) that lead to increased mortality and morbidity and 
higher health care cost.(169, 199, 235)Advancing age is associated with substantial 
pharmacokinetic (PK) and pharmacodynamics (PD) changes, impaired homeostasis and 
increased risk of ADEs as the physiologic changes that occur with aging make the body 
more sensitive to the effects of medications.(236) Renal function declines in older age and 
body composition changes with advancing age (relative lipid content increases; total body 
water and lean body mass decreases) which can affect drug distribution and often will 
result in drug retention and a prolonged half-life.(237) 
 
Age-related changes in PK and PD will occur with several drugs and the action of drugs 
can be altered due to age related up and down regulation of target receptors, transmitters 
and signalling pathways. Hence, the appropriate use of available pharmacotherapy 
requires consideration of both the benefits and risks of the medications. Drugs are 
classified as potentially inappropriate when the risks of treatment outweigh the 
benefits(25); they are prescribed for longer periods than clinically indicated or without any 
clear indication; they are not prescribed when indicated(163); and when they are likely to 
interact with other drugs and diseases.(8) 
 
Inappropriate prescribing in older patients can be detected using either explicit (criterion-
based) or implicit (judgment-based) screening tools.(106, 238, 239)Explicit criteria are 
derived from expert reports or published reviews. They have high reliability and 
reproducibility but focus mainly on specific drugs and disease states. By contrast, implicit 
criteria are person-specific and explore patient preferences, rather than the disease and 
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medications; they rely on evaluator judgment and tend to have low reliability and poor 
clinical utility.(74) Although these criteria address some aspects of prescribing in older 
patients, they seldom consider the frailty of such patients. The omission of health status 
from established prescribing tools may help to explain the lack of clinical benefit from 
algorithm-based medication reviews.(169) 
 
The Beers criteria are commonly used and they do measure some surrogates of frailty. 
They were originally developed in 1991(109) for use in the older nursing home population 
and have been subsequently updated in 1997, 2002 and 2012 so as to be applicable to all 
persons over 65 years of age, regardless of their place of residence.(111) The recently 
updated Beers criteria divide medications into three main categories according to major 
therapeutic classes and organ systems: 34 medications are considered potentially 
inappropriate, independent of diagnosis, 14 are to be avoided in older adults with certain 
diseases and syndromes that can  be exacerbated by the listed drug , while another 14 are 
to be used with caution in older adults.(111) Although many medications on the Beers list 
are not available in Australia, use of these criteria for evaluation of prescribing has the 
advantage of enabling international comparison. 
 
Admission to hospital is an opportune time to review and rationalize prescribing, weighing 
up the benefits of pharmacotherapy against significant risks of polypharmacy and 
inappropriate prescribing in older adults, particularly those who are frail. Pharmacists in 
hospital can play a significant role in the initiation of changes to patient’s therapy and 
management. In Australia, all major government funded hospitals provide inpatient clinical 
pharmacy services.(240) These services encompass medication management reviews 
during inpatient episodes, clinical reviews, medication reconciliation, ADE monitoring, 
patient medication counselling and provision of drug information.(241)However, little is 
known about whether admission to hospital has any effect on appropriateness of 
prescribing.  
 
Potentially inappropriate prescribing (PIP) is particularly common in long-term residents of 
aged care facilities; indeed institutionalization itself is an established independent risk 
factor for PIP.(242) Studies that have compared prevalence of potentially inappropriate 
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medications (PIMs) at admission to hospital and discharge have reported inconsistent 
results. A prospective drug surveillance in an acute medical geriatric unit in France 
reported a decreased prevalence of PIMs from 66% at admission to 43.6% at 
discharge.(243) A retrospective, non-randomised study in the Specialist Health and Ageing 
Unit in England, UK found a decreased prevalence from 26.7% at admission to 22.6% at 
discharge.(244) By contrast a similar study in Norway showed the increased prevalence of 
PIMs from 24% at admission to 35% at discharge.(245) 
 
Similar reports from Australian health care settings are limited and we cannot assume 
identical prevalence rates and PIM types in Australia due to the variations in health care 
systems and prescribing practices across countries. Therefore the main objective of this 
study was to determine the prevalence of PIP using the 2012 version of the American 
Geriatrics Society (AGS) Beers Criteria in patients discharged from acute care to 
residential aged care facilities (RACFs). We also aimed to identify whether polypharmacy, 
age, gender, in-hospital falls, delirium, functional and cognitive decline and the frailty 
status of patients were independent risk factors for receiving an inappropriate medication.  
 
3.2.3 Methods 
Study population: In this study, we undertook secondary data analyses of patients 
recruited as three separate prospective cohorts in studies originally designed to investigate 
prevalence of geriatric syndromes and quality of care in acute care settings.(214, 215, 
246) This is a prospective study of patients, aged 70 and older, who were discharged to 
RACFs (206 out of total 1418 patients) following admission to 11 acute care hospitals in 
Queensland and Victoria, Australia. The sites ranged from small secondary care centres 
(with 120 – 160 beds, n = 2), through rural hospitals (250 – 280 beds, n = 2) to 
metropolitan teaching facilities (300 – 450 beds, n = 4) and major tertiary referral centres 
(>650 beds; n = 3).  All patients were admitted to the acute care hospitals between July 
2005 and May 2010. Patient recruitment has been described in detail elsewhere.(214, 
215) Patients were excluded if they were admitted to coronary or intensive care units, for 
terminal care only or were discharged from hospital within 24 hours. Only those patients 
entering RACFs at discharge were included in the study.  
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Data collection and measurement tools: The interRAI Acute Care assessment tool was 
used for data collection.(247) interRAI is a not-for-profit research consortium with 
international collaboration from over 30 countries. It aims to improve the quality of life of 
vulnerable persons through a unified comprehensive assessment system. The interRAI 
suite consists of tools to support assessment and care planning of persons with chronic 
illness, frailty, disability, or mental health problems across care settings.(217) One of these 
tools is the interRAI Acute Care (interRAI AC) instrument that has been specifically 
developed for use in the acute setting, to support Comprehensive Geriatric Assessment 
(CGA) for older inpatients.(218) This instrument screens a large number of domains 
around socio-demographic information, physical, cognitive and psycho-social functioning, 
medications, medical diagnoses, advance directives, and discharge destination.(218) 
 
A number of scales are embedded within the interRAI instruments combine single items 
belonging to domains such as activities of daily living (ADL), instrumental activities of daily 
living (IADL) and cognition, which are used to describe the presence and extent of deficits 
in these domains.(217)Trained nurse assessors gathered data at admission (within 24 
hours in the ward) and at discharge. In completing the interRAI assessment, all available 
sources of information, including the patient, carers and medical/ nursing/ allied health 
staff were utilized, either directly as verbal reports or from written entries in hospital 
records.  For each patient, all prescribed medication, including Anatomical Therapeutic 
Classification (ATC) codes, was recorded on admission and at discharge. Data were 
entered by pharmacists or pharmacy students and verified by a second pharmacist or 
geriatrician. 
 
Measures of inappropriate prescribing: The prevalence of PIP was determined using 
the 2012 version of AGS Beers criteria. The inappropriate medications found by the study 
were classified as ‘PIMs independent of medical condition’, ‘PIMs in the presence of 
certain pathologies’ and ‘PIMs to be used with caution’, as proposed by the AGS.  
 
Deriving a Frailty Index: A Frailty index (FI), an index of accumulated deficits, was 
calculated for each individual at admission using a well-defined methodology.(46) Data 
collected using the interRAI assessment tool was coded as deficits. For example, in the 
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domain of cognition, an acute change in mental status is recorded as a dichotomous, yes/ 
no response and this was coded as deficit present (1 point) or absent (0 points). Other 
data were recorded on an ordinal scale with cut-offs for 0/ 0.5/1 deficit coded according to 
the distribution of the data. For example, the domain of vision classified into four 
categories (0: adequate, 1: minimal difficulty, 2: moderate difficulty, 3: severe difficulty, 4: 
no vision) is coded with cut-offs of 0/0.5/1 (i.e. 0 = 0, 1 = 0.5, 2-4 = 1). 
 
Deficits crossed the domains of function, cognition, mood and behaviour, disease 
diagnoses and sensory impairments. Medication use was excluded from the FI. Each 
individual’s deficit points were then summed and divided by the total number of deficits 
considered (here, 52). For example, someone with 6 deficits out of 40 counted has a FI of 
0.15. The FI has a potential score of 0-1, where 0= absence of all deficits, and 1= all 
deficits present.(58) Although the FI can be considered as a continuous variable with 
higher values representing greater frailty, 0.25 has been proposed as the cut-off between 
‘fit’ and ‘frail’ individuals.(221) 
 
Polypharmacy: Polypharmacy was categorised into three groups based on the number of 
drugs documented by the interRAI assessors who transcribed the patients’ drug charts. All 
prescribed medications were recorded approximately 24 hours after admission to hospital 
and again at discharge from hospital. These lists may have included medications used for 
a finite period in hospital to manage the patients’ acute medical conditions. Hyper 
polypharmacy was defined as concurrent use of ten or more drugs; polypharmacy was 
defined as use of five to nine drugs and non-polypharmacy represented patients using four 
or less drugs concomitantly. These cut-off points have been selected based on previous 
studies relating the risk of adverse outcomes in older people to numbers of prescribed 
medication.(248, 249) 
 
Covariates 
Fall in hospital: In-hospital fall was defined as having at least one fall during the period of 
hospitalization. These data were collected prospectively by daily chart reviews and ward 
visits by the research nurses using all available sources of information (interviewing the 
patient and medical staff, reviewing the medical records, and checking the forms or 
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systems for recording adverse events).(250) The process of data collection was based on 
the detailed instructions provided in the tool manual.(247) 
 
Delirium in hospital: As part of the interRAI AC, varying mental function and acute changes 
in mental status from baseline was assessed by nurse assessor at admission and 
discharge. The two items were combined to screen for delirium.(219) Delirium in hospital 
was recorded if delirium screened positive at the admission or discharge assessments or if 
noted in the hospital records on daily ward visits by the nurse assessor.  
 
Failure to improve in ADL: Failure in improvement of ADL was recorded as a change in the 
ADL short form scale that consists of four items (personal hygiene, walking, toilet use, and 
eating). Scores on the ADL scale range from 0 to 16, with higher scores indicating greater 
impairment.(215) Failure to improve in ADL was defined as those with some ADL 
impairment on admission who had the same or worse (higher) ADL score on discharge 
compared to admission or who developed a new ADL impairment in hospital.  
 
In-hospital cognitive function decline: The Cognitive Performance Scale (CPS) was used 
to measure cognitive impairment.(215) Score ranges from ‘0’ to ‘6’with higher scores 
indicating greater impairment. In-hospital cognitive decline was defined as having a worse 
CPS score on discharge compared to admission.  
 
Statistical analysis: Data were analysed using the Statistical Package for the Social 
Sciences 21.0 (IBM SPSS Statistics 21.Inc). A paired sample t-test was used to observe 
the relationship between admission and discharge medications. Two multiple logistic 
regression models were used to detect risk factors for PIMs at both admission and 
discharge. The number of PIMs was dichotomised into presence or absence of a PIM. 
Age, gender, number of admission and discharge medications, in-hospital falls, delirium, 
functional and cognitive decline and frailty index of patients were used as predictive 
variables for PIMs. A p-value of 0.05 was considered statistically significant.  
 
Ethics: Ethics approval was obtained from the human research and ethics committee of 
each participating hospitals and The University of Queensland Medical Research Ethics 
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Committee. All patients or their substitute decision-maker gave informed consent for 
participation. 
 
 
3.2.4 Results 
Patient characteristics: Of the 206 patients discharged to RACFs, 142 (69%) were 
female.  The principal characteristics of the study population are described in Table 8. 
They had a mean (SD) age of 84.8 (6.8) years; the majority (57%) were older than 85 
years and mean (SD) Frailty Index was 0.42 (0.15).A total of 35%were admitted from the 
community and 65% from RACFs. The median length of stay in hospital was eight days. 
Of those discharged to RACFs, approximately 60% were discharged to high care (a high 
level care setting for older people with 24-hour nursing care) and remaining 40% 
discharged to low care (residents require accommodation and personal care type services, 
but not 24-hour nursing care). 
 
General prescribing pattern: The number of medications prescribed on admission and 
discharge is shown in Table 9. Patients were prescribed a mean of 7.2 (±3.81) regular 
medications at admission and 8.1 (±3.95) on discharge to RACF. Comparing medication 
regimen at admission and discharge, the prevalence of polypharmacy was stable [106 
(51.5%) vs 102 (49.5%) respectively] but with an increase in hyper-polypharmacy [from 50 
patients (24.3%) to 67 (32.5%)]. 
 
At admission, two patients were prescribed 23 medications with 10 patients receiving at 
least 20 medications. On discharge one (different to admission) patient was prescribed 23 
medications and four patients had at least 20 medications. At discharge, aspirin and anti-
platelet agents were the most frequently prescribed medications (109, 54%), followed by 
anti-ulcer drugs in 105 (52%) patients.  Other prevalent medication included 
antidepressants (28.2%), benzodiazepines (19.3%), antipsychotics (16.3%) and opioids 
(16.3%). Of the potential risk factors, frailty status and in-hospital cognitive decline were 
the only significant predictors of PIMs at both admission (p= 0.047) and discharge (p = 
0.032). However, no association was observed between PIM use, polypharmacy 
categories, age, gender, in-hospital falls, delirium and functional decline.  
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Potentially inappropriate medications at admission: On admission, 112 (54.4%) 
patients were on at least one PIM; 5 patients were on 4 PIMs. Of the 1460 regular 
medications prescribed at admission 187 (12.8%) were PIMs. Of these, 149 (80%) were 
classified as PIMs for older people independent of diagnosis and 38 (20%) PIMs 
contraindicated in older people with certain diseases or syndromes (Table 10).  PIMs to be 
used with caution accounted for 3.8% of total medications prescribed. Commonly 
prescribed PIM categories were central nervous, cardiovascular and gastrointestinal 
system drugs, and analgesics. Multiple regression analysis revealed that frailty 
status[(p<0.05 OR= 0.92 (0.76, 1.12)] and in-hospital cognitive decline were significantly 
associated to PIMs at admission [(p<0.05 OR= 0.82 (0.62, 0.99)] (see Appendix G). 
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Table 8: Characteristics of the study population 
Characteristics Number of patients (%) 
n= 206  
 Value  At least one 
PIM at 
admission  
No PIM at 
admission 
Age distribution  
                    Mean age (SD) 84.8 (6.8) 
                    65-74 years 20 (10) 13 (11.6) 7 (7.5) 
                   75-84 years 69 (33) 41 (36.6) 28 (29.8) 
>85 years 117 (57) 58 (51.8) 59 (62.7) 
Sex (n [%])  
                   Female 142 (69) 78 (55) 64 (45) 
                   Male 64 (31) 34 (53.2) 30 (46.8) 
Admitted from (n [%])  
                  Community 73 (35.4) 35 (48) 38 (52) 
                  RACF low care 64 (31.1) 37 (57.8) 27 (42.2) 
                  RACF high care 69 (33.5) 40 (58) 29 (42) 
Discharged to(n [%])  
                 RACF low care 81 (39.3) 48 (59.2) 33 (40.8) 
                 RACF high care 125 (60.7) 64 (51.2) 61 (48.8) 
Length of stay: Median length of stay      
(days [IQR]) 
8 [4-16] 
Frailty Index: Mean (SD) 0.42 (0.15) 
Fall in hospital 27 (13.1) 16 (59.3) 11 (40.7) 
Delirium in hospital 47 (22.8) 22 (46.8) 25 (53.2) 
Failure to improve in ADL 110 (53.4) 64 (58.1) 46 (41.9) 
In-hospital cognitive function decline 37 (18.0) 11 (29.7) 26 (70.3) 
 IQR: Interquartile range; SD: Standard Deviation; RACF: Residential Aged Care Facility 
 
Potentially inappropriate medications at discharge: At discharge, 102 (49.5%) patients 
were on at least one PIM; one patient was discharged on seven PIMs, five patients on four 
PIMs and eight patients on three. Of all the 1652 regular medications prescribed at 
discharge, 168 (10.1%) were PIMs. Of these 168, 129 (77%) were classified as PIMs for 
older people independent of diagnosis and 39 (23%) of PIMs contraindicated in older 
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people with certain diseases or syndromes (Table 10). PIMs to be used with caution 
accounted for 3.7% of total medications prescribed. Commonly prescribed PIMs 
categories were Central Nervous system (CNS) drugs, cardiovascular, gastrointestinal, 
respiratory medications, analgesics and antimuscarinics. Multiple regression analysis 
showed that frailty status [(p<0.05, OR= 0.93 (0.77, 1.13)] and in-hospital cognitive decline 
[(p<0.05, OR= 0.85 (0.65, 0.96)] were significantly associated with PIMs at discharge. (see 
Appendix G) 
 
Changes in potentially inappropriate medication between admission and discharge: 
Table 9 shows the number of patients with total PIMs at admission and discharge.  Of the 
187 PIMs prescribed at admission, 56 (30%) were stopped and 131 (70%) were continued 
while 32 new PIMs were started. PIMs introduced included CNS drugs [benzodiazepines 
(14/32), antipsychotics (8/32), and antidepressants (1/32)], respiratory medications (3/32), 
antiarrhythmic (2/32), gastrointestinal (2/32) and analgesics (2/32).  
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Table 9: Polypharmacy categories and potentially inappropriate medication (PIM) 
distribution at admission and discharge 
Variables Number of patients (%) 
n= 206 
Admission Discharge 
Medication category  
0 - 4 medications (non-polypharmacy) 47 (22.8) 35 (17.0) 
5-9 medications (polypharmacy) 106 (51.5) 102 (49.5) 
≥10 medications (excessive polypharmacy) 50 (24.3) 67 (32.5) 
Missing 3 (1.5) 2 (1.0) 
Total number of medications 1460 1652 
Number of PIMs  
No PIMs 94 (45.6) 104 (50.5) 
One PIM 60 (29.1) 59 (28.6) 
Two PIMs 34 (16.5) 29 (14.1) 
Three PIMs 13 (6.3) 8 (3.9) 
Four or more PIMs 5 (2.4) 6 (2.9) 
Total number of patients with at least one PIM 112 (54.4) 102 (49.5) 
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Table 10: Potentially inappropriate medications on admission and discharge as determined by 2012 Beers criteria (n= 206) 
PIMs: Potentially Inappropriate Medications; TCAs: Tricyclic antidepressants; SNRIs: Selective Norepinephrine Reuptake Inhibitors; SSRIs Selective Serotonin Reuptake Inhibitors 
PIMs independent of medical condition PIMs in the presence of certain pathologies PIMs to be used with caution 
 Admission Discharge  Admission Discharge  Admission Discharge 
System/ 
therapeutic 
category/drugs 
N % N  % System/ 
therapeutic 
category/drugs 
N % N % System/ 
therapeutic 
category/drugs 
N % N % 
Central Nervous 
System 
106 71.1 102 79 Central Nervous 
System 
11 29.9 10 25.6 Antipsychotics 14 25.5 15 24.6 
Antidepressants 9 6 8 6.2 Antidepressants 2 5.3 2 5.1 SNRIs 3 5.5 4 6.5 
Antipsychotics 50 33.6 40 31 Antipsychotics 9 23.7 8 20.5 SSRIs 31 56.3 35 57.4 
Cardiovascular 47 31.5 54 41.8 Cardiovascular 12 31.5 9 23 TCAs 7 12.7 7 11.5 
Alpha blockers 4 2.7 4 3.1 Gastrointestinal 8 21 10 25.6      
Antiarrhythmic 14 9.4 7 5.4 Respiratory 5 13.1 8 20.5      
Gastrointestinal 23 15.5 12 9.3 Antimuscarinics 2 5.2 2 5.1      
Analgesics 2 1.4 4 3.1           
Total 149 100 129 100  38 100 39 100  55 100 61 100 
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3.2.5 Discussion 
The present study demonstrated frequent use of inappropriate medications in older people 
discharged from acute care hospitals to RACFs. 54.4% of patients were on at least one 
PIM at admission to hospital with a non-significant trend to fewer PIMs on discharge 
(49.5%). The frailty status of patients and in-hospital cognitive decline were the only 
significant predictors for receiving PIMs at both admission and discharge. To our 
knowledge, this is the first study to identify this association.  
 
The prevalence of PIMs observed in this study population differ from those of previous 
studies using the recent updated 2012 Beers criteria. A higher prevalence (82.6%) was 
observed in a Brazilian long term care home study (251) and around 66% was observed in 
an Argentinian geriatric hospital.(252) Yet, a very low prevalence (16% and 25.5%) was 
noticed in tertiary health care setting in India and Nigeria respectively.(253, 254) Inpatient 
studies using the prior versions (1997, 2003) of Beers criteria reported lower prevalence 
than that observed in our study. The 1997 Beers criteria was used for retrospective 
analyses of ED visits in US hospitals that reported 12.6% (255) and 10.6% of patients with 
PIMs (193) and 10% prevalence of PIMs were observed in a Norwegian hospital.(188) 
Using the 2003 Beers criteria, the prevalence of PIMs ranged from 12% to 37% in inpatient 
settings (255-257), was reported as 14.7% in Taiwan (258), and 30% in a study conducted 
in Belgium.(24) Commonly prescribed PIM categories at both admission and discharge 
were CNS, cardiovascular, gastrointestinal and respiratory drugs, and analgesics which 
are similar to those reported in other studies.(156, 162, 168, 259) Medications such as 
non-steroidal anti-inflammatory drugs (NSAIDs) and anticholinergic are routinely 
prescribed to treat many common conditions in older people. Although the efficacy of 
NSAIDs for the treatment of inflammation and pain of various origins is well established, 
prescribing these drugs in older patients is a challenge because of a great variety of 
gastrointestinal and cardiovascular safety factors that need to be considered.(260) 
Medications with anticholinergic effects are associated with several adverse effects such 
as sedation, cognitive decline, delirium and falls.(245) 
 
Of note, 30% of PIMs were stopped and other new PIMs were introduced at discharge. 
Although our study show that number of PIMs at discharge was lower than on admission, 
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the reduction was not significant. The proportion of those on PIMs at discharge remained 
high (49.5%). Australian studies have reported that an average of five to seven changes 
are made during hospitalisation, with cessation of two to three drugs and initiation of three 
to four.43 Over-prescribing (benzodiazepines, antipsychotics, acid suppressants) and 
inappropriate drug selection (metformin in renal impairment, long-acting oral 
hypoglycaemic) is common in Australian hospitals.(261) This contributes to increased risk 
of drug-related problems and higher incidence of PIMs during and immediately following 
hospitalisation. Although pharmacists play an important role in medication reconciliation 
review, it was outside the scope of this study to investigate the appropriateness of 
medication prescribed. The role of the pharmacist in optimising medications in older 
hospitalized patients has been established by several studies.(139, 262) Studies suggest 
that strategies to revaluate drug treatment and reduce PIM use during hospitalisation of 
patients should be undertaken by collaborative efforts of physicians and pharmacists.(263, 
264) 
 
We found a clear association between the use of PIMs, frailty status and cognitive decline 
of patients at admission and discharge. However, no association was observed between 
PIM use, age and gender, which is consistent with previous reports.(265, 266) Also, no 
association of PIM use with in-hospital falls, delirium and functional decline was observed.  
Furthermore, in contrast to other studies,(181, 267, 268) we found no association between 
polypharmacy and PIM use. There might be several reasons behind this which needs to 
be explored further. The goals of care in this vulnerable group are likely to be an 
improvement in quality of life rather than focusing on survival.(269) This could result in a 
higher prevalence of drugs for the prevention of symptoms such as analgesics for pain, 
and laxatives or antiulcer drugs for gastrointestinal symptoms.  Subsequently, although 
multiple drugs are used, the probability of having a PIM might be lower. Prolonged length 
of hospital stay (≥10 days) has been shown to have a significant association with 
polypharmacy and incidence of PIMs use.(270) The median length of hospital stay in this 
study was only 8 days which may have minimised the risk of a PIM being prescribed.  
 
There are a number of limitations to this study. The appropriateness of prescribing at the 
level of individual patients based on clinical indications and contraindications were outside 
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the scope of this study. Although patients were recruited from multiple hospital sites, the 
sample size is relatively small .The recently updated Beers criteria contain medications 
which are either not available in Australia (e.g. carisoprodol and trimethobenzamide) or 
which have been withdrawn from use here (chlorpropamide, reserpine and 
phenylbutazone). Thus, the relevance of the tool within Australia could be 
questioned.(163) Moreover, these criteria also fail to address other factors such as drug 
duplication, under-prescribing, and drug-drug interaction.(111, 116, 119) Hence, the 
prevalence of PIMs may be higher than those reported in this study. However, this study 
demonstrated the prevalence of PIMs in frail older patients on admission and discharge 
and adds to existing research by identifying patient’s frailty status as a unique risk factor 
associated with the use of PIMs.  
 
These discrepancies in Beers and other established criteria should be addressed either by 
developing new criteria or by refining the existing tools to make them more applicable to 
frail older people. The first and foremost step is to identify the frail patient in clinical 
practice by applying clinically validated tools (e.g. frailty index). Once the frail patient has 
been identified, there is a need for specific measures or criteria to assess appropriateness 
of therapy that consider such factors as quality of life, functional status and remaining life 
expectancy and thus modified goals of care.(170) 
 
3.2.6 Conclusion 
A high prevalence of potentially inappropriate drug prescribing was observed in older 
patients on admission to acute care hospitals and on discharge to RACFs. Frailty status 
and in-hospital cognitive decline of patients were risk factors for the use of PIMs.  The 
findings of this study provide a basis for designing interventions to rationalize prescribing 
in older patients. Further studies in different settings with larger population are warranted 
to evaluate the prevalence of potentially inappropriate medications and deviations in 
prescribing practices.  
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3.3 Next Steps 
This chapter provides evidence that patients discharged to RACF from hospital continue to 
be exposed to PIMs. Although an admission to hospital is an opportunity to rationalise 
medications, this was not seen in this study population. There was an increase in number 
of patients with >10 meds at discharge compared to medication regimen at admission. 
However, the results showed no association between polypharmacy and PIM use but 
identified that frailty status of a patient is a unique risk factor for receiving a PIM. This 
correlates with the results from Chapter 2 suggesting that polypharmacy might not always 
be harmful. 
 
The findings of this study suggest the need of more effective interventions in RACFs to 
rationalise prescribing. Therefore in Chapter 4, we aimed to identify if comprehensive 
geriatric assessment undertaken by a geriatric medicine specialist results in changes to 
prescribing patterns, and therefore reduces the prevalence of potentially inappropriate 
medication use in RACF populations. 
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Chapter 4: Geriatrician Interventions in Residential Aged Care Facilities 
 
4.1 Chapter Introduction 
The proven benefits of comprehensive geriatric assessment in the management of the 
clinical complexity in older population were discussed in Chapter 1.  
 
Very few studies have evaluated the impact of a geriatrician-led intervention in aged care 
facilities. The project, ‘An Outcomes Oriented Study Identifying Contributions of 
Geriatric Consultation via Video Conferencing’, based at the Princess Alexandra 
Hospital aimed to identify the contributions made by a geriatrician to the care planning of 
residents at RACFs. An important part of the consultation is the recommendation the 
geriatrician makes about patients’ medications, perhaps advising that some medications 
are stopped or others commenced. The aim of this phase (section 4.2) of research was to 
examine geriatrician reviews of RACF residents to assess advice given on medications.  
 
In the next section (section 4.3) of this chapter, we undertook a prospective review of 
medication charts in RACFs where those reviews had been undertaken to determine if the 
geriatrician recommendations are implemented and sustained in the clinical setting. 
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4.2 Published Paper: Geriatrician interventions on medication prescribing for frail 
older people in residential aged care facilities 
 
Poudel A,Peel NM, Mitchell CA, Gray LC, Nissen LM, Hubbard RE. Geriatrician 
interventions on medication prescribing for frail older people in residential aged care 
facilities. Clinical Interventions in Aging. 2015.10 
 
This paper is reproduced in full in Appendix C. 
 
4.2.1 Abstract 
Objective: In Australian residential aged care facilities (RACFs), the use of certain classes 
of potentially inappropriate medication such as antipsychotics, potent analgesics, and 
sedatives is high. Here, we examined the medications prescribed and subsequent 
changes recommended by geriatricians during comprehensive geriatric consultations 
provided to residents of RACFs via video-conference. 
 
Design: Prospective observational study.  
Setting: Four residential aged care facilities in Queensland, Australia. 
Participants: A total of 153 residents referred by General Practitioners (GPs) for 
comprehensive assessment by geriatricians delivered by video-consultation. 
 
Results: Residents’ mean (SD) age was 83.0(8.1) years and 64.1% were female. They 
had multiple co-morbidities (mean 6), high levels of dependency and were prescribed a 
mean (SD) of 9.6 (4.2) regular medications. Ninety-one percent of patients were taking five 
or more medications daily. Of total medications prescribed (n= 1469), geriatricians 
recommended withdrawal of 9.8% (n= 145) and dose alteration of 3.5% (n= 51) 
medications prescribed. New medications were initiated in 47.7% (n= 73) patients. Of the 
10.3% (n= 151) medications considered as potentially inappropriate, 17.2% were stopped 
and dose altered in 2.6%. 
 
Conclusion: There was a moderate prevalence of potentially inappropriate medications.  
However, geriatricians made relatively few changes, suggesting either that, on balance, 
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prescription of these medications was appropriate or, because of other factors, there was 
a reluctance to adjust medications.  A structured medication review using an algorithm for 
withdrawing medications of high disutility might help optimise medications in frail patients. 
Further research, including a broader survey, is required to understand these dynamics. 
 
Keywords: frail older, geriatrician intervention, potentially inappropriate medications, 
residential aged care facilities  
 
 
4.2.2 Introduction 
Many frail older people spend their final years of life in aged care facilities. In Australia, the 
proportion of older people living in care accommodation increases with age from 2% of 
people aged 65–74 years to 6% of people aged 75–84 years and 26% of people aged 85 
years and over.(271) Those living in care homes often take more medications than non-
institutionalised elderly and the risk of morbidity as a result of medication is high.(272) 
Also, the incidence of adverse drug events increases with the number of medications 
prescribed.(205) Residential aged care facilities (RACFs) in Australia are institutions in 
which prescribing of potentially inappropriate medication such as antipsychotics, potent 
analgesics, and sedatives is high, with between 25% and 30% of patients receiving such 
medication.(149, 162, 273) Ensuring high-quality care and appropriate medication use for 
these residents is challenging given their frailty, complex disabilities and multiple chronic 
conditions.(274) 
 
Despite the growing body of literature indicating that medication errors and potentially 
inappropriate medications are important causes of morbidity and mortality, evidence for 
effective interventions and strategies to improve the pharmacological management of 
patients is still limited.(275)Well-organized approaches are needed to provide specialist 
advice in nursing homes to ensure quality medical care. Practice models that include a 
pharmacist as part of the multidisciplinary team represent best practice in inpatient, 
ambulatory and community settings, and in care transitions between settings.(276) 
Geriatrician-led case conference reviews and comprehensive geriatric assessments (CGA) 
have been shown to be effective in reducing potentially inappropriate medications use and 
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improved suboptimal prescribing.(274, 277) Although access to geriatric services in 
Australian RACFs is limited, expert advice is increasingly provided by videoconferencing.  
 
In the model offered in relation to this study, a specialist geriatrician provides a 
comprehensive assessment of the patient and input into care plans via video conferencing 
(VC). Geriatricians make recommendation about patients’ medications, perhaps advising 
that some medications are stopped or others commenced. We designed this study to 
examine whether VC mediated geriatric assessment resulted in changes to medications 
prescribed, and reduced the prevalence of potentially inappropriate medication use. We 
also aimed to identify if clinical and demographic characteristics of patients influence the 
use of potentially inappropriate medications. 
 
 
4.2.3 Methods 
Study population and setting: We conducted a prospective observational cohort study of 
four RACFs in Queensland, Australia that currently have regular access to geriatric 
consultations via video-conferencing (VC).  The participating facilities were the first four to 
be supported by the geriatrician service operating out of the Centre for Research in 
Geriatric Medicine. We were able to record the information for 153 patients assessed by 
four geriatricians over the research timeframe. 
 
Data collection and Intervention: At participating facilities, geriatrician-supported CGA is 
encouraged within 4 to 12 weeks of admission. All residents are offered CGA at entry into 
the participating RACF. However, uptake is determined by referral from the treating 
general practitioners. The CGA is conducted using a structured protocol based on the 
interRAI (Resident Assessment Instrument) Long Term Facility assessment system, 
administered by a senior registered nurse. The assessment includes a comprehensive 
diagnosis list, justification of all medications documented, functional profile, cognitive 
assessment confirming the presence or absence of cognitive and mood disorders, 
recommendations for prevention and management and advanced care planning. 
Observations made by the nurse are entered into a clinical decision support system 
(CDSS) which generates a draft resident health care profile and care plan. The CDSS is 
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mounted on a web based platform to permit review and comment by a specialist 
geriatrician. interRAI is a not-for-profit research consortium with international collaboration 
from more than 30 countries that aims to improve the quality of life of vulnerable persons 
through a unified comprehensive assessment system. 
 
Ideally, one to four weeks following admission to the facility, residents who have been 
referred to a geriatrician by the GP are assessed via VC consultation by the specialist. The 
geriatrician is able to speak with the resident as well as attending RACF staff and 
resident’s family members if present. Recommendations to the GP and RACF are made, 
as necessary, regarding the resident’s care plan following the consultation. CGA is also 
offered to existing residents on an ‘as needs’ basis.  A formal functional profile is prepared, 
and a report is generated recording recommendations made by the geriatrician.  Data for 
this study were retrieved from these sources over an 18 month period from January 2013 
to August 2014.  
 
Ethics: Ethics approval was obtained from the University of Queensland Medical 
Research Ethics Committee. All patients or their substitute decision-maker gave informed 
consent for participation. 
 
Key measures: The primary outcome measure was the appropriateness of prescribing. A 
potentially inappropriate medications list was created based on those recognised by the 
American Geriatric Society (AGS) 2012 Beers Criteria (194), the McLeod criteria (118), the 
Laroche criteria (196), the PRISCUS criteria(278), and the Norwegian General Practice 
(NORGEP) criteria (279) (Table 11).  These criteria consider a medication as potentially 
inappropriate when it has a tendency to cause adverse drug events and drug toxicity in 
older adults due to its pharmacological properties and the physiologic changes of aging. 
For our study, we defined potentially inappropriate medications as those that are listed on 
any one of these criteria.  We excluded medications not available in Australia. 
Polypharmacy status was categorized into three groups based on the number of 
medications prescribed: non-polypharmacy (0–4 medications), polypharmacy (5–9 
medications) and hyper-polypharmacy (≥10 medications) (280). Complementary and as-
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required medications were excluded. Three levels of change on current prescription were 
defined as: drug stopped, dose altered, and new drug started.  
 
Statistical analysis: The Statistical Package for Social Science 21.0 (IBM SPSS Statistics 
21. Inc) was used for statistical analysis. Categorical variables were summarised using 
proportions and continuous variables using mean, standard deviation (SD) and range. In 
univariate analysis, the differences in the distribution of variables between patients with or 
without potentially inappropriate medications were compared using the chi-squared test for 
categorical variables, and non-parametric or parametric comparison of means for 
continuous variables, depending on the distribution of the data. Tests of significance were 
two-tailed, using a significance level of p ≤ 0.05.  
 
Table 11:Potentially inappropriate medications list 
Medication ATC 
Codes 
Main concerns References 
Analgesics, anti-inflammatory 
NSAID 
Aspirin >325mg/day N02BA01 – very high risk of gastrointestinal hemorrhage, ulceration, or 
perforation, which may be fatal 
 
- risk of  renal toxicity especially in patients with pre-existing 
chronic kidney disease 
 
- risk of fluid retention and fluid overload leading to 
decompensated heart failure in pati8ents with underlying cardiac 
dysfunction  
 
-  indomethacin may also have CNS side effects 
 
 
(194) 
Diclofenac M01AB05 (194) 
Ketoprofen M01AE03 (194, 278) 
Ketorolac M01AB15 (118, 194) 
Mefenamic acid M01AG01 (118, 194) 
Meloxicam M01AC06 (194, 278) 
Naproxen M01AE02 (194) 
Piroxicam M01AC01 (118, 194, 278) 
Indometacin M01AB01 (118, 194, 196, 
278) 
Etoricoxib M01AH05 (278) 
Ibuprofen M01AE01 (194) 
Opioid analgesics 
Pethidine N02AB02 – elevated risk of delirium and falls 
-  risk of neurotoxicity 
(118, 194, 278) 
    
Antiarrhythmic 
Amiodarone C01BD01 - predisposition to bradycardia and heart block (194) 
Flecainide C01BC04 - pro-arrhythmic effects (194, 278) 
Sotalol C07AA07 - pro-arrhythmic effects (194, 278, 279) 
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Disopyramide C01BA03 - potent negative inotropic effects predisposing to heart failure 
- anticholinergic activity 
(118, 194, 196) 
Digoxin > 0.125 mg/d C01AA05 - risk of toxicity especially in presence of renal insufficiency (194, 196, 278) 
Nifedipine C08CA05 - potential for postural hypotension 
- short-acting formulations associated with increased mortality in 
elderly 
(194, 196, 278) 
Spironolactone > 25 
mg/d 
C03DA01 - risk of hyperkalemia  (194) 
Diltiazem C08DB01 - potential to promote fluid retention and exacerbate heart failure (194) 
Verapamil C08DA01 (194) 
Antibiotics 
Nitrofurantoin J01XE01  long-term use associated with pulmonary side effects, renal 
impairment, liver damage 
(194, 196, 278) 
Anticholinergics 
Antihistamines 
Chlorpheniramine R06AB02 - risk of anticholinergic effect: constipation, dry mouth, visual 
disturbance, bladder dysfunction 
-  clearance reduced with advanced age, 
- increased risk of confusion and sedation, impaired cognitive 
performance 
(194, 278) 
Cyproheptadine R06AX02 (194, 196) 
Dexchlorpheniramine R06AB02 (194, 196, 279) 
Diphenhydramine R06AA02 (194, 196, 278) 
Doxylamine R06AA09 (194, 196, 278) 
Promethazine R06AD02 (194, 196, 279) 
Antiparkinson agents 
Benztropine N04AC01 - risk of anticholinergic side effects - not recommended for 
prevention of extrapyramidal symptoms due to antipsychotics 
(194) 
Antispasmodics 
Propantheline A03AB05 - highly anticholinergic, uncertain effectiveness (194) 
Oxybutynin G04BD04 – anticholinergic side effects  
– ECG changes (prolonged QT) 
(194, 196, 278) 
Solifenacin G04BD08 (194, 196, 278) 
Tolterodine (non- 
sustained release) 
G04BD07 (194, 196, 278) 
Antithrombotics 
Dipyridamole (short-
acting) 
B01AC07 - risk of orthostatic hypotension (118, 194, 196) 
Warfarin  B01AA03 - increased risk of bleeding 
 
(194, 278) 
Prasugrel B01AC22 (194, 278) 
Ticlopidine B01AC05 (194, 278) 
Antidepressants 
TCA 
Amitriptyline N06AA09 – peripheral anticholinergic side effects (e.g., constipation, dry 
mouth, orthostatic hypotension, cardiac arrhythmia) 
– central anticholinergic side effects (drowsiness, inner unrest, 
confusion, other types of delirium) 
(118, 194, 196, 
278, 279) 
Clomipramine 
 
N06AA04 (194, 196, 278, 
279) 
88 
 
 
 
Doxepin (>6mg) N06AA12 – cognitive impairment 
– increased risk of falls 
(194, 196, 278, 
279) 
Imipramine N06AA02 (118, 194, 196, 
278) 
Nortriptyline N06AA10 (194) 
SSRI 
Fluoxetine (daily use) N06AB03 – central nervous side effects (nausea, insomnia, dizziness, 
confusion) 
– hyponatremia 
(194, 278, 279) 
Paroxetine N06AB05 - confusion and other types of delirium 
– cognitive impairment 
 
11 
MAO inhibitors 
Tranylcypromine N06AF04 - hypertensive crises 
- cerebral hemorrhage  
- malignant hyperthermia 
(194, 278) 
Antiemetic drugs 
Trimethobenzamide NA - can cause extrapyramidal adverse effects (194) 
Antiepileptic drugs (AED) 
Phenobarbitone N03AA02 – sedation 
– paradoxical excitation 
- highly addictive 
(194, 278) 
Antihypertensive agents  
Clonidine C02AC01 - hypotension (orthostatic), bradycardia, syncope 
- CNS side effects: sedation, cognitive impairment 
- hypotension (orthostatic) 
– bradycardia 
– sedation 
(194, 196, 278) 
Methyldopa C01AB01 (194, 196, 278) 
Moxonidine C02AC05 (196) 
Nifedipine  C08CA05 – short-acting nifedipine: increased risk of myocardial infarction, 
increased mortality in elderly patients 
(194, 196) 
Prazosin C02CA01 - hypotension  
- dry mouth 
- urinary incontinence/impaired micturition 
- increased risk of cerebrovascular and cardiovascular disease 
(194, 196, 278) 
Terazosin G04CA03 (194, 278) 
Antipsychotics (Neuroleptic drugs) 
First-Generation (Conventional) Agents 
Chlorpromazine N05AA01 – anticholinergic and extrapyramidal side effects  
– parkinsonism 
– hypotonia 
– sedation and  risk of falls 
– increased mortality in patients with dementia 
 
(118, 194, 196, 
279) 
Fluphenazine N05AB02 (194, 196, 278) 
Haloperidol (>2mg) N05AD01 (194, 278) 
Promazine N05AA03 (194, 196) 
Trifluoperazine N05AB06 (194) 
Prochlorperazine N05AB04 (194, 196, 278, 
279) 
Second-Generation (Atypical) Agents 
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Aripiprazole N05AX12 – fewer extrapyramidal side effects 
– clozapine: increased risk of agranulocytosis and myocarditis 
(194) 
Asenapine N05AH05 (194) 
Clozapine N05AH02 (194, 196, 278) 
Olanzapine (>10mg) N05AH03 (194, 196, 278, 
279) 
Muscle relaxants 
Baclofen M03BX01 – CNS effects: amnesia, confusion, falls (196, 278) 
Solifenacin G04BD08 - anticholinergic side effects: constipation, dry mouth, CNS side 
effects 
(194, 196, 278) 
Orphenadrine N04AB02 - more sedation and anticholinergic side effects than safer 
alternatives 
(194) 
Sedative and hypnotics 
Long acting benzodiazepines 
Clonazepam N03AE01 in general, all benzodiazepines increase risk ofcognitive 
impairment, delirium, falls (muscle-relaxing effect, prolonged 
sedation) with risk of hip fracture, depression, psychiatric reactions 
(can cause paradoxical reactions, e.g., agitation, 
irritability,hallucinations, psychosis)and motor vehicle accidents in 
older adults 
(194) 
Diazepam N05BA01 (118, 194, 196, 
278, 279) 
Bromazepam N05BA08 (196, 278) 
Clobazam N05BA09 (196) 
Nitrazepam N05CD02 (196, 278, 279) 
Flunitrazepam N05CD03 (196, 278, 279) 
Short- and intermediate acting 
benzodiazepines 
 
Alprazolam N05BA12 (194, 196, 278) 
Lorazepam N05BA06 (194, 196, 278) 
Oxazepam N05BA04 (194, 196, 278, 
279) 
Temazepam N05CD07 (194, 196, 278) 
Triazolam N05CD05 (118, 194, 196, 
278) 
Non benzodiazepine hypnotics (118, 194, 196, 
278) 
Zolpidem N05CF02 (194, 196, 278) 
Zopiclone N05CF01 (196, 278, 279) 
Chloral hydrate N05CC01 (194, 278) 
Others 
Theophylline R03DA02 - risk of arrhythmias 
- no proof of efficacy in COPD 
(194, 279) 
Glipizide A10BB07 - long half-life leading to possible prolonged hypoglycemia (196) 
Cimetidine A02BA01 - confusion 
- more interactions than other H2 antagonists 
(118, 194, 196) 
Diphenoxylate A07DA01 - no proof of efficacy 
- blocks the muscarinic receptors 
(118, 196) 
ATC: Anatomical therapeutic chemical, COPD: Chronic obstructive pulmonary disease, CNS: Central nervous system, ECG: Electrocardiogram, MAO: Monoamine oxidase 
inhibitors, NSAID: Non- steroidal anti-inflammatory drugs, SSRI: Selective serotonin reuptake inhibitors, TCA: Tricyclic antidepressants.  
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4.2.4 Results 
Over the course of the study, 153 patients were assessed by the four participating 
geriatricians across four facilities. Demographics and clinical characteristics of the study 
population are presented in Table 12. The mean (± SD) patient age was 83.0 (± 8.1) years 
and 64.1% were female. The median length of stay in the facility at the time of assessment 
was 488 days (Range 6 – 3213 days). Twenty-four percent of patients were assessed 
within 12 weeks of admission to the facility. Patients had multiple co-morbidities (mean 6), 
including dementia diagnosed in 67.3%, depression in 46.4% and delirium in 11.7%.  
Other prevalent comorbidities were hypertension (35.9%); diabetes (20.9%); heart 
diseases (13.7%); and respiratory diseases (11.1%). Patients were prescribed a mean (± 
SD) of 9.6 (4.2) regular medications. Polypharmacy (≥5 medications) was seen in 91% (n= 
139) residents, half of whom (n=69) were exposed to hyper-polypharmacy (≥ 10 
medications).  
 
Of all medications prescribed (n= 1469), the geriatrician recommended withdrawal of 9.8% 
(n= 145) and dose alteration for 3.5% (n= 51) medications. Medications were stopped 
because of: adverse effects (n= 66), no clear indication/medication burden (n= 63) and 
disease cured (n= 16). Similarly, the medication dose was altered because of: adverse 
effects and other factors (n= 36), changed to ‘as required’ (n= 5), and ineffective dose (n= 
10). New medications were initiated in 47.7% (n= 73) patients (see Table 13). Potentially 
inappropriate medications prescribed (10.3%; n=151) and intervention by geriatrician are 
listed by drug classes in Table 14. At least one potentially inappropriate medication was 
prescribed to 58.2% (n= 89) patients. The univariate analysis showed that the length of 
stay was the only variable significantly associated with patients having at least one 
potentially inappropriate medication (see Table 15). Of the potentially inappropriate 
medications, the geriatrician ceased 17.2% (n= 26) medications and altered the dose in 
2.6% (n= 4). Potentially inappropriate medications stopped were: analgesics (n= 6), 
antispasmodics (n= 5), sedative and hypnotics (n= 5), antipsychotics (n= 3), antiarrhythmic 
(n= 3), antihypertensive (n= 2), gastrointestinal medications (n= 1), and antibiotics (n=1). 
The dose was altered for: antiarrhythmic (n= 2), antidepressants (n= 1) and sedative and 
hypnotics (n= 1). 
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Table 12: Demographic and clinical characteristics of study population 
Characteristics  Total 
N=153 
Age, y 
              Mean ± SD 83.0 ± 8.1 
              Median 83 
Females, n (%) 98 (64.1) 
Length of stay at the time of assessment : median length of 
stay, days [IQR] 
488 [6- 3213] 
Marital status (%) 
              Married 50 (32.6) 
              Widowed 73 (47.7) 
              Separated/Divorced 19 (12.4) 
              Never married 11 (7.1) 
Comorbidities (%) 
              Dementia 103 (67.3) 
              Delirium 18 (11.7) 
              Depression 71 (46.4) 
              Under nutrition 49 (32.0) 
              COPD*/Asthma 17 (11.1) 
              Hypertension 55 (35.9) 
              Diabetes 32 (20.9) 
Ischemic Heart Disease 21 (13.7) 
Prescription medications 
             Total number of prescribed medications 1469 
              Mean ± SD 9.6 ± 4.2 
Polypharmacy categories (%)                
              0-4 medications (non-polypharmacy) 14 (9.2) 
              5-9 medications (polypharmacy) 70 (45.8) 
              ≥ 10 medications (hyper-polypharmacy) 69 (45.1) 
*COPD: Chronic obstructive pulmonary disease; RACF: Residential aged care facility 
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Table 13: Outcomes of geriatrician intervention 
Interventions No of 
Medications 
Reasons 
Drug stopped [145 
(9.8%)] 
66 adverse effects 
63 no clear indication/medication burden 
16 disease cured or quiescent 
Dose altered [51 (3.5%)] 36 dose reduced (because of adverse effects 
and other factors) 
10 dose increased (because of ineffective 
dose) 
5 changed to  “as required’ 
New drug started [102 
(6.9%)] 
58 untreated morbidity 
23 better alternative to present therapy 
21 symptom relief 
Total medication prescribed: 1469; Total potentially inappropriate medications prescribed: 151(10.3%) 
 
Table 14: Potentially inappropriate medication prescribed and geriatrician intervention 
System/therapeutic 
category/medications 
Potentially 
inappropriatemedications 
prescribed n(%) 
Result of 
geriatrician 
intervention 
Central nervous system medications 80 (52.9)  
Antidepressants 10 (6.6) DA - 1 
Antipsychotics 21 (13.9) DS - 3 
NDS - 1 
Sedative and hypnotics 49 (32.4) DS - 5 
DA - 1 
NDS - 2 
Cardiovascular system medications 21 (13.9)  
Antiarrhythmic 12 (7.9) DS - 3 
DA - 2 
NDS - 1 
Antihypertensive 9 (5.9) DS - 2 
Gastrointestinal 6 (3.9) DS - 1 
Antihistamines 5 (3.3)  
Antithrombotic 22 (14.5)  
Antiparkinson agents 1 (0.6)  
Antispasmodics 5 (3.3) DS - 5 
Analgesics 9 (5.9) DS - 6 
Antibiotics 2 (1.3) DS - 1 
 
Total 
 
151 (100) 
DA – 4 
DS – 26 
NDS – 4 
DA: Dose altered; DS: Drug stopped; NDS: New drug started 
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Table 15: Univariate analysis of variables influencing the use of potentially inappropriate 
medications 
Characteristics Patients p-value 
Without PIMs (n= 
64) 
With at least one 
PIM (n= 89) 
Socio-demographic  
Age 83.55 ± 8.5 82.67 ± 7.8 0.513 
Sex(Female) 44 (68.8) 54 (60.7) 0.304 
Clinical 
Length of Stay 303 [70.75 – 780.50] 630 [100- 1022.50] 0.044 
Assessment status (within 12 
weeks of admission) 
18 (28.1) 19 (21.3) 0.334 
Polypharmacy (>4medications) 57 (89.1) 82 (92.1) 0.516 
Comorbid conditions 
Delirium 7 (10.9) 11 (12.4) 0.788 
Dementia 44 (68.8) 59 (66.3) 0.749 
Depression 27 (42.2) 44 (49.4) 0.375 
Undernutrition 24 (37.5) 25 (28.1) 0.218 
PIM: Potentially inappropriate medication, Values represent frequency (% of n). 
 
 
4.2.5 Discussion 
To our knowledge, this is the first study of a geriatrician intervention where the medication 
advice for residents at long term residential care facilities was specifically assessed via 
video consultation. We found moderate levels of potentially inappropriate medications 
prescribed to residents in RACFs. Geriatricians made relatively few changes. This 
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suggests that either the prescription of these medications was appropriate or other factors 
influenced the decision not to adjust medications.  
 
The aim of defining potentially inappropriate medication use is to focus on a group of 
medications for which there is common consensus about potential inappropriateness. In 
principle, the potentially inappropriate medications prescribed to RACF residents in our 
study should not have been started or continued except under certain conditions ; for 
example, amiodarone, a potentially inappropriate medication used in older people, is a 
therapy that may be indicated to treat supraventricular arrhythmias effectively in patients 
with heart failure(281); and benzodiazepines, that may increase the risk of mental decline, 
delirium, falls and fractures in older adults, may be appropriate for treating seizures, 
certain sleep disorders and anxiety disorders.(194) The reluctance on the part of the 
geriatrician in adjusting/stopping many of these potentially inappropriate medications might 
suggest that prescription of some of these medications was appropriate. It is also possible 
that patients’ (or primary care medical practitioners’) strong belief in their medications 
might impact on an otherwise appropriate reduction in the number of medications taken, 
but this was not specifically explored in our study. Despite the GPs' recognition that use of 
multiple medication is hazardous in their older patient population and the fact that GPs 
perceive it as their role in addressing the problem; they experience obstacles at different 
levels such as difficulties in keeping an overview of the exact medication intake caused by 
polypharmacy and patients' strong belief in their medication.(282) Patients are not always 
inclined to stop medication that they have been using chronically.(283) In addition to these 
patient-related factors, there might be some prescriber-related factors that hinder 
medication adjustment, such as involvement of several prescribers, use of preventive 
medication and evidence based medicine guidelines that often induce polypharmacy, 
uncertainties of precipitating disease relapse or drug withdrawal syndromes, and lack of 
risk/benefit information for the frail older residents.(203) 
 
Interventions for appropriate prescribing in older people such as education, medication 
reviews, computerised support systems and interdisciplinary team review have a positive 
impact on prescribing.(277) Yet, evidence for effective interventions to improve care in 
residential care settings is limited. A study by Crotty et al. suggested that case 
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conferences help an outreach geriatrician team to optimise medication management.(274) 
They describe the use of multidisciplinary case conference meetings to review medication 
in RACFs with significant improvement in medication appropriateness in the intervention 
group. There is conflicting evidence, however, concerning the efficacy of case conference 
medication reviews. One study using case conferencing to review the prescription and use 
of medications for community-dwelling older adults was unsuccessful in demonstrating 
change in inappropriate use of medications.(284)  A similar study in residential care 
facilities was unsuccessful in establishing changes in the number of medications.(285) 
Other approaches to optimise prescribing in frail older people might be the integration of a 
pharmacist in a team to make a collaborative approach on the quality of prescribing. 
Studies from inpatient settings suggest that the addition of a pharmacist to health care 
teams could lead to major reductions in morbidity and improved patient outcomes.(24, 
286) Another study on older patients transferring from hospital to a long-term care facility 
showed that adding a pharmacist transition coordinator on evidence-based medication 
management and health outcomes could improve aspects of inappropriate use of 
medications.(287) 
 
Optimising prescribing requires appropriate ways to taper or withdraw potentially 
inappropriate medications in older adults. Available explicit and implicit criteria for 
appropriate prescribing encompass medications that have been validated in, and applied 
to, robust, healthy populations aged 65 and older. Therefore, these approaches may not 
be applicable to the more frail and multi-morbid oldest old who reside in RACFs.(169) Most 
attention has been paid to the development of guidelines on how to initiate medications but 
there are limited studies on the most effective way to cease medications.(288, 289) 
Barriers to ceasing medications include time constraints on medical practitioners. This had 
led some to advocate that there should be some systematic approaches to follow in 
ceasing medications.(290, 291) In responding to polypharmacy and minimising potentially 
inappropriate medications, there appears a need for a practical algorithm that helps 
clinicians identify and discontinue potentially inappropriate medications using a systematic 
approach. This algorithm should signify a range of different clinical scenarios in relation to 
potentially inappropriate medications and offer an evidence-based approach to identifying 
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and, if appropriate, discontinuing such medications and/or suggesting alternative 
treatments when required.  
 
Our study has several limitations. Although, combining five different explicit criteria gives 
us an opportunity to extract a comprehensive list of potentially inappropriate medications, 
this list is not meant to regulate practice in a manner that surpasses the clinical judgement 
and the assessment of a prescriber. Also, because of our definition of potentially 
inappropriate medications as a list of drugs, the further domains of inappropriate 
prescribing such as underuse of medications and drug-drug interaction might be missed. 
Any adverse health events occurring among the residents using potentially inappropriate 
medications were also not investigated in our study. 
 
 
4.2.6 Conclusion 
In this study of 153 residents in four RACFs, we found a moderate prevalence of 
potentially inappropriate medications.  However, geriatricians made relatively few changes, 
suggesting either that, on balance, prescription of these medications was appropriate or, 
because of other factors, there was a reluctance to adjust medications.  Further research, 
including a broader survey, is required to understand these dynamics.  Medication review 
algorithms for withdrawing medications of high disutility might help optimise medication 
prescribing in frail older people. 
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4.3 A Prospective Review to Evaluate the Impact of Medication Changes 
Recommended by Consultant Geriatricians 
 
4.3.1 Introduction 
A study to identify contributions of geriatric consultation via video conferencing (VC) for 
residents at long term Residential Aged Care Facilities (RACF) was started in 2012 at 
The Centre for Research in Geriatric Medicines (CRGM), Princess Alexandra Hospital 
(PAH). Geriatricians made recommendations on patients’ medication (stopped 
medication, altered dose or commenced a new medication). Following up on such 
recommendations at the VC consultation is important for patient outcomes and safety.  
 
One of the important aspects of transition care is a follow up on recommendations 
made at the time of hospital discharge. Although data on transition of patients to 
nursing home is lacking, it has been postulated that errors in transitional care may 
result in adverse patient outcomes.(292) Similarly in our study, once the geriatrician’s 
consultation has been completed there is currently no follow-up on the 
recommendations that have been made. 
 
The aim of this study was to review the impact of these recommendations on patient 
medications 3 months after the initial VC consultation to determine the extent to 
which the medication changes recommended by the consultant geriatricians have been 
implemented in clinical practice. 
 
 
4.3.2 Methods 
This study was designed to review medication charts and care plans of patients in 
one RACF three months after they have been seen by a consultant geriatrician via VC 
where 89 subjects were assessed between January 2013 and August 2014. This RACF 
was the first among others to use this service. From the 89 subjects, 50 were randomly 
selected for review using a random number generator program. 
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To appropriately assess the impact of the geriatricians review on medication, the 
medication chart and patient medical record were reviewed. Each patient was assigned 
a unique identification number which eliminated the requirement to collect identifiable 
data at the RACF site, thus protecting the anonymity of patient specific data. Data 
collection included information on demographic characteristics of the subject, 
recommendations made by the geriatrician during initial consultation, and whether or 
not these recommendations had been implemented.  
 
 
4.3.3 Results 
Sixty records were reviewed to obtain the required sample of 50 subjects. 10 subjects’ 
medical record could not be accessed because they had passed away. The baseline 
characteristics of study sample are presented in Table 16.The mean age was 82.7 ± 8.1 
(range 62-103) and 57% were female. The median length of stay in the RACF at the time 
of assessment was 475 days (range 25-3000 days).  
 
Table 16: Baseline characteristics of study population (N=50) 
Characteristics Total 
N=153 
Age, y 
              Mean ± SD 82.7 ± 8.1 
              Median 83 
Females, n (%) 57 (64.0) 
Length of stay at the time of assessment : median length 
of stay, days [IQR] 
475 (25- 3000) 
 
Table 17 lists the categories of 126medication recommendations made for the 50 subjects 
made by the geriatricians. The most common recommendation was to stop medication 
(n=55; 43.6%), start a new medication (n=44; 35%) and alter dose (n=27; 21.4%).Table 18 
lists the categories of recommendation that were not followed within 90 days of geriatrician 
assessment. Of those 126 recommendations, only 17 (13.5%) were not followed.  
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Table 17: Categories of medication recommendations made by geriatrician 
Recommendations Frequency (%) 
Stop current medication 55 (43.6) 
Alter dose  27 (21.4) 
Start new medication 44 (35.0) 
Total  126 
 
 
Table 18: Categories of recommendations not followed 
Recommendations  Total number of recommendations not 
followed (% of categories of medication 
recommended) 
Stop current medication 7 (12.7) 
Alter dose  6 (22.2) 
Start new medication 4 (9.0) 
Total  17 
 
 
4.3.4 Discussion 
Three months after the initial consultation, we reviewed the recommendations made by 
geriatricians for patients in RACF. Almost 14% of recommendations made during 
consultations were not followed by the patients’ usual prescriber – the local GP).  
 
The reason behind the variation between the recommendation and what had been 
implemented was not determined in this study. For example, stopping a sedative may 
have resulted in increased patient agitation leading the local general practitioner (GP) to 
restart the medication. Another reason might be that sometime after the geriatrician 
assessment, the patient’s health might have declined which favoured changes in goals of 
care so the GP returned back to the previous treatment plan. Other reasons might be the 
personal views of the treating GP, costs to the patient and availability of various 
interventions. The potential reasons why some recommendations were not followed were 
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not directly investigated during the chart review. This requires further investigation that 
could include semi-structured interviews or other direct feedback from the patients’’ usual 
prescriber. 
 
This study has limitations. This was a single site study with a relatively small sample size. 
Only 60 medical records were selected and 50 reviewed because of restricted time and 
resources.  
 
 
4.3.5 Conclusion 
While most of the recommendations made by the geriatrician were acted upon by the local 
GP, approximately one in seven recommendations were not followed. This discrepancy 
needs further evaluation in order to best understand potential barriers to achieving optimal 
pharmacotherapy for this group of patients. It is hoped that the outcomes of this project will 
provide a clearer picture of the value of the geriatricians’ recommendations regarding 
RACF patient medication management.  
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4.4 Next Steps 
Given that in this group of RACF patients, geriatricians made relatively few 
recommendations to reduce the frequency of PIM use, a pragmatic and easily applied 
approach is needed to assist clinicians in identifying potentially inappropriate medications 
in order they might consider their cessation. Also, the availability and feasibility of non-drug 
alternatives needs to be better addressed. The outcomes of the research we have 
undertaken so far suggests the need for an algorithm of medication review that focuses on 
minimisation of potentially inappropriate medications in frail older people. Such an 
approach is described in Chapter 5.   
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Chapter 5: Best Practice Guidelines for Prescribing in Frail Older People 
 
5.1 Chapter Introduction 
The findings from Chapter 4 suggested that geriatrician intervention in aged care facilities 
led to relatively few changes in patients’ potentially inappropriate medication. One of the 
tools that might assist is nursing home/aged care facility specific prescribing practice 
guidelines.  
 
The well-documented prevalence and harm from potentially inappropriate medications in 
this setting should prompt clinicians to identify and stop, or reduce the dose of, 
inappropriate medications as a matter of priority.  Clinical research, guidelines and models 
of care seldom support the complex and difficult decisions about when to stop existing 
drugs or withhold new ones in frail older patients. Although tools have been developed to 
assess the appropriateness of prescribing in older people, these tools and instruments are 
often used to audit current practice and provide feedback in regard to specific patient 
cohorts. They are rarely used by clinicians in making prescribing decisions for individual 
patients in routine practice. 
 
We therefore developed a practical algorithm to help clinicians identify and discontinue 
potentially inappropriate medications that predispose older patients to develop various 
geriatrics syndromes. 
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5.2 Accepted Paper: An Algorithm of Medication Review in Frail Older People: 
Focus on Minimizing Use of Potentially Inappropriate Medications 
 
This paper has been accepted for publication in Geriatrics & Gerontology International. 
 
5.2.1 Abstract 
Aim: Frail older people typically suffer several chronic diseases, receive multiple 
medications and are more likely to be institutionalized in residential aged care facilities 
(RACFs). In such patients, optimising prescribing and avoiding use of potentially 
inappropriate medications might prevent adverse events.  This study aimed to develop a 
pragmatic, easily applied algorithm for medication review to help clinicians identify and 
discontinue potentially inappropriate medications.  
 
Methods: The literature was searched for robust evidence of association of adverse 
effects related to potentially inappropriate medications (PIMs) in older patients to identify 
potentially inappropriate medications. Prior research into the cessation of PIMs in older 
patients in different settings was synthesised into a 4-step algorithm for incorporation into 
clinical assessment protocols for patients, particularly those in RACFs.  
 
Results: The algorithm comprises several steps leading to individualised prescribing 
recommendations: 1) identify a potentially inappropriate medication; 2) ascertain the 
current indications for the medication and assess their validity; 3) assess if the drug is 
providing ongoing symptomatic benefit; 4) consider withdrawing, altering, or continuing 
medications. Decision support resources were developed to complement the algorithm in 
ensuring a systematic and patient-centred approach to medication discontinuation. These 
include a comprehensive list of potentially inappropriate medications and the reasons for 
inappropriateness, lists of alternative treatments, and suggested medication withdrawal 
protocols.  
 
Conclusions: The algorithm captures a range of different clinical scenarios in relation to 
PIMs and offers an evidence-based approach to identifying and, if appropriate, 
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discontinuing such medications. Studies are required to evaluate algorithm effects on 
prescribing decisions and patient outcomes. 
 
Keywords: algorithm, potentially inappropriate medications, medication review, 
medication withdrawal, residential aged care facilities. 
 
 
5.2.2 Introduction 
While many older people remain robust and independent, others become  frail, suffer 
chronic diseases, receive multiple medications, and are susceptible to adverse drug 
events (ADEs).(124) In addition, age-related changes in drug pharmacokinetics and 
pharmacodynamics complicate medication prescribing.(293) Identifying ways for 
optimising prescribing and minimizing harm in this vulnerable population is increasingly a 
priority for health care providers and policy makers. This is of particular importance for 
patients in residential aged care facilities (RACFs).  Frail older people are more likely to be 
institutionalized in RACFs with approximately 40% of people aged greater than 75 years 
requiring long-term residential care: this proportion is predicted to increase further as 
family and work patterns change(294). Age-specific death rates are higher among 
institutionalized versus community-living older people as a result of a higher burden of co-
morbidity and frailty.(295) 
 
Higher risks of ADEs result from medication errors, adverse drug reactions and drug-drug 
and drug-disease interactions.(296, 297) Risk factors for medication-related harm include 
polypharmacy (defined as 5 or more regularly prescribed drugs)(249) and use of 
potentially inappropriate medications (PIMs) such as selective serotonin reuptake 
inhibitors (SSRIs), hypnotics, antipsychotics, analgesics (opiates), anxiolytics and 
anticholinergic drugs which are regularly prescribed to 25% to 30% of patients in 
Australian RACFs.(149, 162, 273) Many of these drugs predispose to falls which occur in 
more than 50% of RACF residents each year (at a rate of 1.5 falls per bed per year) some 
with serious consequences such as hip fracture, hospitalization, depression and a mobility-
limiting morbid fear of falling.(273) About 40% of all hip fractures occur in RACF 
populations.(298) Delirium occurs in between 22% and 70% of patients (299), with 
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medications the sole precipitant in 12% to 39% of cases (300). Urinary incontinence 
occurs in more than 50% of RACF patients, often exacerbated by diuretics, while 
malnutrition affects about half of RACF residents secondary to reduced appetite, nausea 
or lack of attention to eating, with  analgesics, sedatives and metformin being contributory 
agents.(301) 
 
Polypharmacy is seen in over  80% of residents in RACFs (302) with between 40% and 
50%  being prescribed one or more potentially inappropriate medications (PIMs) 
associated with incidence rates of adverse drug reactions ranging  from 1 to 7 per 100 
residents per month, depending upon the method of detection.(303)  This high rate of 
polypharmacy in frail older people is driven by the high prevalence of diseases and the 
perceived need, on the part of prescribers, for more medications, reinforced by disease 
specific guidelines that invariably advocate multidrug regimens.(304) Although data on 
factors that predict individual risk of adverse consequences related to inappropriate 
prescribing are limited, it is likely that frail patients who are more likely to develop geriatric 
syndromes constitute a high risk group.(175) 
 
A number of explicit and implicit criteria for identifying instances of potentially inappropriate 
under- or over-prescribing in older people have been assessed. Some widely used and 
validated criteria include The Beers Criteria (194), the Medication Appropriateness Index 
(MAI) (125), the Screening Tool of Older Person’s Prescriptions/Screening Tool to Alert 
Doctors to the Right Treatment (STOPP/START) (305) and the Inappropriate Prescribing 
in the Elderly Tool (IPET) (121). The majority of these tools are aimed at general 
populations aged 65 and older that include healthy, robust, older adults. Hence, they may 
be less useful in identifying drugs associated with considerable risk of harm among the 
more frail and multi-morbid oldest old who reside in RACFs.(106) Moreover, there is little 
guidance on recognizing geriatric syndromes strongly associated with specific PIMs and 
how to safely taper or withdraw PIMs in such adults.  
 
Hence, we sought to develop a practical algorithm to help clinicians identify and 
discontinue PIMs that predispose older patients to develop various geriatrics syndromes. 
The algorithm aims to provide step-by-step instructions to taper and withdraw 
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inappropriate medications. It differs from the generic ‘drugs-to-avoid’ list in that it targets 
drugs of highest risk, suggests alternative therapies (which can include non-
pharmacological approaches), and informs the discontinuation process by highlighting risk 
of withdrawal or disease recurrence syndromes while recommending appropriate tapering 
regimens. In particular, this algorithm might be easier to apply by prescribers to individual 
patients and exert more impact than generic ‘drugs-to-avoid’ lists in reducing medication-
related adverse effects in long term care facilities.  
 
5.2.3 Methods 
First, we created a provisional list of PIMs based on those recognized by the American 
Geriatric Society (AGS) 2012 Beers Criteria (194), the McLeod criteria (118), the Laroche 
list (196), the PRISCUS list (278), and the Norwegian General Practice (NORGEP) criteria 
(279). These criteria consider a medication as potentially inappropriate when it has a well-
documented tendency to cause adverse drug events and drug toxicity in older adults due 
to its pharmacological properties and the physiologic changes of aging. For our study, we 
defined PIMs as those that are listed on any one of these criteria. We excluded drugs that 
are not frequently used or unavailable in Australia.  
 
Second, while not intending to perform a systematic review, we undertook a  structured 
PubMed literature search of each drug and its association with adverse effects using 
search terms including ‘falls’, ‘delirium’,  ‘depression’, ‘cognitive impairment’, ‘activities of 
daily living’, ‘adverse health outcomes’, ‘adverse effects’ and ‘geriatric syndromes’.  This 
was followed by a citation search of relevant articles.  For each of these relevant articles, a 
cited reference search was conducted using Web of Science. The final list of drugs and 
their most prevalent side effects are listed in Table 11. 
 
Third, to gather information about safe discontinuation of PIMs in older patients, a 
literature search using PubMed was made using the final list of PIMs and terms such as 
“withdrawal”, “cessation” and “discontinuation”, “stopping” and “deprescribing”. A 
comprehensive table of clinical manifestations of withdrawal or disease recurrence 
syndromes, suggested withdrawal regimen, and specific facts or recommendations 
concerning discontinuation, where applicable, was developed (Table 19). This search 
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revealed several recently published systematic reviews of strategies for minimizing use of 
potentially inappropriate medications in older patients,(211, 212, 306-310) including use of 
algorithms, which informed the design of the present algorithm, and which obviated the 
need for us to perform a more formal systematic review.  While several deprescribing 
algorithms have been proposed,(1, 103, 311) no randomized controlled trials have been 
performed to date to evaluate their effectiveness in routine care. 
 
Finally, we constructed a 4 step algorithm that guided clinicians in assessing medication 
lists of patients in RACFs, identifying medications potentially eligible for discontinuation, 
and formulating withdrawal regimens. This algorithm is a condensed form of an earlier 
version of a 10-step conceptual framework developed by Scott and colleagues that has 
been shown to have face validity in observational studies.(124) This condensed algorithm 
is targeted to a specific frail population and is expected to have easy application in busy 
clinical settings.
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Table 19: Withdrawal regimens for commonly used medications in older people 
 
GROUP OF MEDICATIONS SUGGESTED WITHDRAWAL REGIMENT 
FACTORS INFLUENCING RATE 
OF WITHDRAWAL 
TYPE OF 
SYNDROME 
CLINICAL MANIFESTATION 
REFERENCES 
CNS ACTING DRUGS 
Opioid analgesics 
 
 Slow approach: 10% dose reduction per 
week 
 Rapid approach: 25-50% dose reduction 
every few days 
Factors influencing the reduction 
rate 
Slow: 
- High starting dose 
- Occurrence of withdrawal 
syndrome 
Rapid: 
- Reason of discontinuation – 
adverse effects of the drug 
- Presence of psychiatric 
comorbidities 
- Lower starting dose 
D, W 
Restlessness 
Irritability 
Tremor 
Nausea 
Vomiting 
Diarrhea 
Increased blood pressure 
Watery eyes, runny nose, yawning, 
sweating 
Cramps and muscles aches 
(312) 
(313) 
Anxiolytics/hypnotics 
Benzodiazepines 
Z-drugs 
Dosage tapering: 
 Slow withdrawal schedules, usually 
effective in long half-life 
benzodiazepines  
 Low dose tapering with cognitively-
behavioral therapy is recommended 
depending on the indication of the drug 
(anxiety/insomnia) 
 
Switching to diazepam: 
 When using short half-life 
benzodiazepines 
- Short and intermediate half-life W 
symptoms 24-36 hr. after 
interruption, W symptoms can be 
more acute and intense 
 
- Long half-life = W symptoms up to 
1 week after interruption 
 
- W symptoms duration = 6-8 hr 
after cessation 
 
- Peak intensity = second and third 
D,W 
Most frequent:  
Tremor, confusion, anxiety, insomnia, 
nightmares, sweating, tachycardia, 
irritability 
 
Severe:  
Convulsions, psychotic reactions, 
substantial increase in blood pressure, 
increased risk of myocardial ischemia 
(314) 
(315) 
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 Might be beneficial just when patient 
experiences a severe withdrawal 
syndrome, and those who should be 
under supervision for adverse effects 
(e.g. fall, cognitive impairment, delirium)   
 
weeks 
Antidepressants 
Amitriptyline,  
Clomipramine,  
Doxepin,  
Imipramine 
Taper slowly with caution 
 
W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
H1- antihistaminics 
Dexchlorpheniramine, 
Doxylamine,  
Promethazine 
Taper slowly with caution 
 
W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
Antiepileptic 
Carbamazepine Taper slowly with caution 
 
W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
Antipsychotics 
Chlorpromazine,  
Fluphenazine,  
Trifluoperazine 
Taper slowly with caution 
 
W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
Antiparkinsonics 
Dopamine agonists 
Taper slowly with caution – for doses tapering 
refer to medication information sheets of 
individual drugs 
- Onset of W is variable 
 
- The rate of the taper does not 
appear to influence the risk of W – 
patients can experience W even 
with extremely low taper 
D, W, R 
DOPAMINE AGONIST WITHDRAWAL 
SYNDROME 
- Appears to be a class effect 
- Dopamine dysregulation syndrome – 
severe dyskinesia  
- Anxiety, panic attacks, social phobia, 
(317) 
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- Duration of W is variable  (months 
to years)  
 
- Doesn’t react to levodopa 
treatment – avoid overmedication 
 
- Levodopa treatment can be used 
for fixation of baseline non-motor 
and motor PD symptoms 
 
agoraphobia, irritability, dysphonia, 
depression, suicidal ideation 
- Diaphoresis, fatigue, flushing, nausea, 
vomiting (these autonomic symptoms can 
be extremely severe) 
- Paradoxical orthostatic hypotension 
- Generalized pain, restless legs (even if 
there is no prior history) 
 
 
Levodopa Taper slowly with caution 
Additional risk factor leading to W:  
- Neuroleptic medication 
- Dehydration 
- Excessively hot weather 
- Wearing-off phenomenon 
 
 
W, D, R 
PARKINSONISM-HYPERPYREXIA 
SYNDROME (also called NEUROLEPTIC 
MALIGNANT-LIKE SYNDROME, 
LEVODOPA-WITHDRAWAL 
HYPERTERMIA): 
- Typically develop in 18 hours to 7 days 
after trigger – patient becomes rigid, 
sometimes with tremor, and progresses to 
immobile status 
- Within 72-96 hours most patients develop 
pyrexia ( >38 °C) and a reduced conscious 
level ranging from conscious to coma 
- After that autonomic dysfunction with 
tachycardia, labile blood pressure and 
diaphoresis follows 
- Laboratory leukocytosis, elevated 
creatinine kinase 
(318) 
Drugs for Alzheimer’s disease 
Anticholinesterases Taper slowly with caution  W, D Delirium (319) 
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CARDIOVASCULAR DRUGS 
Antihypertensives 
Alpha-blockers Taper slowly with caution  W, R 
Agitation, headache, hypertension, 
palpitations 
(316) 
Central-acting drugs Taper slowly with caution  W, D, R Hypertension (320) 
Beta-blockers Taper slowly with caution  W, D, R 
Angina, anxiety, hypertension, acute 
coronary syndrome, tachycardia  
(316) 
ACEI Taper slowly with caution  D Heart failure, hypertension (316) 
Sartans Taper slowly with caution  D Heart failure, hypertension (316) 
Calcium channel blockers Taper slowly with caution  D Hypertension  
Diuretics Taper slowly with caution  D Heart failure, hypertension (316) 
Antiarrhythmics 
Amiodarone Can be withdrawn without tapering 
Drug has a very long half-life and 
therefore no need to taper 
   
Digoxin   D Heart failure, palpitations (316) 
Other CVS medications 
Disopyramide Taper slowly with caution  W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
GASTROINTESTINAL TRACT DRUGS 
Antiulcerotics 
Proton pump  inhibitors Taper slowly  
- R can occur after a second week 
of discontinuation and can last up to 
2-3 months (probably depends on 
the previous length of treatment with 
PPI) 
- Evidence shows higher prevalence 
among patients not infected by H. 
pylori 
D, R 
REBOUND ACID HYPERSECRETION 
- Increase in gastric acid secretion above 
pre-treatment levels 
- Contribution to recurrence of 
gastroesophageal reflux disease (GERD)  
(321) 
(322) 
(323) 
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ACEI: Angiotensin-converting enzyme inhibitors, CNS: Central Nervous System, D: Disease recurrence, R: Rebound, W: Withdrawal 
 
H2 antagonists Taper slowly  
Evidence suggest short term, not 
severe rebound phenomena 
compared to PPI  
D, R 
REBOUND ACID HYPERSECRETION  
- Increase in gastric acid secretion above 
pre-treatment levels 
- Contribution to recurrence of GERD 
 
(323) 
Stimulant laxatives  
Bisacodyl, senna, sodium 
picosulfate 
Taper slowly 
- Usually need cognitively-
behavioral therapy 
- Need for control of electrolyte and 
metabolic disturbances 
- Utilization of fiber/osmotic 
supplements to establish normal 
bowel movements 
D, W Obstipation, GIT disorders and discomfort (324) 
Spasmolytics with anticholinergic effect 
Dicyclomine, Hyoscyamine, 
Belladonna, Scopolamine, 
Diphenoxylate 
Taper slowly with caution  W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
OTHER DRUGS 
Genital-urinary antispasmodics 
Oxybutynin,  
Tolterodine 
Taper slowly with caution  W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia, 
restlessness 
(316) 
Antiasthmatics 
Ipratropium bromide Taper slowly with caution  W 
Anxiety, nausea, vomiting, headache, 
dizziness, dyskinesia, insomnia 
(316) 
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5.2.4 Results 
Proposed medication review algorithm 
The 4-step algorithm is shown in Figure 4. Each step and the recommended process for 
withdrawing medications identified as inappropriate are described below with supporting 
evidence. 
 
1) Identify a high risk PIM: Potentially inappropriate medications are those that tend to 
cause ADEs in older adults due to their pharmacological properties interacting with the 
physiologic changes of aging. The list of potentially inappropriate medications and their 
associated risk of adverse effects contained in Table 11 underscored this step. We do not 
claim this list is exhaustive, and the safety of other drugs not included here has to be 
considered depending on the patient’s individual circumstances. 
 
2) Ascertain and validate current indications for each PIM: Once PIMs are identified, 
their indications must be ascertained and validated, which involves 2 steps – verifying the 
diagnosis against formal diagnostic criteria and then verifying the indication according to 
evidence of benefit (or utility) of the drug gained from clinical studies whose participants 
resemble patients living in RACFs. In validating indications in this patient population with 
limited life expectancy, evidence of the effects of drugs on improving symptoms, function 
and quality of life should be considered no less important than that which relates to 
reduction in risk of future adverse clinical events.  
 
In cases where there is no valid diagnosis or indication, medication withdrawal should be 
strongly considered, although the outcome of any previous trial of discontinuation needs to 
be taken into account. If a previously discontinued medication was recommenced because 
of withdrawal symptoms, disease relapse or for other reasons, then further assessment of 
the current or future level of benefit or harm which the drug confers on the patient should 
be considered in justifying another trial of discontinuation. If no previous attempt at 
discontinuation has been performed, then the medication should be ceased using an 
appropriate withdrawal regimen (Table 19). For those PIMs where a valid current 
diagnosis-specific indication appears to exist, further steps of the algorithm should be 
followed. 
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Figure 4: Algorithm of medication review process identifying potentially inappropriate 
medications, their indications, and protocols for modification 
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3) Determine if the drug is providing ongoing symptomatic benefit: Use of 
medications in frail patients should be prioritised according to their ability to suppress 
disabling or troubling symptoms of currently active disease as opposed to primary or 
secondary prevention of future disease events, especially those unlikely to occur within the 
patient’s remaining lifespan.(325) According to this step, a medication can essentially 
belong to one of two categories: 1) drugs providing immediate symptomatic benefits (e.g. 
analgesics or thyroxine) or essential to preventing rapid symptomatic deterioration (e.g. 
diuretics and ACE inhibitors in severe systolic heart failure); 2) drugs having no effect on 
symptoms and primarily used to prevent disease complications in the medium to long-term 
future. Potentially inappropriate medications in the former category will need to be 
assessed for eligibility for discontinuation on a case by case basis, based on the balance 
between the magnitude of immediate symptomatic benefit and the magnitude of risk of 
short-term harm, and the availability of equally effective non-pharmacological treatment 
options. Potentially inappropriate medications in the second category should be 
considered for discontinuation in almost all cases, unless it is estimated that the risk of a 
catastrophic disease event is very high and likely to occur in the relatively near future (6 to 
12 months).   
 
4) Consider withdrawing, altering, or continuing medications: Randomized and 
observational trials involving patients over 65 years of age have demonstrated minimal 
harm and improved outcomes when certain classes of medications such as anti-
hypertensives, benzodiazepines, and antipsychotics are withdrawn under supervision in 
appropriate cases.(326) Where a currently prescribed PIM is causing, or has caused, an 
ADE, a trial of discontinuation is definitely warranted. Review of the medication in the 
context of each patient’s clinical status should seek to determine which of the following 
four steps should occur next:  
 Adjustment of the medication dosage or frequency 
 Change to a safer alternative from the same drug class or from another 
pharmacologically similar drug class which is generally considered to be safer 
(Table 20) 
 Use of a non-pharmacological strategy when available and appropriate (Table 20) 
 Withdrawal of the medication (Table 19) 
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Any decision regarding stopping, altering or starting medicines must be tailored to 
individual patient circumstances and take into account  each patient’s  life expectancy, 
values and preferences, and the likely positive or negative impact of the drug on the 
patient’s quality of life.  
 
It is important to note that, in recognition of the complexity of a patient’s clinical status and 
limitations in the available evidence of benefit of many drugs in older, frail, multi-morbid 
patients, the algorithm is not intended to be a normative tool but more a cognitive guide to 
help clinicians including pharmacists determine whether, in individual patients, medications 
pose inordinate risk of harm and, if so, to consider what can be done to reduce this risk. 
 
Table 20: Alternative management strategies for commonly used PIMs in older people 
Medication ATC Codes 
ALTERNATIVE MANAGEMENT STRATEGIES  
Alternative medication/Non-pharmacological interventions 
References 
Analgesics, anti-inflammatory 
NSAID 
Aspirin >325mg/day N02BA01 
ALTERNATIVE MEDICATION: 
- Paracetamol 
- Opioids – tramadol, codeine 
- NSAIDs in low dose  for a limited period of time 
 
 
 
NON-PHARMACOLOGICAL  INTERVENTIONS  
- Cognitive-behavioral therapy 
- Cold/heat application 
- Massage 
- Exercise 
- Immobilization 
(278, 327) 
 
Diclofenac M01AB05 
Ketoprofen M01AE03 
Ketorolac M01AB15 
Mefenamic acid M01AG01 
Meloxicam M01AC06 
Naproxen M01AE02 
Piroxicam M01AC01 
Indomethacin M01AB01 
Etoricoxib M01AH05 
Ibuprofen M01AE01 
Opioid analgesics 
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Pethidine N02AB02 - Relaxation techniques 
Antiarrhythmic 
Flecainide C01BC04 
ALTERNATIVE MEDICATION: 
- Beta blockers 
- Amiodarone  
(278) 
Sotalol C07BA07 
ALTERNATIVE MEDICATION: 
- Cardio selective beta blockers (metoprolol, bisoprolol, carvedilol) 
- Amiodarone, propafenon (depending on the type of arrhythmia) 
(278) 
Disopyramide C01BA03 
ALTERNATIVE MEDICATION: 
- Amiodarone, or other antiarrhythmic 
(196) 
Digoxin > 0.125 mg/d C01AA05 
ALTERNATIVE MEDICATION: 
- Digoxin 0.125mg/day with serum concentration between 0.5 – 1.2 
ng/ml 
(196) 
Nifedipine C08CA05 
ALTERNATIVE MEDICATION: 
- Other antihypertensive, e.g. ACEI, AT1 blockers, thiazide diuretics, 
beta blockers 
- Long-acting calcium channel blockers  with peripheral effect 
(278) 
Antibiotics 
Nitrofurantoin J01XE01 
ALTERNATIVE MEDICATION: 
- Antibiotics with renal  elimination according to the antibiogram 
- Other antibiotics – cephalosporin, cotrimoxazole, trimethoprime 
- Use of the sensitivity and resistance test 
(196, 278) 
Anticholinergics 
Antihistamines 
Chlorpheniramine R06AB02 
ALTERNATIVE MEDICATION: 
- Cetirizine, desloratadin, loratadine 
(196, 278) 
Cyproheptadine R06AX02 
Dexchlorpheniramine R06AB02 
Diphenhydramine R06AA02 
Doxylamine R06AA09 
Promethazine R06AD02 
Antiparkinson agents 
118 
 
 
 
Benztropine N04AC01 
ALTERNATIVE MEDICATION: 
- Other antiparkinsonian drugs 
(194) 
Antispasmodics 
Oxybutynin G04BD04 ALTERNATIVE MEDICATION: 
- Other drugs with lower anticholinergic activity 
 
NON-PHARMACOLOGICAL  INTERVENTIONS 
- Exercise of pelvic floor 
- Physical and behavioral therapy 
(196, 278) 
Solifenacin G04BD08 
Tolterodine (non- 
sustained release) 
G04BD07 
Antithrombotics 
Dipyridamole (short-
acting) 
B01AC07 
ALTERNATIVE MEDICATION: 
- Clopidogrel 
- Aspirin  
(196, 278) 
Warfarin B01AA03 
Prasugrel B01AC22 
Ticlopidine B01AC05 
Antidepressants 
TCA 
Amitriptyline N06AA09 
ALTERNATIVE MEDICATION: 
- SSRI: citalopram, sertraline 
- Mirtazapine 
 
NON-PHARMACOLOGICAL  INTERVENTIONS (328) 
- Behavioral therapy 
- Problem solving therapy 
- Interpersonal psychotherapy 
 
(196, 278) 
Clomipramine 
 
N06AA04 
Doxepin (>6mg) N06AA12 
Imipramine N06AA02 
Nortriptyline N06AA10 
Paroxetine N06AB05 
SSRI 
Fluoxetine (daily use) N06AB03 
MAO inhibitors 
Tranylcypromine N06AF04 
Antiemetic drugs 
Trimethobenzamide NA ALTERNATIVE MEDICATION: (278) 
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Diphenhydramine R06AA02 - Domperidone 
Antiepileptic drugs (AED) 
Phenobarbitone N03AA02 
ALTERNATIVE MEDICATION: 
- Other antiepileptic: lamotrigine, valproic acid, levetiracetam, 
gabapentin 
(278) 
Antihypertensive agents and other cardiovascular drugs 
Clonidine C02AC01 
ALTERNATIVE MEDICATION: 
- Other antihypertensives except short-acting calcium channel 
blockers and reserpine 
- Other antihypertensives, e.g. ACEI, AT1 blockers, thiazide 
diuretics, long acting calcium channel blockers with peripheral effect 
 
(196, 278) 
Methyldopa C01AB01 
Moxonidine C02AC05 
Nifedipine  C08CA05 
Prazosin C02CA01 
Terazosin G04CA03 
Antipsychotics (Neuroleptic drugs) 
First-Generation (Conventional) Agents 
Chlorpromazine N05AA01 ALTERNATIVE MEDICATION: 
- Neuroleptics with better risk/benefit ratio, e.g. risperidone, 
pipamperone, haloperidol (in acute psychosis, short term use less 
than 3 days) 
 
NON-PHARMACOLOGICAL  INTERVENTIONS – DELIRIUM  
- Prevention 
- Avoid use of delirium related drugs 
- STOP DELIRIUM – multicomponent intervention 
- Identification of clinical changes during the prodromal phase 
 
NON-PHARMACOLOGICAL  INTERVENTIONS  
- Psychological strategies tailored to patients: music, reminiscence 
therapy, exposure to pets, outdoor activities, bright light exposure 
 
- In agitation and aggression try to identify the cause of the problem 
– can be disease, pain, medication 
(196, 278, 
329, 330) 
Fluphenazine N05AB02 
Haloperidol (>2mg) N05AD01 
Promazine N05AA03 
Trifluoperazine N05AB06 
Second-Generation (Atypical) Agents 
Aripiprazole N05AX12 
Asenapine N05AH05 
Clozapine N05AH02 
Olanzapine (>10mg) N05AH03 
Sedatives, hypnotic agents 
Long-acting benzodiazepines 
Clonazepam N03AE01 ALTERNATIVE MEDICATION: 
(196, 278, 
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ATC: Anatomical therapeutic chemical, COPD: Chronic obstructive pulmonary disease, CNS: Central nervous system, ECG: Electrocardiogram, MAO: Monoamine oxidase inhibitors, 
NSAID: Non- steroidal anti-inflammatory drugs, SSRI: Selective serotonin reuptake inhibitors, TCA: Tricyclic antidepressants. 
 
5.2.5 Discussion 
We have proposed a prescribing algorithm specifically designed to minimize prescribing of 
potentially inappropriate medications in frail older patients in residential care settings. This 
algorithm incorporates a systematic approach to identifying, evaluating and, if indicated, 
withdrawing such medications on an individual basis. However, we acknowledge that there 
will be potential practical difficulties in using this algorithm, for example, ascertaining the 
reasons why medications (which have been prescribed for a considerable period of time) 
were originally commenced. In some cases, even the past diagnosis, which served as the 
original indication for the drug, may be difficult to reconfirm using currently accepted 
diagnostic criteria. Both tasks can be difficult and time consuming in elderly individuals 
Diazepam N05BA01  In anxiety indication: 
- Short-acting benzodiazepines –less than half of the dose 
usually given to adults 
- Mirtazapine, trazodone, mianserine 
 In hypnotic indication: 
- Ise non benzodiazepine hypnotics: zolpidem, zopiclone 
- Valeriana  
 
NON-PHARMACOLOGICAL  INTERVENTIONS – ANXIETY  
- Cognitive-behavioural therapy 
 
NON-PHARMACOLOGICAL  INTERVENTIONS – INSOMNIA  
- Sleeping hygiene 
- Explore the cause of sleep disorder – can be disease, medication, 
environment 
- Light therapy 
331-333) 
Bromazepam N05BA08 
Clobazam N05BA09 
Nitrazepam N05CD02 
Flunitrazepam N05CD03 
Short- and intermediate acting 
benzodiazepines 
Alprazolam N05BA12 
Lorazepam N05BA06 
Oxazepam N05BA04 
Temazepam N05CD07 
Triazolam N05CD05 
Others 
Cimetidine A02BA01 
ALTERNATIVE MEDICATION: 
- Proton pump inhibitors 
- Other H2 antagonists: ranitidine, famotidine,  
(196) 
Diphenoxylate A07DA01 
ALTERNATIVE MEDICATION: 
- Mebeverin, fluoroglucinol 
(196) 
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with polypharmacy and multiple co-morbidities, and no algorithm will be able to reconcile 
the complexity of this task with the desire for simplicity and specificity in its application. 
 
Although current national quality measures give us an opportunity to extract a 
comprehensive list of potentially inappropriate and potentially inappropriate medications, 
the further domains of inappropriate prescribing such as underuse of medications, drug-
drug interaction, drug-disease interaction and medication duplication might be missed. 
Hence, we do not claim this list is exhaustive, and the safety of other drugs not included 
here has to be considered depending on the patients individual circumstances as research 
indicates medications other than PIMs also have the potential to cause adverse drug 
events.(334) 
 
We acknowledge that the utility of the algorithm in routine clinical practice needs to be 
evaluated, especially in view of the mixed effects reported in some studies of various 
interventions designed to minimize the use of PIMs among patients in RACFs.(310) 
Barriers to its application need to be determined, with a particular focus on logistical 
constraints of busy clinical settings where there may be few financial reimbursements for 
the extra time spent applying the algorithm.  
 
Studies involving a randomized controlled trial might validate the algorithm. Prescriber 
outcome measures that might be relevant in any controlled trial could be the number of 
medications identified as potential candidates for discontinuation (and the rationale for 
such decisions) and the specific actions enacted by prescribers in regards to drug 
withdrawal. Patient outcome measures could include incidence rates of ADEs (including 
geriatric syndromes) and medication-related hospitalizations. Process measures could 
include time taken to conduct medication reviews (does the algorithm speed up or prolong 
consultations?) and the ease of use of the algorithm (as determined by questionnaire and 
focus group discussions).  In the meantime, current prescribers may find the algorithm of 
use and we welcome feedback as to their perceptions of its utility.   
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5.3 Next Steps 
We believe that the algorithm described in this chapter covers a range of different clinical 
scenarios and offers an evidence-based approach to identifying and, if appropriate, 
discontinuing potentially inappropriate medication.  
 
The lack of strong evidence to guide clinicians to avoid or discontinue treatment in frail 
older people might make this a particularly challenging and time-consuming process. 
Widespread adoption of this strategy might have its challenges but also has considerable 
potential to relieve suffering and minimise harm in vulnerable older persons. Although 
there are a few recent studies to support the feasibility and safety of discontinuing 
medication in the elderly,(335, 336) stronger evidence could be obtained if future trials 
incorporate a discontinuation arm or post discontinuation follow-up. 
 
The next logical step would be to evaluate the usefulness of the algorithm in routine 
clinical practice, particularly identifying the enablers and barriers to its application. This has 
not been rigorously assessed as part of this thesis, but is discussed in Chapter 6 under 
‘Future Research’.  
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Chapter 6: Discussion, Future Research, and Conclusions 
 
6.1 Discussion 
Older patients pose a complex challenge for the health care system, as they often present 
with multiple co-morbidities, polypharmacy, disability and frailty. The risk of adverse drug 
events is particularly high in this population. ADEs are associated with polypharmacy,(205) 
frailty,(64) use of potentially inappropriate medications,(159), and age-related changes that 
affect the pharmacodynamics and pharmacokinetics of drugs.(337) When compared with 
younger adults, ADEs are approximately twice as frequent in older adults, with a significant 
proportion considered preventable.(338) Optimization of appropriateness of prescribing in 
this vulnerable population should be a priority of health care providers. 
 
The objective of this thesis was the optimization of medication prescribing in frail older 
people, with a focus on polypharmacy, frailty and potentially inappropriate medications, 
with a view to developing best practice guidelines for prescribing in frail older people. In 
this section, the findings of the studies reported in this thesis will be discussed from a 
broader perspective. 
 
The thesis commenced with a literature review that provided a comprehensive background 
on ageing populations, appropriate and inappropriate prescribing, existing screening tools 
to assess inappropriate prescribing, the prevalence of inappropriate prescribing, frailty and 
its measurement and a systematic review of criteria that evaluated appropriateness of 
medications in frail older people (Chapter 1). This literature review indicated that older 
people are at increased risk of polypharmacy, inappropriate prescribing and adverse drug 
outcomes. The frailty status of patients is rarely considered overtly during prescribing and 
in identifying inappropriate prescribing in older people. This suggests the need for a 
standardized approach to assessing appropriateness of medication in frail older individuals 
considering both patient and medication related factors.  
 
Chapter 2 explored issues around polypharmacy and adverse outcomes in older 
hospitalised patients and investigated the potential role of frailty status. Polypharmacy is 
generally associated with adverse outcomes but, in our study, we did not find any 
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association between polypharmacy and adverse outcomes studied except for delirium. 
This led us to explore further to see if the frailty status of patient adds another dimension 
to this relationship.  
 
Our study showed that, within each polypharmacy category, the incidence of adverse 
outcome increased with increasing frailty, and the most robust patients taking 10 or more 
drugs had the lowest incidence of adverse events compared with other 
polypharmacy/frailty categories. This indicates that polypharmacy in the presence of frailty 
is much worse than polypharmacy in those who are not frail. Therefore, extensive 
medication withdrawal or de-prescribing in all older inpatients might not be the ideal 
intervention as many patients are likely to benefit from appropriate multiple medications if 
not frail. The assumption that polypharmacy is always hazardous and that it indicates 
suboptimal care needs to be reconsidered.  
 
As such, this phase of our study suggested that polypharmacy is not always an 
independent risk factor for predicting an adverse outcome in older inpatients. By 
considering the frailty status of the patient, we may better appraise risk and lead to 
improved clinical care.  
 
Patients who are frail are often discharged from hospitals to RACFs. Thus, in Chapter 3, 
we aimed to identify the prevalence of PIMs and explore the association of risk factors for 
receiving PIMs in a subset of patients who are discharged to RACFs from our initial larger 
cohort of 1418 inpatients. Among the widely used tools for detecting inappropriate 
prescribing such as Beers, STOPP/START and MAI, we used the latest 2012 version of 
the American Geriatrics Society Beers criteria for several reasons. Beers criteria were 
updated in 2012 providing a more comprehensive list more in line with current clinical 
practice. The quality of criteria has been improved using an evidence based approach that 
now includes a clear indication of the strength of the evidence and of the recommendation. 
The updated version excluded medications that are no longer available while newly 
marketed medications were added in the list.(194) The 2012 Beers criteria detected the 
highest number of PIMs in a comparative study of the STOPP, the 2003 Beers criteria, and 
the 2012 AGS update of the Beers criteria determining the prevalence of PIMs.(339) The 
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2012 update has also been shown to be the most sensitive tool despite concerns related 
to the applicability of the previous version of the Beers criteria in Europe. Despite these 
updates, the relevance of the tool for data collected outside the US could be questioned. 
For example this recent update contain medications that are either not available in 
Australia or that have been withdrawn from use. 
 
In our study, the current Beers criteria demonstrated frequent use of PIMs in older people 
discharged from acute care hospitals to RACFs. However, the number of PIMs was lower 
on discharge than on admission although this reduction was not significant. During the 
hospital admission, few PIMs were stopped, and other new PIMs had been started. A clear 
association between the use of PIMs, frailty status, and cognitive decline of patients at 
admission and discharge was observed. Although an admission to hospital is an 
opportunity to rationalise medications according to their appropriateness, this did not occur 
in this study. Patients discharged to RACF from hospital continued to be exposed to 
extensive polypharmacy and medications with uncertain risk–benefit ratios. This suggests 
the need of interventions in hospitals and RACFs to rationalise prescribing in these frail 
older patients.  
 
Following the identification of PIMs in patients discharged to RACF, Chapter 4 evaluated a 
prospective observational study to examine if geriatrician intervention during 
comprehensive video-conference geriatric consultations resulted in changes to prescribing 
patterns, and reduced the prevalence of PIMs use for residents of aged care facilities. 
Comprehensive geriatric assessments supported by a geriatric medicine specialist has 
been shown to be beneficial to older patients (66, 136), but many of these patients are 
unable to travel to seek such advice because they are physically impaired, or they live in 
remote areas. Telemedicine has been used to address this concern, whereby 
consultations are undertaken using video conferencing. An important part of the 
consultation is the recommendations the geriatrician makes about patients’ medications. 
 
A moderately high prevalence of potentially inappropriate medications was prescribed to 
residents in RACFs but geriatricians made relatively few changes. This suggests that 
either the prescription of these medications was appropriate or other factors (which may 
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include patients’ beliefs in their medications, involvement of several prescribers, use of 
preventive medication and evidence based medicine guidelines that often lead to 
polypharmacy, and lack of risk/benefit information for the frail older residents) influenced 
the decision not to modify medications. Although specialist geriatrician involvement helps 
optimise medication in this age group, potentially inappropriate medications were still 
observed in our study. This suggests the need for an algorithm for withdrawing 
medications of high disutility which might help optimise medication prescribing in frail older 
people. 
 
We also aimed to review prospectively the medication charts in a RACF to determine if 
medication changes recommended by geriatrician were implemented and sustained. A 
follow up study at 3 months after the initial consultation showed that most of the 
recommendations were followed by RACF staff or the GP overseeing the care of the 
patient. Occasionally, the recommendations were not followed but the reasons for this 
have not been established in this study. Although this was a single site study with a 
relatively small sample size, the outcome of this follow-up has implications for geriatricians’ 
recommendations regarding patient medication management.  
 
In Chapter 5, we have addressed polypharmacy and minimisation of potentially 
inappropriate medications by developing a practical algorithm that helps clinicians identify 
and discontinue potentially inappropriate medications using a logical and practical 
approach. We propose a 4-step algorithm that provides instructions when and how to taper 
and withdraw inappropriate medications. It adds to the previously available generic ‘drugs-
to-avoid’ list in that it targets drugs of highest risk, suggests alternative therapies (which 
can include non-pharmacological approaches), and informs the discontinuation process by 
highlighting the risks of withdrawal on disease and syndrome recurrence and recommends 
appropriate tapering regimens.  
 
Given the lack of evidence surrounding the topic, various logistical constraints, and the 
practical complexity of medication cessation in elderly individuals, this algorithm is not 
intended as a normative decision aid but more a conceptual framework that may prompt 
clinicians to more critically examine factors that influence their prescribing. Although, 
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widespread adoption of a medication withdrawing protocol in clinical care has its 
challenges, it also has significant potential to relieve unnecessary suffering and disability in 
older patients.(306) Ceasing medications might be complex and time consuming, yet, 
minimising the potential harm and waste of resources arising from inappropriate 
polypharmacy in frail older patients is a responsibility of prescribers.(316) The utility of the 
algorithm developed in this study needs to be evaluated in routine clinical practice. The 
enablers and barriers to its use need to be determined and studies involving randomised 
controlled trials are needed.  
 
This study focused only on institutionalized elderly. Given the current long-term trend to 
deinstitutionalize health care, more frail elderly persons are now receiving care through 
public home care programs where supports for frail elderly patients are not as continuous 
or readily available as they are in an institution. 
 
6.3 Conclusion 
This thesis demonstrates that prescribing in frail older people remains a significant 
problem but that optimisation of prescribing should be attainable by accurate identification 
of frail patients in various clinical settings. By individualising prescribing based on each 
patient’s own goal of care and frailty status, better outcomes could be achieved for the 
individual patient and the health system as a whole.  
 
While polypharmacy stands as a valuable indicator for medication review, it might not be 
an independent marker of the quality use of medicines in the individual patient. Assessing 
the frailty status of patients better appraises risk. Frail older patients continue to be 
exposed to polypharmacy and potentially inappropriate medications. A medication review 
algorithm for withdrawing medications of high disutility, particularly in those who are frail, 
should assist clinicians to optimise medication prescribing in this vulnerable population. 
 
Future research should focus on incorporating frailty assessment in various clinical 
settings to investigate the effectiveness of the proposed medication review algorithm for 
specific potentially inappropriate medications.  
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The findings of this thesis should stimulate further evaluation by researchers, policy 
makers and clinicians into the relationship between polypharmacy, frailty status and 
adverse outcomes. 
 
6.2 Future Research Directions 
Future research should include the impact of frailty measurement on clinical decisions in 
the elderly. Management of chronic disease and optimisation of prescribing will differ 
between frail and non-frail individuals. Identifying those at risk of developing frailty will be 
important when recruiting for clinical trials that evaluate interventions that target and 
prevent frailty.(340) Furthermore, unless frail individuals are included in clinical trials, the 
effectiveness of treatment and interventions cannot be established in this group.(341)Only 
in this way will clinical research lead to improvements in care of older adults. 
 
Although a significant body of research has focused on the negative consequences of 
polypharmacy, it is now time that further research should focus on other dimensions to this 
phenomenon. Constantly assuming that polypharmacy inevitably leads to adverse 
outcomes needs to be reassessed because some patients would appear to benefit from 
receiving a greater number of drugs provided that they are not frail. Similarly, it should not 
be assumed that de-prescribing in all older patients will always improve outcomes.  
 
Future research should validate the medication review algorithm developed in this study 
using a randomized controlled trial. Enablers and barriers to its application in routine 
clinical practice also need to be evaluated especially when there are few financial benefits 
for the extra time spent applying this algorithm in busy clinical settings. 
 
Some studies have found that pharmacist involvement can lead to better medication 
management.(124, 342, 343). Pharmacists would be in a position to apply the medication 
management tools such as the algorithm developed in this study in real clinical settings 
and liaise with primary care providers and specialists in decision-making.(344)Pharmacists 
are usually not integrated into the care process as well as they could be. Hence, future 
research should evaluate the potential benefits of integrating pharmacists in to 
multidisciplinary teams to see if this can improve outcomes in a cost effective manner.  
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Appendix B: Published Paper: Potentially Inappropriate Prescribing in Older Patients 
Discharged from Acute Care Hospitals to Residential Aged Care Facilities 
 
 
170 
 
 
 
 
171 
 
 
 
 
 
172 
 
 
 
 
173 
 
 
 
 
 
174 
 
 
 
 
175 
 
 
 
 
 
176 
 
 
 
 
 
177 
 
 
 
 
 
178 
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Appendix F: Logistic regression analysis for relationship between polypharmacy and 
frailty on having at least one adverse outcome 
 
Variables OR (95% CI) p-value 
Low FI, 0-4 meds 2.03 (1.01 – 4.08) 0.045 
Low FI, 5-9 meds 1.89 (1.03 – 3.47) 0.038 
Intermediate FI, 0-4 meds 11.72 (5.72 – 24.01) 0.000 
Intermediate FI, 5-9 meds 6.01 (3.36 – 10.76) 0.000 
Intermediate FI, ≥ 10 meds 4.28 (2.37 – 7.74) 0.000 
High FI, 0-4 meds 28.51 (12.52 – 64.87) 0.000 
High FI, 5-9 meds 21.07 (11.37 – 39.05) 0.000 
High FI, ≥ 10 meds 15.72 (8.34 – 29.61) 0.000 
Outcome variable: Composite Adverse Outcome, FI: Frailty Index 
Reference group: Low FI, 10+ meds
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Appendix G: Logistic regression for risk factors of receiving potentially inappropriate medications 
PIMS at admission 
Variables  95% confidence interval for 
Exp (B) 
B Std. Error Wald df Sig Exp (B) Lower Bound Upper Bound 
Age (yrs)         
      65-74a - - - - - 1.00 - - 
      75-84 .168 .218 .594 1 .471 .912 .742 1.124 
      ≥ 85 .188 .221 .721 1 .877 .981 .767 1.227 
Sex         
     Female .028 .253 .012 1 .643 1.031 .814 1.325 
Fall in hospital .475 .286 .382 1 .293 1.231 .836 1.854 
Delirium in hospital .158 .708 .501 1 .906 .945 .326 2.152 
Failure to improve in ADL .024 .021 1.262 1 .267 .965 .913 1.026 
In-hospital cognitive function 
decline 
.816 .395 4.362 1 .032 .821 .625 .991 
Frailty Index .041 .020 4.671 1 .037 .923 .764 1.124 
PIM: Potentially Inappropriate Medication; a: Reference category; Cox & Snell R Square: 0.382 
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Appendix G (continued) 
PIMS at discharge 
Variables  95% confidence interval for 
Exp (B) 
B Std. Error Wald df Sig Exp (B) Lower Bound Upper Bound 
Age (yrs)         
      65-74a - - - - - 1.00 - - 
      75-84 .168 .218 .594 1 .462 .912 .742 1.124 
      ≥ 85 .187 .215 .624 1 .881 .914 .767 1.127 
Sex         
     Female .028 .253 .012 1 .643 1.031 .814 1.325 
Fall in hospital .351 .218 .318 1 .561 1.121 .794 1.144 
Delirium in hospital .213 .762 1.201 1 .291 1.214 .823 1.815 
Failure to improve in ADL .026 .023 1.261 1 .266 .975 .862 1.032 
In-hospital cognitive function 
decline 
.831 .326 4.272 1 .021 .853 .652 .962 
Frailty Index .044 .031 4.622 1 .031 .932 .771 1.134 
PIM: Potentially Inappropriate Medication; a: Reference category; Cox & Snell R Square: 0.335
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